

CURRICULUM VITAE
BART STAELS, Ph.D.

1. GENERAL INFORMATION

- Name: Bart STAELS
- Date & Place of birth: August 20 1961, Ukkel, Belgium
- Nationality: Belgian
- Civil State: Married to Marleen Van D'Huynslager
- Children: Vincent (° May 17 1994), Emily (° Januari 31 1997)
- Titles: Pharmacist; Doctor of Philosophy (Ph.D.); Professor
- Military service:
- Officer (Lt.) of the Belgian Army, Medical Service (1985-1986)

-
- Professional address:
 - Unité 545 Inserm, Département d'Athérosclérose
 - Institut Pasteur de Lille
 - 1 rue du Professeur Calmette
 - BP 245 - 59019 Lille Cédex - FRANCE
 - TEL: 33-3-20-87 73 88
 - FAX: 33-3-20-87 71 98
 - E-mail: Bart.Staels@pasteur-lille.fr

2. FUNCTIONS & FELLOWSHIPS

Previous functions:

- Research Fellow (Dr.G.Verhoeven) at the *Laboratorium voor Experimentele Geneeskunde en Endocrinologie* (LEGENDO), Katholieke Universiteit Leuven, Belgium (1985-1989)
- Research assistant of the *Belgian Foundation for Scientific Research* (NFWO/FNRS) (1989-1991)
- Fellow of the *D.Collen Research Foundation* (1991-1993)
- Postdoctoral Research Fellow (Dr.W.L.Miller) at the *Metabolic Research Unit*, University of California, San Francisco, USA (1991-1992)
- Postdoctoral Research Fellow (*Chercheur*) of the *Reverse Cholesterol Transport/Atherosclerosis Project, BioAvenir* (Rhône-Poulenc Rorer), Vitry sur Seine, France (1993)
- Research Associate at the *Département d'Athérosclérose* (Prof. J.-C.Fruchart), Institut Pasteur de Lille, France (1994)
- Chargé de recherche de 1ère classe at the C.N.R.S. (1994-1998)

Present functions:

- Full professor, 1st Class, Faculty of Pharmacie, University of Lille II, Lille, France

- Research group leader in the *Département d'Athérosclérose* (Dir.: Prof. J.-C.Fruchart), Institut Pasteur de Lille, France
- Member of the Scientific Council of the Institut Pasteur de Lille (2003-)

3. EDUCATION

A. Scientific Education:

<u>Subject</u>	<u>School & Address</u>	<u>Dates attended</u>	<u>Results</u>
Secondary education (lat-math)	St-Jozefscollege St-Pieters-Woluwe Belgium	1973-1979	
Lic. in Pharmac. Sciences	Institute for Pharmaceutical Sciences, Univ. of Leuven, Belgium	1979-1984	Magna cum laude
Certif. in Biotechnol.	Univ. of Leuven, Belgium	1984-1985	Magna cum laude
Doctor of Philosophy	Institute for Pharmaceutical Sciences, Univ. of Leuven, Belgium	1986-1991	Summa cum laude
Habilitation à diriger des recherches	Fac. de Pharmacie Université de Lille II Droit et Santé	9-4-1997	

B. Knowledge of Languages:

Mother tongue: Dutch

Knowledge of:

English: 6 year course at secondary school

1 month course at Scarborough, England (1975)

1 month course at Wimbledon, London, England(1977)

French : 9 year course at primary and high school

Second language in Belgium

German : 3 year course at high school

Spanish: 1 month course at Leuven Language Learning, Catholic Univ. Leuven

4. MEMBERSHIP OF LEARNED SOCIETIES

- Member of the Belgian Lipid Club
- Member of the European Atherosclerosis Society
- Member of the 'Association pour les Etudes sur les Peroxysomes en Biologie' (AEP-BIO)

- Member of the 'American Heart Association' and the Council on Arteriosclerosis, Thrombosis and Vascular Biology.
- Full member of the 'Endocrine Society' (1998-2004)
- Member of the American Diabetes Association (ADA)
- Member of the American Society for Biochemistry and Molecular Biology (2003-2004)
- Member of the 'Nouvelle Société Française d'Athérosclérose' Board

5. GRANTS, AWARDS & SCIENTIFIC PRIZES

- Merck Sharp & Dohme Award of the Belgian Lipid Club 1988-1989 (500 000 BF) on '*Regulation of Apolipoprotein, Hepatic Triglyceride Lipase and LDL-Receptor Gene Expression*'.
- Recipient of a Contrat de Recherche (70 000 FF) from ARCOL (Comité Français de Coordination des Recherches sur l'Athérosclérose et le Cholestérol) 1993
- Recipient of a grant "Aides à l'implantation de nouvelles équipes" (300 000 FF) from La Fondation pour la Recherche Médicale 1994
- Recipient of a Bourse d'Aide à la Recherche (60 000 FF) from Laboratoires Fournier 1994
- Coordinator of a Contrat Est/Ouest INSERM (350 000 FF) entitled "Régulation hépatique des gènes du métabolisme des lipoprotéines" 1995-1997.
- Young Investigator Award (800 USD) of the European Atherosclerosis Society, 66th Congress of the European Atherosclerosis Society, Florence, July 15, 1996
- Médaille de bronze du CNRS (Bronze Medal of the CNRS), 1996
- "The Original Spa Water 1998" award, 1998 (30000 ECU)
- ISI French Citation Laureate 1981-1998
- Special Prize of the « Société des Sciences, de l'Agriculture et des Arts de Lille », 15 October 2005

6. REVIEWER FOR INTERNATIONAL JOURNALS

Arterioscler Thromb Vasc Biol, Atherosclerosis, Bioch Biophys Acta, Biochem Biophys Res Commun, Biochem J, Biochem Pharmacol, Blood, BMC Pharmacol, Circ Res, Circulation, Clinical Science, Diabetes, Diabetologia, Drugs , Endocrinology, Eur J Clin Invest, Eur J Biochem, Eur J Immunol, Exp Opin Invest Drugs, Febs Lett, J Cardiovasc Pharmacol, J Clin Invest, J Immunol, J Lipid Res (Associate Editor), J Mol Endocrinol (Associate Editor), J Neurochem, J Pharmacol Expt Ther, Mol Cell, Proteomics, Mol Cell Biol, Mol Cell Proteomics, Mol Endocrinol, Nature, Nature Med, Science, Soc Biol

And Granting agencies : Wellcome Trust, Nederlandse Hart Stichting, Nederlands Diabetes Fonds, Arthritis Research Campaign

7. SCIENTIFIC ANIMATIONS

- Participation in European Contracts (Mafaps, Biomed Lipases, Diabesity, EVGN, Hepadip, X-Tra-net)
- Organization of Congresses (PPARs Florence, Italy (2003), and Monaco, France (2005) - Organizing Committee; IAS Paris & Kyoto International Advisory Board; European Lipoprotein Club Annual Meetings; Soc. Française d'Athérosclérose Annual meetings; Member of the organizing committee 'DB Brown Research Chair on Obesity' Laval University Quebec, Canada)

- Member of Directory Boards (Société Française d'Athérosclérose, European Lipoprotein Club 1999-2003); Member of the CSS n° 8 Inserm (2001-2002); Member of the FASEB Directory Board; Member of the Editorial Board of the Journal of Molecular Endocrinology and of the Journal of Lipid Research (July 1st 2003 - June 30, 2005).
- Contributor to The Sigma-RBI Handbook of Receptor Classification and Signal Transduction – 4th Edition, 2001.
- Co-editor of the Book “Peroxisome Proliferator Activated Receptors : From basic science to clinical applications” – Giovanni Lorenzini Medical Foundation – Kluwer Academic Publishers 2002 - Vol 18.
- Founding Member of Genfit S.A., Member of the Genfit Advisory Board (Lille, France)
- Member of the Pasteur Institute Scientific Council (2004)
- Member of the Scientific Board of the Leem Research Council – Paris, France (2004-2005)

8. PATENT authorships

- ✓ Patent n° WO0078986 published 2000-12-28 “Regulation system of expression using nuclear PPAR receptors”.
- ✓ Patent n° WO0216638 published 2002-02-28 “Method fo identifying substances useful for treating inflammation using the response element to the I kappa B alpha ROR receptor”
- ✓ Patent n° FR2755699 published 2002-10-03 regarding novel constructs and novel vectors for the targeted and inducible expression of genes (requested patent n° WO9821349).
- ✓ Patent n° WO0360106 published 2003-07-24 “Method and device for identifying substances capable of modulating adipocyte differentiation
- ✓ Patent n° WO02063038 published 2004-06-17 “Method for identifying compounds modulating reverse cholesterol transport

9. PARTICIPATION IN THESIS PRESENTATIONS

- Examineur; Thèse de Doctorat Label Européen de l'Université de Lille II de K.Schoonjans (20-6-1995). Title: "Rôle du PPAR dans la régulation génique par les fibrates et les acides gras: conséquences fonctionnelles sur le métabolisme des lipides et des lipoprotéines."
- Rapporteur; Thèse de Doctorat de l'Université Henri Poincaré-Nancy I de M.El Yaagoubi (7-7-1995). Title: "Régulation de l'expression de la gamma- γ lutamyltransférase. Importance de la méthylation de l'ADN et des régions 5' non traduites de ses ARNm."
- Examineur; Thèse de Doctorat en Sciences de la Vie et de la Santé de l'Université de Sciences et Technologies de Lille de R.Saladin (14-2-1996). Title: "Régulation de gènes impliqués dans l'athérosclérose et l'obésité : Rôle des facteurs nutritionnels, hormonaux et pharmacologiques sur la régulation des gènes de l'apolipoprotéine A-I, du PPAR α et de l'ob."
- Examineur; Thèse de Doctorat en Sciences de l'Université Paris XI Orsay de L.Berthou (2-7-1996). Title: "Approche Pharmacologique de la Régulation de l'Expression des Gènes des Principales Apolipoprotéines Constitutives des Lipoprotéines de Haute Densité."
- Thesis Director - Université - Lille II, 6 avril 1998 G. Martin. Title : « Régulation de l'apport des acides gras et du cholestérol dans les cellules. Isolement et caractérisation du gène humain codant

pour la protéine de transport des acides gras, FATP. Expression et régulation de CLA-1, récepteur des HDL ».

- Rapporteur; Thèse de Doctorat de l'Univ.de Rotterdam, Pays-Bas, de B.Neve (15-5-1998). Title : "Hepatic lipase: Regulation at the Post-transcriptional Level."
- Rapporteur; Thèse de Doctorat de l'Univ.de Leiden, Pays-Bas, de D.Neele (11-1998). Title : "Regulation of apolipoprotein(a) and apolipoprotein A-I synthesis."
- Thèse de Doctorat de l'Université - Lille II, 30 novembre 1998, A.M. Lefebvre. Title : « Rôle des activateurs du récepteur activé par les proliférateurs des peroxysomes gamma (PPAR γ) dans les métabolismes du tissu adipeux et du colon ».
- Rapporteur; Thèse de Doctorat de l'Université des Sciences et Technologies de Lille I de F.Leprêtre (4-1999). Title : "Etude génétique du diabète non insulino-dépendant chez une population d'Indiens Tamils de Pondichery."
- Thèse de Doctorat de l'Université - Lille II, 26 avril 1999, N. Hennuyer Title : « Les récepteurs nucléaires et le métabolisme lipidique. Effets des PPAR et de RXR ».
- Examineur; Thèse de Doctorat en Sciences de l'Université des Sciences et Technologies de Lille I de S.Delannoy (21-09-99). Title : "Fonction et localisation subcellulaire du récepteur nucléaire Rev-erb alpha."
- Examineur ; Thèse de Doctorat de l'Université de Lille II, G.F.Gbaguidi (06-1999). Title : « Etude des différences structurales entre les isoformes de l'apolipoprotéine CIII et de leur impact sur l'inhibition de l'activité enzymatique de la LPL. Régulation de l'expression des gènes de la LPL et du CLA-1/SR-BI par les activateurs des PPARs et les lipoprotéines dans les macrophages et les lésions athérosclérotiques ».
- Examineur; Thèse pour le Diplôme d'Etat de Docteur en Pharmacie de l'Univ. d'Amiens de E.del Alamo (5-07-99). Title : "Mise en évidence et étude des différents transcrits d'un nouveau gène à homéobox, Lsx."
- Examineur ; Thèse de Doctorat de l'Université de Leiden, Pays-Bas, M.Kockx (28-10-1999). Title : « Regulatory aspects of fibrinogen and plasminogen activator inhibitor-1. Gene regulation. Role of the peroxisome proliferator activated receptor ».
- Examineur; Thèse de Doctorat en Sciences Pharmaceutiques et Biologiques de l'Université de Lille II de P.Gervois (01-03-2000). Title : « Peroxisome proliferator-activated receptor α : Modulation de son activité transcriptionnelle, rôle dans la régulation négative de l'expression de l'apolipoprotéine A-I et du fibrinogène par les fibrates ».
- Examineur ; Ph.D. Thesis, Univ. Gand, Belgium, K.De Bosscher (23-03-2000). Title : « Onderzoek naar het mechanisme van Genrepressie door Glucocorticoïden ».
- Rapporteur ; Habilitation à Diriger des Recherches F.Trottein (02-05-2000) - Université des sciences et technologies de Lille I. Titre : "Bases immunologiques des relations hôte/parasite au cours de la schistosomiase".
- Thèse de Doctorat de l'Université - Lille II, 3 octobre 2000, P. Delerive. Title : « PPARs et transrépression : mécanismes moléculaires et conséquences physiopathologiques ».

- Examineur ; PhD.Thesis, Univ. Sciences Pharmaceutiques Lille II, A.Pilon (07-12-2000). Title : « Le SR-BI, récepteur des HDL : ligands et régulation dans une lignée de cellules surrénales humaines ».
- Examineur ; PhD.Thesis, Dpt of Medical Nutrition, Karolinska Institute-Stockholm, Sweden, J. Liden (12-12-00). Title : Repression of transcription factor NF-kB by glucocorticoids ».
- Habilitation à Diriger des Recherches, Université des Sciences et Technologies de Lille I, Corine Glineur (14-03-2001) « Etudes des modifications post-traductionnelles de différentes protéines ».
- Examineur ; PhD Thesis, University of Maastricht, The Netherlands, KAJM Van Der Lee (21-03-2001) « Fatty acid-mediated gene expression in the cardiac muscle ».
- Examineur; Habilitation à Diriger des Recherches, Université Claude Bernard de Lyon 1, Jean-Marc Vanacker (02/05/2001) “Fonctions des récepteurs nucléaires orphelins ERR”.
- Examineur; PhD Thesis, University of Lille2, Christophe Furman (03-05-2001) “Protection des cellules endothéliales exposées à un stress oxydant par les polyphénols et les activateurs du PPAR α »
- Thesis Director; PhD Thesis, University of Lille2, Ines Pineda-Torra (18-06-2001) “Role of PPAR α in human metabolic diseases : genetic studies and regulation of PPAR α expression”.
- Examineur; PhD Thesis, University of Paris 7 UFR Lariboisière, Paris, France. Sandrine Besnard (21/12/2001) “Expression et fonctions de ROR α dans le système vasculaire »
- Habilitation à Diriger des Recherches, Université des Sciences et Technologies de Lille I, Giulia Chinetti (08-01-2002) « Etude du rôle des PPAR (Peroxisome Proliferator-Activated Receptors) dans l’homéostasie du cholestérol des macrophages ».
- Examineur ; PhD Thesis, University Pierre et Marie Cuire Paris VI (Physiopathologie Cellulaire et Moléculaire), Wilfried Le Goff (10-12-2002) « Regulation de l’expression du gène de la protéine de transfert des esters de cholestérol (CETP) : caractérisation d’éléments distaux contrôlant l’activité du promoteur ».
- Directeur de Mémoire ; DES de Pharmacie spécialisée et Diplôme d’Etat de Docteur en Pharmacie, Virginie Bocher (08-01-2003) « Les récepteurs nucléaires LXR α et LXR β : implications dans l’athérosclérose ».
- Thesis Director ; PhD Thesis, University of Lille II, Thierry Claudel (13-06-2003) “Role du récepteur nucléaire FXR dans le métabolisme lipidique ».
- Thesis Director ; PhD Thesis, University of Lille II, Hélène Duez (01-07-2003) “Rôle des récepteurs nucléaires PPAR α et Rev-erb α dans le métabolisme des lipids et lipoproteins, et le développement de l’athérosclérose.
- Rapporteur ; PhD Thesis, Université Paris VI, Soazig LeLay (19-09-2003) « Role des facteurs de transcription SREBP dans le métabolisme adipocytaire : Implication de SREBP-1c dans la réponse à l’insuline et activation de SREBP-2 au cours de l’obésité.
- Rapporteur ; PhD Thesis, Université de Bourgogne, Thomas Gautier (17-10-2003) « Identification et caractérisation de l’inhibiteur physiologique de la protéine de transfert des esters de cholestérol (CETP) chez l’homme.
- Examineur ; PhD Thesis, University of Lille II, Christophe Blanquart (05/12/2003) « Etude des modifications post traductionnelles du PPARalpha et de leurs conséquences sur les fonctions biologiques de ce récepteur nucléaire »

- Rapporteur ; PhD Thesis, University of Bourgogne, Jean-François Landrier (17/12/2003) « I-BABP et L-FABP : Portrait croisé de deux protéines à la recherche de leur fonction »
- Rapporteur; PhD Thesis, Université Paris XI, Caroline Chauvet (29/06/2004) « Etude du rôle du récepteur nucléaire RORalpha : analyse des effets de l'hypoxie sur l'expression du gène Rora et recherche de gènes cibles de RORalpha dans le foie »
- Examineur; PhD Thesis, University of Rotterdam, Jessica Lie (15/09/2004) TITRE
- Rapporteur, PhD Thesis, University of Toulouse III, Sébastien Jacquet (23/09/2004) « HDL, ATP synthase, récepteur nucléotidique P2Y₁₃ = un trio de choc contre l'athérosclérose ? »
- Examineur, PhD Thesis, University of Lille II, Patrick Gelé (28/09/2004) « TITRE »
- President, PhD Thesis, University of Lille II, Audrey Sirvent (02/11/2004) « Le récepteur nucléaire FXR : identification de nouveaux gènes cibles impliqués dans le contrôle du métabolisme lipidique et étude de l'effet de la phosphorylation sur son activité »
- Thesis Director, PhD Thesis, University of Lille II, Daniel Duran-Sandoval (25/11/2004) « Rôle du récepteur nucléaire FXR dans le métabolisme glucidique : une fonction potentielle dans le diabète de type 2 et dans l'adaptation métabolique du foie »
- Thesis Director, PhD Thesis, University of Lille II, Caroline Duval (08/03/2005) « Etude du récepteur nucléaire PPARalpha in vivo par recombinaison homologue »
- Rapporteur, PhD Thesis, University of Paris VII, Renaud Dentin (02/02/2006) « Rôle du facteur de transcription ChREBP dans la régulation transcriptionnelle par le glucose des gènes de la glycolyse et de la lipogenèse dans le foie. Implication dans la physiopathologie de l'obésité et/ou du diabète de type 2. »
- Director, HDR, University of Lille II, Philippe Gervois (07/04/2006)

8. PUBLICATIONS

ORIGINAL PAPERS

1. Staels B., Auwerx J., Chan L., van Tol A., Rosseneu M., Verhoeven G.: Influence of development, oestrogens and food intake on apolipoprotein A-I, A-II and E mRNA in rat liver and intestine. *J.Lipid Res.* 1989;**30**:1137-1145
2. Staels B., Jansen H., van Tol A., Stahnke G., Will H., Verhoeven G., Auwerx J.: Development, food intake, and ethinylestradiol influence hepatic triglyceride lipase and LDL-receptor mRNA levels in rats. *J.Lipid Res.* 1990;**31**:1211-1218
3. Staels B., van Tol A., Verhoeven G., Auwerx J. Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. *Endocrinology* 1990;**126**:2153-2163
4. Auwerx J., Staels B., Sassone-Corsi P.: Coupled and uncoupled induction of fos and jun transcription by different second messengers in cells of hematopoietic origin. *Nucl. Acids Res.* 1990;**18**:221-228
5. Staels B., van Tol A., Chan L., Will H., Verhoeven G., Auwerx J.: Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. *Endocrinology*, 1990;**127**:1144-1152

6. de Groot R.P., Auwerx J., Karperien M., Staels B., Kruijer W.: Activation of jun B by PKC and PKA signal transduction through a novel cis-acting element. *Nucl. Acids Res.*, 1991;**19**:775-781
7. Staels B., van Tol A., Chan L., Verhoeven G., Auwerx J.: Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. *Arterioscler. Thromb.*, 1991;**11**:760-769
8. Staels B., van Tol A., Jansen H., Auwerx J.: The effects of probucol on lipoprotein metabolism in the rat. *Biochim.Biophys.Acta*, 1991;**1085**:131-135
9. Staels B., Demacker P.N.M., Stalenhoef A.F.H., Auwerx J.: Increased removal of β -very low density lipoproteins after ethinylestradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase and the low density lipoprotein receptor in Watanabe Heritable Hyperlipidemic rabbits. *Arterioscler. Thromb.*, 1991;**11**:1652-1659
10. Staels B., Peinado-Onsurbe J., Auwerx J.: Down-regulation of hepatic lipase gene expression and activity by fenofibrate. *Biochim.Biophys.Acta*, 1992;**1123**:227-230
11. Auwerx J., Staels B., Van Vaeck F., Ceuppens J.L.: Changes in IgG Fc receptor expression induced by phorbol 12-myristate 13-acetate treatment of THP-1 monocytic leukemia cells. *Leukemia Res.*, 1992;**16**:317-327
12. Staels B., van Tol A., Andreu T., Auwerx J.: Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. *Arterioscler. Thromb.*, 1992;**12**:286-294
13. Staels B., van Tol A., Skretting G., Auwerx J.: Lecithin:cholesterol acyltransferase gene expression is regulated in a tissue-selective manner by fibrates. *J.Lipid Res.*, 1992;**33**:727-735
14. Staels B., Peinado-Onsurbe J., Deeb S., Ramirez I., Llobera M., Auwerx J.: Neonatal extinction of liver lipoprotein lipase expression. *Biochim.Biophys.Acta*, 1992;**1131**:281-286
15. Staels B., Auwerx J.: Perturbation of developmental gene expression in rat liver by fibric acid derivatives: lipoprotein lipase and α -fetoprotein as models. *Development*, 1992;**115**:1035-1043
16. Peinado-Onsurbe J., Staels B., Deeb S., Auwerx J.: Lipoprotein lipase expression in undifferentiated hepatoma cells is regulated by progesterone and protein kinase A. *Biochemistry*, 1992;**31**:10121-10128
17. Jansen H., van Tol A., Skretting G., Auwerx J., Staels B., Opposite regulation of hepatic lipase and lecithin:cholesterol acyltransferase by glucocorticoids in rats. *Biochim.Biophys.Acta*, 1992;**1128**:181-185
18. Staels B., Hum D.W., Miller W.L.: Regulation of steroidogenesis in NCI-H295 cells: a cellular model of the human fetal adrenal. *Mol. Endocrinol.*, 1993;**7**:423-433
19. Hum D.W., Staels B., Black S.M., Miller W.L.: Basal transcriptional activity and cyclic adenosine 3',5'-monophosphate responsiveness of the human cytochrome P450_{scc} promoter transfected into MA-10 Leydig cells. *Endocrinology*, 1993;**132**:546-552
20. Bristow J., Gitelman S.E., Tee M.K., Staels B., Miller W.L.: Abundant adrenal-specific transcription of the human P450_{c21A} "pseudogene". *J.Biol.Chem.*, 1993;**268**:12919-12924

21. Schoonjans K., Staels B., Grimaldi P., Auwerx J.: Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding, and liver proliferation. *Eur. J. Biochem.*, 1993;**216**:615-622
22. Schoonjans K., Staels B., Devos P., Szpirer J., Szpirer C., Deeb S., Verhoeven G., Auwerx J.: Developmental extinction of liver lipoprotein lipase mRNA expression might be regulated by an NF-1 like site. *FEBS Lett.*, 1993;**329**:89-95
23. Hoogerbrugge N., Jansen H., Staels B., Seip M.J.E., Birkenhäger J.C.: Growth hormone normalizes hepatic lipase in hypothyroid rat liver. *Metabolism*, 1993;**42**:669-671
24. Peinado-Onsurbe J., Staels B., Vanderschueren D., Bouillon R., Auwerx J.: Effects of sex steroids on hepatic and lipoprotein lipase mRNA and activity in the rat. *Hormone Res.*, 1993;**40**:184-188
25. Staels B., Lemberger T., Saladin R., Desvergne B., Auwerx J., Wahli W.: Regulation of the peroxisome proliferator activated receptor α gene by glucocorticoids. *J.Biol.Chem.*, 1994;**269**:24527-24530
26. Staels B., Berthou L., Saldicco I., Toutain H., Foster M., Fruchart J.-C., Denèfle P., Branellec D.: Opposite in vitro and in vivo regulation of hepatic apo A-I gene expression by retinoic acid. Absence of effects on apo A-II gene expression. *Arterioscler.Thromb.*, 1994;**14**:1657-1664
27. Vu-Dac N., Schoonjans K., Laine B., Fruchart J.-C., Auwerx J., Staels B.: Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the Peroxisome Proliferator Activated Receptor with its response element. *J.Biol.Chem.*, 1994;**269**:31012-31018
28. Staels B., Vu-Dac N., Kosykh V., Fruchart J.-C., Dallongeville J., Auwerx J.: Fibrates down-regulate apolipoprotein C-III expression by a mechanism independent of peroxisomal enzyme induction. A potential mechanism for the hypolipidemic action of fibrates. *J.Clin.Invest.*, 1995;**95**:705-712
29. Berthou L., Saladin R., Yaqoob P., Branellec D., Calder P., Fruchart J.-C., Denèfle P., Auwerx J., Staels B.: Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-CoA oxidase gene expression by fibrates and dietary fatty acids. *Eur.J.Biochem.* 1995;**232**:179-187
30. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.-C., Staels B., Auwerx J.: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. *J.Clin.Invest.* 1995;**96**:741-750
31. Staels B., Mehlum A., Duverger N., Tailleux A., Castro G., Fievet C., Luc G., Olivecrona G., Skretting G., Auwerx J., Prydz H.: Tissue specific expression of the human gene for lecithin : cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile. *Eur.J.Biochem.*, 1995;**230**:567-575
32. Schoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W., Grimaldi P., Staels B., Yamamoto T., Auwerx J.: Induction of the Acyl-Coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. *J.Biol.Chem.* 1995;**33**:19269-19276
33. De Vos P., Saladin R., Auwerx J., Staels B.: Induction of *ob* gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. *J.Biol.Chem.* 1995;**270**:15958-15961

34. Geffroy S., DeVos P., Staels B., Duban B., Auwerx J., de Martinville B.: Localization of the human *ob* gene to chromosome 7q32 by fluorescence in situ hybridization. *Genomics* 1995;**28**:603-604
35. Saladin R., De Vos P., Staels B., Auwerx J.: Transient increase in *obese* gene expression after food intake or insulin administration. *Nature* 1995;**377**:527-529
36. Bossu J.P., Chartier F.L., Fruchart J.-C., Auwerx J., Staels B., Laine B.: Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene. *Biochem.J.* 1996;**318**:547-553
37. Lemberger T., Saladin R., Vazquez M., Assimacopoulos F., Staels B., Desvergne B., Wahli W., Auwerx J.: Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. *J.Biol.Chem.* 1996; **271**:1764-1769
38. Berthou L., Duverger N., Emmanuel F., Langouët S., Auwerx J., Guillouzo A., Fruchart J.-C., Rubin E., Denèfle P., Staels B., Branellec D.: Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apo A-I transgenic mice. *J.Clin.Invest.* 1996;**97**:2408-2416
39. Staels B., van Tol A., Fruchart J.-C., Auwerx J.: The effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. *Isr. J.Med.Sci.* 1996;**32**:490-498
40. Casaroli Marano R.P., Peinado-Onsurbe J., Reina M., Staels B., Auwerx J., Vilaro S.: Lipoprotein lipase in highly vascularized structures of the eye. *J.Lipid Res.* 1996; **37**:1037-1044
41. Staels B., Vilaro S., Hum D.W., Reina M., Saladin R., Auwerx J.: Expression and regulation of the lipoprotein lipase gene in human adrenal cortex. *J.Biol.Chem.* 1996;**271**:17425-17432
42. Saladin R., Vu-Dac N., Fruchart J.-C., Auwerx J., Staels B.: Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile tissue-specific protein. *Eur.J.Biochem.* 1996;**239**:451-459
43. Schoonjans K., Peinado-Onsurbe J., Heyman R.A., Briggs M., Cayet D., Deeb S., Staels B., Auwerx J.: PPAR α and PPAR γ activators direct a tissue-specific response via a PPRE in the lipoprotein lipase gene. *EMBO J.* 1996;**15**:5336-5348
44. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Staels B., Auwerx J.: Retinoids increase human apolipoprotein A-II expression through activation of the Retinoid X Receptor but not the Retinoic Acid Receptor. *Mol.Cell.Biol.* 1996;**16**:3350-3360
45. Vidal H., Auboeuf D., De Vos P., Staels B., Riou J.P., Auwerx J., Laville M.: The expression of *ob* gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. *J.Clin.Invest.* 1996;**98**:251-255
46. Miller S. De Vos P., Guerre-Millo M., Wong K., Hermann T., Staels B., Briggs M., Auwerx J.: The adipocyte specific transcription factor C/EBP α modulates human *ob* gene expression. *Proc.Natl.Acad.Sci.USA* 1996;**93**:5507-5511

47. De Vos P., Lefebvre A.-M., Miller S.G., Guerre-Millo M., Wong K., Saladin R., Hamann L., Staels B., Briggs M.R., Auwerx J.: Thiazolidinediones repress *ob* gene expression via activation of PPAR γ . *J.Clin.Invest.* 1996;**98**:1004-1009
48. Hoogerbrugge N., Jansen H., Staels B., Kloet L.T., Birkenhäger J.C.: Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. *Metabolism*; 1996;**45**:680-685
49. Rodriguez H., Hum D.W., Staels B., Miller W.L.: Transcription of the human genes for cytochrome P450 $c17$ and P450 $c11$ is regulated differently in human adrenal NCI-H295 cells than in mouse adrenal Y1 cells. *J.Clin.Endocrinol.Metab.* 1997;**82**:365-371
50. Lefebvre A.-M., Peinado-Onsurbe J., Leitersdorf I., Briggs M.R., Paterniti J.R., Fruchart J.-C., Fievet C., Auwerx J., Staels B.: Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. *Arterioscler.Thromb.Vasc.Biol.* 1997;**17**:1756-1764
51. Froyland L., Madsen L., Vaagenes H., Totland G.K., Auwerx J., Kryvi H., Staels B., Berge R.: Mitochondrion is the principal target for nutritional and pharmacological regulation of triglyceride metabolism. *J.Lipid Res.* 1997;**38**:1851-1858
52. Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., Laville M., Staels B., Auwerx J., Vidal H.: Tissue distribution and quantification of the expression of the peroxisome proliferator activated receptors and of LXR α mRNAs in human: effect of obesity and NIDDM in adipose tissue. *Diabetes* 1997;**46**:1319-1327
53. Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.-M., Saladin R., Najib J., Laville M., Fruchart J.-C., Deeb S., Vidal-Puig A., Flier J., Briggs M.R., Vidal H., Staels B., Vidal H., Auwerx J.: The human PPAR γ gene: organization, promoter analysis, and expression. *J.Biol.Chem.* 1997;**272**:18779-18789
54. Vu-Dac N., Grötzinger T., De Vos P., Schoonjans K., Fruchart J.-C., Mariani J., Tedgui A., Auwerx J., Staels B.: Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor ROR α . *J.Biol.Chem.* 1997;**272**:22401-22404
55. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., Auwerx J.: Alterations in lipoprotein metabolism in PPAR α -deficient mice. *J.Biol.Chem.* 1997;**272**:27307-27312
56. Martin G., Schoonjans K., Lefebvre A.-M., Staels B., Auwerx J.: Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl-CoA synthetase (ACS) genes by PPAR α and PPAR γ activators. *J.Biol.Chem.* 1997;**272**:28210-28217
57. Fajas L., Staels B., Auwerx J.: Cycle sequencing on large DNA templates. *BioTechniques* 1997;**23**:1034-1036
58. van Vlijmen B.J.M., Pearce N.J., Bergö M., Staels B., Yates J.W., Gribble A.D., Stylianou A., Hofker M.H., Havekes L.M., Groot P.H.E.: Apolipoprotein E3-Leiden transgenic mice as a test model for hypolipidemic drugs. *Arzneimittelforschung* 1998;**48**:396-402
59. Staels B., Koenig W., Habib A., Merval R., Lebret M., Pineda Torra I., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A.: Activation of human aortic smooth-muscle cells by PPAR α , but not by PPAR γ activators. *Nature* 1998;**393**:790-793

60. Mamontova A., Duverger N., Séguret-Macé S., Esposito B., Chanial C., Delhay-Bouchaud N., Staels B., Mariani J., Tedgui A.: Severe atherosclerosis and hypoalphalipoproteinemia in the *staggerer* mouse, a mutant of ROR α gene. *Circulation* 1998;**98**:2738-2743
61. Vu-Dac N., Gervois P., Pineda-Torra I., Fruchart J.-C., Kosykh V., Kooistra T., Princen H.M.G., Dallongeville J., Staels B.: Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. *J.Clin.Invest.* 1998;**102**:625-632
62. Edgar A.D., Tomkiewicz C., Costet P., Legendre C., Aggerbeck M., Bouguet J., Staels B., Guyomard C., Pineau T., Barouki R.: Fenofibrate modifies transaminase gene expression via a PPAR α -dependent pathway. *Toxicol.Lett.* 1998;**98**:13-23
63. Vu-Dac N., Chopin-Delannoy S., Gervois P., Bonnelye E., Martin G., Schoonjans K., Fruchart J.-C., Laudet V., Staels B.: The nuclear receptors PPAR α and Rev-erb α mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. *J.Biol.Chem.* 1998;**273**:25713-25720
64. Chinetti G., Griglio S., Antonucci M., Pineda-Torra I., Delerive Ph., Majd Z., Fruchart J.-C., Chapman J., Najib J., Staels B.: Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. *J.Biol.Chem.* 1998;**273**:25573-25580
65. Kockx M., Gervois P.P., Poulain P., Derudas B., Peters J.M., Gonzalez F.J., Princen H.M.G., Kooistra T., Staels B.: Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor- α . *Blood* 1999;**93**:2991-2998
66. Gervois P., Chopin-Delannoy S., Fadel A., Dubois G., Kosykh V., Fruchart J.-C., Najib J., Laudet V., Staels B.: Fibrates increase human Rev-erb α expression in liver via a novel PPAR response element. *Mol.Endocrinol.* 1999;**13**:400-409
67. Andersson Y., Zouher Majd, Lefebvre A.-M., Martin G., Sechkin A.V., Kosykh V., Fruchart J.-C., Jamila Najib, Staels B.: Developmental and pharmacological regulation of apolipoprotein C-II gene expression. Comparison with apo C-I and apo C-III gene regulation. *Arterioscler.Thromb.Vasc.Biol.* 1999;**19**:115-121
68. Martin G., Pilon A., Albert C., Vallé M., Hum D.W., Fruchart J.C., Najib J., Clavey V., Staels B.: Comparison of expression and regulation of the high density lipoprotein receptor SR-BI and the LDL-receptor in human adrenocortical carcinoma NCI-H295 cells. *Eur.J.Biochem.* 1999;**261**:481-491
69. Hennuyer N., Poulain P., Madsen L., Berge R., Houdebine L.-M., Branellec D., Fruchart J.-C., Fievet C., Duverger N., Staels B.: The beneficial effects of fibrates on high density lipoprotein metabolism occur independent of any peroxisome proliferative response. *Circulation* 1999;**99**:2445-2451
70. Clavey V., Copin C., Mariotte M.C., Baugé E., Chinetti G., Fruchart J., Fruchart J.-C., Dallongeville J., Staels B.: Cell culture conditions determine apolipoprotein C-III secretion and regulation by fibrates in human hepatoma HepG2 cells. *Cell.Physiol.Biochem.* 1999;**9**:139-149
71. Asset G., Staels B., Wolff R.L., Baugé E., Fruchart J.C., Dallongeville J.: Effects of delta5-olefinic acids from *Pinus pinaster* and *Pinus koraiensis* seed oils on lipoprotein metabolism in rats. *Lipids* 1999;**34**:39-44

72. Neele D.M., Buytenhek R., Staels B., Dallongeville J., Wallnöfer A.E., Kooistra T., Princen H.M.G.: No short-term effect of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LpA-I and LpA-I:A-II in healthy volunteers. *Ann.Intern.Med.* 1999;**246**:120-122
73. Gervois P., Pineda Torra I., Chinetti G., Grötzinger T., Dubois G., Fruchart J.-C., Fruchart-Najib J., Leitersdorf E., Staels B.: A truncated human PPAR α splice variant with dominant negative activity. *Mol.Endocrinol.* 1999;**13**:1535-1549
74. Bernard C., Merval R., Lebret M., Delerive P., Dusanter-Fourt I., Lehoux L., Créminon C., Staels B., Maclouf J., Tedgui A.: Oncostatin M Induces Interleukin-6 and cyclooxygenase-2 expression in human vascular smooth muscle cells : synergy with interleukin-1 β . *Circulation Res.* 1999;**85**: 1124-1131
75. Raspé E., Madsen L., Lefebvre A.-M., Leitersdorf I., Gelman L., Peinado-Onsurbe J., Dallongeville J., Fruchart J.-C., Berge R., Staels B.: Modulation of liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPAR α activation. *J.Lipid Res.* 1999;**40**:2099-2110
76. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J., Gonzalez F.J., Fruchart J.-C., Tedgui A., Haegeman G., Staels B.: Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- κ B and AP-1. *J.Biol.Chem.* 1999;**274**:32048-32054
77. Trottein F., Nutten S., Angeli V., Delerive P., Teissier E., Capron A., Staels B., Capron M.: *Schistosoma mansoni* schistosomula reduce E-selectin and VCAM-1 expression in TNF- α -stimulated lung microvascular endothelial cells by interfering with the NF- κ B pathway. *Eur.J.Immunol.* 1999;**29**:3691-3701
78. Beghin L., Capps N., Duhal N., Davies J., Staels B., Luc G.: Metabolism of apolipoproteins A1 and A11 in a patient with paradoxical reduction in HDL due to ciprofibrate. *Ann.Clin.Biochem.* 1999;**36**:523-525
79. Delerive P., Martin-Nizard F., Chinetti G., Trottein F., Fruchart J.-C., Najib J., Duriez P., Staels B.: Peroxisome Proliferator-Activated Receptor Activators Inhibit Thrombin-Induced Endothelin-1 Production in Human Vascular Endothelial Cells by Inhibiting the Activator Protein-1 Signaling Pathway. *Circulation Res.* 1999;**85**:394-402
80. Mallat Z., Besnard S., Duriez M., Deleuze V., Emmanuel F., Bureau M.F., Soubrier F., Esposito B., Duez H., Fievet C., Staels B., Duverger N., Scherman D., Tedgui A.: Protective role of Interleukin-10 in Atherosclerosis. *Circ. Res.* 1999;**85**:e17-e24
81. Delerive P., Furman C., Teissier E., Fruchart J.C., Duriez P., Staels B. : Oxidized phospholipids activate PPAR α in a phospholipase A2-dependent manner. *FEBS Lett.* 2000;**471**:34-38
82. Flavell D.M., Pineda Torra I., Jamshidi Y., Evans D., Diamond J.R., Elkeles R.S., Bujac S.R., Miller G., Talmud P.J., Staels B., Humphries S.E.: Variation in the peroxisome proliferator-activated receptor alpha gene is associated with altered function *in vitro* and plasma lipid concentrations in type 2 diabetic subjects. *Diabetologia* 2000;**43**:673-680
83. Guerre-Millo M., Gervois P., Raspé E., Madsen L., Poulain P., Derudas B., Herbert J.-M., Winegar D.A., Willson T.M., Fruchart J.-C., Berge R.K., Staels B.: PPAR α activators improve insulin sensitivity and reduce adiposity. *J.Biol.Chem.* 2000;**275**:22- 16638-16642

84. Chinetti G., Gbaguidi F., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J.-C., Tedgui A., Najib-Fruchart J., Staels B.: CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. *Circulation* 2000; 101: 2411-2417
85. Pineda Torra I., Tsibulsky V., Delaunay F., Saladin R., Laudet V., Fruchart J.C., Kosykh V., Staels B.: Circadian and glucocorticoid regulation of Rev-erba expression in liver. *Endocrinology* 2000, 141,10:3799-3806
86. Delerive P., Gervois P., Fruchart J.C., Staels B. : Induction of Ikb α expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor- α activators. *J.Biol.Chem.* 2000, 275:47:36703-36707
87. Lacquemant C., Lepretre F., Pineda Torra I., Manraj M., Charpentier G., Ruiz J., Staels B., Froguel Ph. : Mutation screening of the PPAR α gene in type 2 diabetes associated with coronary heart disease. *Diab. Metab.* 2000, 26 : 393-401
88. Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti G, Gosset P, Delerive P, Maliszewski C, Capron M, Staels B, Moser M, Trottein F : PPAR γ activators inhibit interleukin-12 production in murine dendritic cells. *Febs Lett.* 2000, 486 : 261-266
89. Chinetti G., Lestavel S., Bocher V., Remaley A., Neve B., Pineda Torra I., Teissier E., Minnich A., Jaye M., Duverger N., Brewer HB., Fruchart J.C., Clavey V., Staels B. : PPAR α and PPAR γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABC1 pathway. *Nature Med.* 2001, 7(1): 53-58
90. Raspé E., Duez H., Gervois Ph., Fievet C., Fruchart J.C., Besnard S., Mariani J., Tedgui A., Staels B. : Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor ROR α . *J.Biol.Chem.*, 2001;276,4:2865-2871
91. Delerive P., Monte D., Dubois G., Trottein F., Fruchart J., Mariani J., Fruchart J.C., Staels B. : The orphan nuclear receptor ROR α is a negative regulator of the inflammatory response. *EMBO Rep.* 2001, 2(1) / 42-48
92. Neve B.P., Corseaux D., Chinetti G., Zawadzki C., Fruchart J.-C., Duriez P., Staels B., Jude B.: PPAR α agonists inhibit tissue factor expression in human THP-1 cells, monocytes and macrophages. *Circulation*, 2001;103:207-212
93. Junquero D., Pilon A., Carilla-Durand E., Patoiseau J.-F., Tarayre J.-P., Torpier G., Staels B., Fruchart J.-C., Colpaert F.C., Clavey V., Delhon A.: Lack of toxic effects of F12511, a novel potent ACAT inhibitor of acylcoenzyme A : cholesterol O-acyltransferase, on human adrenocortical cells in culture. *Biochem.Pharmacol.* 2001, 61:387-398
94. Hourton D., Delerive P., Stankova J., Staels B., Chapman J., Ninio E.: Oxidised low density lipoprotein and peroxisome proliferator activated receptor a down-regulate PAF receptor expression in human monocyte macrophages. *Biochem.J.* 2001, 354 :225-232
95. Dallongeville J., Baugé E., Tailleux A., Peinado J., Peters J.M., Gonzalez F.J., Fruchart J.C., Staels B. : Peroxisome proliferator activated receptor α is not rate limiting for the lipoprotein-lowering action of fish oil. *J.Biol.Chem.*, 2001;276(7):4634-4639

96. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart JC., Fruchart J., Glineur C., Staels B. : Statins induced inhibition of the Rho-signaling pathway activates PPAR α and induces HDL Apo A-I. *J.Clin.Invest.* 2001; 107(11) : 1423-1432
97. Dol F., Mares A.M., Martin G., Staels B., Mares A-N., Cazaubon C., Nisato D., Bidouard JP., Janiak Ph., Schaeffer P., Herbert J.M. : Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression and macrophage accumulation in apolipoprotein E-deficient mice. *J. Cardiovasc. Pharmacol.* 2001, 38(3) : 395-405
98. Gervois P., Vu-Dac N., Kleemann R., Kockx M., Dubois G., Laine B., Kosykh V., Fruchart JC., Kooistra T., Staels B. : Negative regulation of human fibrinogen gene expression by PPAR α agonists via inhibition of CCAAT box/enhancer-binding protein β . *J.Biol.Chem.* 2001, 276(36) : 33471-33477
99. Baroukh N., Ostos MA., Vergnes L., Recalde D., Staels B., Fruchart JC., Ochoa A., Castro G., Zakin MM : Expression of human Apolipoprotein A-I/C-III/A-IV gene cluster in mice reduces atherogenesis in response to a high fat-high cholesterol diet. *Febs Lett.* 2001, 502(1,2) : 16-20
100. Singaraja R., Bocher V., James ER., Clee SM., Zhang L-H., Leavitt BR., Brooks-Wilson A., Kwok A., Yang Y-Z., Liu G., Wellington CL., Fievet C., Staels B., Hayden MR. : Human ABCA1 BAC transgenic mice show increased HDL-C and Apo AI dependent efflux stimulated by an internal promoter containing liver X receptor response elements in Intron 1. *J.Biol.Chem.* 2001, 276 (36) : 33969-33979
101. Akiyama T., Nicol CJ., Fievet C., Staels B., Ward JM., Auwerx J., ST Lee S., Gonzalez FJ., Peters JM : PPAR α regulates lipid homeostasis but is not associated with obesity studies with congenic mouse lines. *J.Biol.Chem.*, 2001, 276 (42) : 39088-39093
102. Angeli V., Faveeuw C., Delerive P., Fontaine J., Barriera Y., Franchimont N., Staels B., Capron M., Trottein F.: *Schistosoma mansoni* induces the synthesis of interleukin-6 in pulmonary microvascular endothelial cells : role of IL-6 in the control of lung eosinophilia during infection. *Eur. J. Immunol.* 2001, 31(9) : 2751-2761
103. Gosset Ph., Charbonnier A-S., Delerive Ph., Fontaine J., Staels B., Pestel A., Tonnel A-B., Trottein F. : PPAR γ activators affect the maturation of human monocyte-derived dendritic cells. *Eur. J. Immunol.* 2001, 31(10) : 2857-2865
104. Post S.M., Duez H., Gervois P., Staels B., Kuipers F., Princen H.M.G. : Fibrates suppress bile acid synthesis via PPAR α -mediated down-regulation of cholesterol 7 α -hydroxylase and sterol 27-hydroxylase gene expression. *Arterioscler.Thromb.Vasc.Biol.* 2001, 21 : 1840-1845
105. Guerre-Millo M., Rouault C., Poulain P., André J., Poitout V., Peters JM., Gonzalez FJ., Fruchart JC., Reach G., Staels B. : PPAR α -null mice are protected from high fat diet-induced insulin resistance. *Diabetes* 2001, 50 : 2809-2814
106. Morton NM., Holmes MC., Fievet C., Staels B., Tailleux A., Mullins JJ., Seckl JR. : Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11 β -hydroxysteroid dehydrogenase type 1 null mice. *J.Biol.Chem.* 2001, 276 (44) : 41293-41300
107. Lehto M., Laitinen S., Chinetti G., Johansson M., Ehnholm C., Staels B., Ikonen E., Olkkonen VM. : The OSBP-related protein family in humans. *J. Lipid Res.* 2001, 42 : 1203-1213

108. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G : Induction of the Phospholipid Transfer Protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. *J. Biol. Chem* 2001, 276(28) : 25841-25847
109. Gbaguidi F.G., Chinetti G., Milosavljevic D., Teissier E., Chapman J., Olivecrona G., Fruchart J.-C., Griglio S., Fruchart-Najib J., Staels B.: PPAR agonists decrease lipoprotein lipase secretion and glycated-LDL uptake by human macrophages. *Febs Lett.* 2002, 512 : 85-90
110. Jamshidi Y., Montgomery H., Hense HW., Myerson S., Pineda Torra I., Staels B., World M., Doering A., Erdmann J., Hengstenberg C., Humphries S., Schunkert H., Flavell D. : The peroxisome proliferator activated receptor alpha (PPAR α) gene regulates left ventricular growth in response to exercise and hypertension. *Circulation* 2002, 105 : 950-955
111. Claudel T., Sturm E., Duez H., Pineda-Torra I., Sirvent A., Kosykh V., Fruchart JC., Dallongeville J., Hum WD., Kuipers F., Staels B. : Bile acid-bound nuclear receptor FXR suppresses apolipoprotein A-I transcription via an FXR negative response element. *J.Clin.Invest.* 2002, 109 : 961-971
112. Delerive P., De Bosscher K., Vanden Berghe W., Fruchart JC., Haegeman G., Staels B. : DNA-binding independent induction of I κ B α gene transcription by PPAR α . *Mol.Endocrinol.* 2002, 16(5) : 1029-1039
113. Madsen L., Guerre-Millo M., Flint E.N., Berge K., Tronstad KJ., Bergene E., Sebokova E., Rustan A.C., Jensen J., Mandrup S., Kristiansen K., Klimes I., Staels B., Berge R.K.: Tetradecylthioacetic acid prevents high fat diet induced adiposity and insulin resistance. *J.Lipid.Res.* 2002, 43 : 742-750
114. Khandoudi N., Delerive P., Berrebi-Bertrand I., Buckingham R., Staels B., Bril A. : Rosiglitazone, a PPAR γ activator, inhibits the Jun NH2-Terminal kinase/activating protein 1 pathway and protects the heart from ischaemia-reperfusion injury. *Diabetes* 2002, 51: 1507-1514
115. Pineda Torra I., Jamshidi Y., Flavell D., Fruchart JC., Staels B. : Characterization of the human PPAR α promoter: identification of a functional nuclear receptor response element. *Mol.Endocrinol.* 2002 (16) 1013-1028
116. Blanquart C., Barbier O., Fruchart JC., Staels B., Glineur C. : PPAR α turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. *J.Biol.Chem.* 2002 (277) : 37254-37259
117. Singaraja R., Fievet C., Castro G., James ER., Hennuyer N., Mclee S., Bissada N., Choy JC., Fruchart JC., McManus BM., Staels B., Hayden MR : Increased ABCA1 activity protects against atherosclerosis. *J.Clin.Invest.* 2002, 110 (1) : 35-42
118. Kandoussi A., Martin F., Hazzan M., Noël C., Fruchart JC., Staels B., Duriez P. : HMG CoA reductase inhibition and PPAR α activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. *Clin. Sci.* 2002 (103) : 81S-83S
119. Flavell DM, Jamshidi Y., Hawe E., Pineda Torra I., Taskinen MR., Frick H., Nieminen MS., Kesäniemi YA., Pasternack A., Staels B., Humphries SE., Talmud PJ., Path FRC., Syväne M. : PPAR α gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. *Circulation* 2002 (105) : 1440-1445

120. Darteil R., Wang M., Latta-Mahieu M., Caron A., Mahfoudi A., Staels B., Thuillier V. : Efficient gene regulation by PPAR γ and thiazolidinediones in skeletal muscle and heart. *Mol. Ther.* 2002, 6(2) : 265-271
121. Clément L., Poirier H., Niot I., Bocher V., Guerre-Millo M., Staels B., Besnard P. : Dietary trans-10, cis-12 conjugated linoleic acid (CLA) induces hyperinsulinemia and fatty liver in the mouse. *J. Lipid. Res.* 2002 (43) : 1400-1409
122. Meir K., Kitsberg D., Alkalay I., Szafer F., Rosen H., Shpitzen S., Ben Avi L., Staels B., Fievet C., Meiner V., Bjorkhem I., Leitersdorf E. : Human sterol 27-hydroxylase (Cyp27) overexpressor transgenic mouse model. Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis. *J. Biol. Chem.* 2002 (277) : 34036-34041
123. Gizard F., Lavallée B., Dewitte F., Teissier E., Staels B., Hum D. : The transcriptional regulating protein of 132 kDa (TreP-132) enhances P450sc gene transcription through interaction with steroidogenic factor-1 in human adrenal cells. *J. Biol. Chem.* 2002 (277) : 39144-39155
124. Martin-Nizard F., Furman C., Delerive P., Kandoussi A., Fruchart JC., Staels B., Duriez P. : PPARs inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. *J Cardiovasc. Pharmacol.* 2002; 40(6) : 822-831
125. Gizard F., El-Alfy M., Duguay Y., Lavallee B., DeWitte F., Staels B., Beatty BG., Hum DW : Function of the transcriptional regulating protein of 132kDa (TreP-132) on human P450sc gene expression. *Endocr. Res.* 2002; 28(4) : 559-574
126. Raspé E., Duez H., Mansen A., Fontaine C., Fiévet C., Fruchart J.-C., Vennström B., Staels B.: Identification of Rev-erb α as a physiological repressor of apolipoprotein C-III gene transcription. *J. Lipid Res.* 2002 (43) : 2172-2179
127. Raspe E., Mautino G., Duval C., Fontaine C., Duez H., Barbier O., Monte D., Fruchart J., Fruchart JC., Staels B. : Transcriptional regulation of human Rev-erb α gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor α . *J.Biol.Chem.* 2002 (277)51 : 49275-49281
128. Kintscher U., Lyon C., Wakino S., Bruemmer D., Feng X., Goetze S., Graf K., Moustakas S., Staels B., Fleck E., Hsueh WA., Law RE. : PPAR α inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. *Circ. Res.* 2002; 91(11) : e35-e44
129. Sturm E., Franssen C., Gouw A, Staels B., Boverhof R., De Knegt R., Stellaard F., Bijleveld C., Kuipers F. : Extracorporeal albumin dialysis (MARCH) improves cholestasis and normalizes low apo A-I levels I a patient with benign recurrent intrahepatic cholestasis (BRIC). *Liver* 2002 (supl2) : 72-75
130. Duez H., Chao YS., Hernandez M., Torpier G., Poulain P., Mundt S., Mallat Z., Teissier E., Burton CA., Tedgui A., Fruchart JC., Fievet C., Wright S. Staels B. : Reduction of atherosclerosis by PPAR α agonist fenofibrate in mice. *J.Biol.Chem.* 2002;277(50) : 48051-48057
131. Kleemann R., Gervois P., Verschuren L., Staels B., Princen H., Kooistra T. : Fibrates down-regulate IL-1 stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear P50-NF κ B ~C/EBP- β complex formation. *Blood* 2003; 101(2) : 545-551

132. Kok, T., Bloks VW., Wolters H., Havinga R., Jansen P., Staels B., Kuipers F. : PPARalpha mediated regulation of MDR2 expression and function in mice. *Biochem. J.* 2003 (369) : 539-547
133. Pineda-Torra I., Claudel T., Duval C., Kosykh V., Fruchart JC., Staels B. : Bile acids induce the expression of the human PPAR α gene via activation of the farnesoid X receptor. *Mol. Endocrinol.* 2003; 17(2) : 259-272
134. Kok T., Wolters H., Bloks VW., Havinga R., Jansen LM P., Staels B., Kuipers F. : Induction of hepatic ABC transporter expression is part of the PPARalpha mediated fasting response in the mouse. *Gastroenterology* 2003; 124(1) : 160-171
135. Devos S., De Bosscher K., Staels B., Bauer E., Roels F., Berghe W., Haegeman G., Hooghe-Peters EL. : Inhibition of cytokine production by the herbicide atrazine. Search for nuclear receptor targets. *Biochem. Pharmacol.* 2003; 65(2) : 303-308
136. Johansson M., Bocher V., Lehto M., Chinetti G., Kuismanen E., Ehnholm C., Staels B., Olkkonen V. : The two variants of OSBP-related protein-1 (ORP1) display different tissue expression patterns, have different intracellular localization, and are functionally distinct. *Mol. Biol. Cell* 2003, 14 (3) : 903-915
137. Mardones P., Pilon A., Bouly M., Duran D., Nishimoto T., Arai H., Kozarsky KF., Altayo M., Miquel JF., Luc G., Clavey V., Staels B., Rigotti A : Fibrates down-regulate hepatic scavenger receptor class B type I (SR-BI) protein expression in mice. *J Biol. Chem.* 2003, 278 (10) : 7884-7890
138. Pilon A., Martin G., Bultel S., Junquero D., Delhon A., Fruchart JC., Staels B., Clavey V. : Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. *Biochim. Biophys. Acta* 2003, 1631 (3) : 218-228
139. Chinetti G., Lestavel S., Fruchart JC., Clavey V., Staels B. : PPAR α reduces cholesterol esterification in macrophages. *Circ. Res.* 2003 92 (2) :212-217
140. Gilde AJ., Van Der Lee K., Willemsen P., Chinetti G., Van Der Leij FR., Van Der Vusse GJ., Staels B., Van Bilsen M. : Both PPAR α and PPAR β/δ , but not PPAR γ , modulate the expression of genes involved in cardiac lipid metabolism. *Circ. Res.* 2003, 92 (5) : 518-524
141. Barbier O., Villeneuve L., Bocher V., Fontaine C., Pineda-Torra I., Duhem C., Kosykh V., Fruchart JC., Guillemette C., Staels B. : The UDP-glucuronosyltransferase 1A9 enzyme is a PPARalpha and gamma target gene ». *J. Biol. Chem.* 2003, 278 (16) : 13975-13983
142. Vu-Dac N., Gervois P., Jakel H., Nowak M., Bauge E., Dehondt H., Staels B., Pennacchio L., Rubin E., Fruchart J., Fruchart JC : Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to PPAR α activators. *J. Biol. Chem.* 2003, 278(20) : 17982-17985
143. Pellegatta F., Bertelli AA., Staels B., Duhem C., Fulgenzi A., Ferrero ME : Different short and long term effects of resveratrol on nuclear factor kappaB phosphorylation and nuclear appearance in human endothelial cells. *Am. J. Clin. Nutr.* 2003, 77(5) : 1220-1225
144. Angeli V., Hammad H., Staels B., Capron M., Lambrecht BN., Trottein F. : PPARgamma inhibits the migration of dendritic cells : consequences for the immune response. *J. Immunol.* 2003, 170(10) : 5295-5301

145. Barbier O., Pineda-Torra I., Sirvent A.; Claudel T., Blanquart C., Duran-Sandoval D., Kuipers F., Kosykh V., Fruchart JC, Staels B. : FXR induces the Uridine 5'-Disphosphate-glucuronosyltransferase 2B4 enzyme in hepatocytes : a potential mechanism of negative feedback control of Farnesoid X Receptor activity. *Gastroenterology* 2003; 124 (7) :1926-1940
146. Claudel T., Inoue Y., Barbier O., Duran-Sandoval D., Kosykh V., Fruchart J., Fruchart JC., Gonzalez F., Staels B. : Farnesoid X Receptor agonists suppress hepatic apolipoprotein CIII expression. *Gastroenterology* 2003; 125(2) : 544-555
147. Woerly G., Capron M., Honda K., Loyens M., Papin JP., Auwerx J., Staels B., Dombrowicz D. : PPARalpha and gamma down-regulate allergic inflammation and eosinophil activation. *J. Exp. Med.* 2003, 198 (3) : 411-421
148. Westergaard M., Henningsen J., Johansen C., Rasmussen S., Svendsen ML., Jensen UB., Daa Shroder H., Staels B., Iversen L., Bolund L., Kragballe K, Kristiansen K. : Expression and localization of PPARs and NF-kB in normal and lesional psoratic skin. *J. Invest. Dermatol.* 2003, 121(5):1104-1117
149. Deplanque D., Gelé P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart JC., Cecchelli R., Staels B., Duriez P., Bordet R. : PPARalpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. *J. Neurosci.* 2003, 23(15) : 6564-6271
150. Fontaine C., Dubois G., Duguay Y., Helledie T., Vu-Dac N., Gervois P., Soncin P., Mandrup S., Fruchart JC., Fruchart-Najib J., Staels B. : The orphan nuclear receptor Rev-Erb α is a PPAR γ target gene and promotes PPAR γ -induced adipocyte differentiation. *J Biol.Chem.* 2003, 278(39) : 37672-37680
151. Barbier O., Duran-Sandoval D., Pineda-Torra I., Kosykh V., Fruchart JC., Staels B. : PPAR alpha induces hepatic expression of the human bile acid glucuronidating UGT2B4 enzyme. *J. Biol.Chem.* 2003, 278(35) : 32852-32860
152. Froment P., Fabre S., Dupont J., Pisselet C., Chesneau D., Staels B., Monget P. : Expression and functional role of PPAR γ in ovarian folliculogenesis in the sheep. *Biol. Reprod.* 2003, 69(5) : 1665-1674
153. Barbier O., Guillemette C., Staels B. : Fibrates and glitazones stimulate fibrate metabolism through PPAR dependent Up-Regulation of the drug metabolizing UGT1A9 enzyme. *Int. Soc. Study Xenobiotics* 2003, 23(2) : 8-10
154. Chinetti G., Zawadski C., Fruchart JC., Staels B: Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPAR α , PPAR γ and LXR. *Biochem. Biophys. Res. Commun.* 2004; 314(1):151-158
155. Martin G., Dol F., Mares AM., Berezowski V., Staels B., Hum DW., Schaeffer P., Herbert JM. : Lesion progression in apoE-deficient mice: implication of chemokines and effect of the AT1 angiotensin II receptor antagonist irbesartan. *J. Cardiovasc. Pharmacol.* 2004; 43(2):191-199
156. Masson D., Staels B., Gautier T., Desrumaux C., Ahias A., Le Guern N., Schneider M., Zak Z., Dumont L., Deckert V., Tall A., Jiang XC., Lagrost L. : Cholesteryl ester transfer protein (CETP) modulates the effect of LXR agonists on cholesterol transport and excretion in the mouse. *J. Lipid Res.* 2004, 45:543-550

157. Meissner M., Stein M., Urbich C., Reisinger K., Suske G., Staels B., Kaufmann R., Gille J. : PPAR α activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. *Circ. Res.* 2004, 94(3):324-332
158. Gizard F, Teissier E, Dufort I, Luc G, Luu-The V, Staels B., Hum D: The transcriptional regulating protein of 132kDa (TreP-132) differentially influences steroidogenic pathways in human adrenal NCI-H295 cells. *J. Mol. Endocrinol.* 2004;32(2):557-569
159. Luc G., Jacob N., Bouly M., Fruchart J.C., Staels B., Giral P.: Fenofibrate increases homocysteinemia through a PPAR α -mediated mechanism. *J. Cardiovasc. Pharmacol.* 2004;43(3):452-453
160. Bandsma R., Van Dijk T., Harmsel A., Kok T., Reijngoud DJ., Staels B., Kuipers F. : Hepatic de novo synthesis of glucose-6-phosphate is not affected in PPAR α deficient mice but is preferentially directed towards hepatic glycogen stores after a short-term fast. *J. Biol. Chem.* 2004;279(10):8930-8937
161. Paterson JM., Morton MN., Fievet C., Kenyon CJ., Holmes MC., Staels B., Seckl JR., Mullins JJ.: Metabolic syndrome without obesity : hepatic over-expression of 11 β -Hydroxysteroid Dehydrogenase Type 1 in transgenic mice. *Proc. Natl. Acad. Sci. USA* 2004;101(18):7088-7093
162. Gervois P., Kleemann R., Pilon A., Percevault F., Koenig W., Fruchart JC., Staels B., Kooistra T. : Global suppression of the IL-6 induced acute phase response gene expression after chronic in vivo treatment with the PPAR α activator fenofibrate. *J. Biol. Chem.* 2004, 279 :16154-16160
163. Duran-Sandoval D., Mautino G., Martin G., Percevault F., Barbier O., Fruchart JC., Kuipers F., Staels B. : Glucose regulates the expression of the Farnesoid X Receptor in Liver. *Diabetes* 2004;53(4):890-898
164. Morton MN., Paterson JM., Masuzaki H., Holmes MC., Staels B., Fievet C., Walker BR., Flier JS., Mullins JJ., Seckl JR.: Novel adipose tissue-mediated resistance to diet-induced visceral obesity 11 beta-hydroxysteroid dhydrogenase type 1-deficient mice. *Diabetes* 2004;53(4):931-938
165. Mavri A., Bastelica D., Staels B., El Ayachi S., Juhan-Vague I., Alessi MC. : PPAR α deficiency does not modify age dependency but prevents high diet increase in plasma PAI-1 as well as insulin resistance. *Thromb. Haemost.* 2004;91(5):1051-1052
166. Blanquart C., Mansouri R., Paumelle R., Fruchart JC., Staels B., Glineur C. : The protein kinase C signalling pathway regulates a molecular switch between transactivation and transrepression activity of PPARalpha. *Mol. Endocrinol.* 2004;18(8):1906-1918
167. Sirvent A., Claudel T., Martin G., Brozek J., Kosykh V., Darteil R., Hum D., Fruchart JC., Staels B. : The Farnesoid X receptor induces very low density lipoprotein receptor gene expression. *Febs Lett.* 2004;566(1-3):173-177
168. Blanquart C., Mansouri R., Fruchart JC., Staels B., Glineur C. : Different ways to regulate the PPAR α stability. *Biochem. Biophys. Res. Commun.* 2004;319(2):663-670
169. Temelkova-Kurktschiev T., Hanefeld M., Chinetti G., Zawadzki C., Haulon S., Kubaszek A., Koehler C., Leonhardt W., Staels B., Laakso M. : A1a12A1a genotype of the PPARgamma2 protects against atherosclerosis. *J. Clin. Endocrinol. Metab.* 2004;89(9):4238-4242

170. Huss J., Pineda-Torra I., Staels B., Giguere V., Kelly DP. : ERR α directs PPAR α signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. *Mol. Cell. Biol.* 2004;24(20):9079-9091
171. Landrier JF., Thomas C., Grobert J., Duez H., Percevault F., Souidi M., Linard C., Staels B., Besnard P. : Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is Peroxisome Proliferator-activated Receptor- α -dependent. *J. Biol. Chem.* 2004;279(44):45512-45518
172. Sirvent A., Verhoeven AJM., Jansen H., Kosykh V., Darteil R., Hum D., Fruchart JC., Staels B. : Farnesoid X Receptor represses hepatic lipase gene expression. *J. Lipid Res.* 2004;45:2110-2115
173. Teissier E., Nohara A., Chinetti G., Paumelle R., Cariou B., Fruchart JC., Brandes RP., Shah A., Staels B. : PPAR α induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR- α activation properties. *Circ. Res.* 2004;95:1174-1182
174. Desmet C., Warzée B., Gosset P., Mélotte D., Rongvaux A., Gillet L., Fiévez L., Seumois G., Vanderplasschen A., Staels B., Lekeux P., Bureau F. : Pro-inflammatory properties for thiazolidinediones. *Biochemical Pharmacology* 2005,69:255-265
175. Barbier O, Girard H, Inoue Y, Duez H, Villeneuve L, Kamiya A, Fruchart JC, Guillemette C, Gonzalez F, Staels B : Hepatic expression of the UGT1A9 gene is governed by HNF4 α . *Mol. Pharmacol.* 2005,67(1):241-249
176. Nowak M., Helleboid-Chapman A., Jakel H., Martin G., Duran-Sandoval D., Staels B., Rubin EM., Pennacchio LA., Taskinen MR., Fruchart-Najib J., Fruchart JC. : Insulin mediated down-regulation of the Apolipoprotein A5 gene expression through the Phosphatidylinositol 3-kinase pathway : Role of the upstream stimulatory factor. *Mol. Cell. Biol.* 2005,25(4):1537-1548
177. Duez H., Lefebvre B., Poulain Ph., Pineda-Torra I., Percevault F., Luc G., Peters JM., Gonzalez FJ., Gineste R., Helleboid S., Fruchart J-C., Fievet C., Lefebvre Ph., Staels B. : Regulation of human apo A-I by gemfibrozil and fenofibrate through selective PPAR α modulation. *Arterioscler. Thromb. Vasc. Biol.* 2005,25(3):585-591
178. Sandberg MB., Bloksgaard M., Duran-Sandoval D., Duval C., Staels B., Mandrup S. : The gene encoding acyl-CoA binding protein is subject to metabolic regulation by both SREBP and PPAR α in hepatocytes. *J. Biol. Chem.* 2005,280(7) :5258-5266
179. Van der Veen JN., Kruit JK., Havinga R., Baller JFW., Chimini G., Lestavel S., Staels B., Groot PHE., Groen AK., Kuipers F. : Reduced cholesterol absorption upon PPAR δ activation coincides with decreased intestinal expression of NPC1L1. *J. Lipid. Res.* 2005,46:526-534
180. Genoux A., Dehondt H., Helleboid-Chapman A., Duhem C., Hum DW., Martin G., Pennacchio LA., Staels B., Fruchart-Najib J., Fruchart JC. : Transcriptional regulation of Apolipoprotein A5 gene expression by the nuclear receptor ROR α . *Arterioscler. Thromb. Vasc. Biol.* 2005;25(6):1186-1192
181. Poirier B., Bidouard JP., Cadrouvele C., Marniquet X., Staels B., O'Connor SE., Janiak P., Herbert JM : The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. *Diabetes, Obesity and Metabolism* 2005,7:65-72

182. Gizard F., Robillard R., Barbier O., Quatannens B, Faucompre A., Révillion F., Peyrat JP., Staels B., Hum DW : TreP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27^{kip1}. *Mol Cell Biol* 2005;25(11):4335-4348
183. Bihan H., Rouault C., Reach G., Poitout V., Staels B., Guerre-Millo M. : Pancreatic islet response to hyperglycemia is dependent on PPAR α . *Febs Lett* 2005;579(11):2284-2288
184. Countinho JM., Singaraja RR., Kang M., Arenillas DJ., Bertram LN., Bissada N., Staels B., Fruchart JC., Fievet C., Joseph-George AM., Wassermann WW., Hayden MR. : Complete functional rescue of the ABCA1^{-/-} mouse by human BAC transgenesis. *J Lipid Res* 2005;46(6):1113-1123
185. Duran-Sandoval D., Cariou B., Percevault F., Hennuyer N., Grefhorst A., Van Dijk TH., Gonzalez FJ., Fruchart JC., Kuipers F., Staels B. : The farnesoid X receptor modulates hepatic carbohydrate metabolism during fasting/refeeding transition. *J Biol Chem* 2005;280(33):29971-29979
186. Chauvet C., Bois-Joyeux B., Fontaine C., Gervois P., Bernard MA., Staels B., Danan JL : The gene encoding fibrinogen β is a target for Retinoic acid receptor-related Orphan Receptor. *Mol. Endocrinol.* 2005 ;19(10) :2517-2526
187. Hennuyer N., Tailleux A., Torpier G., Mezdour H., Fruchart JC., Staels B., Fievet C. : PPAR α , but not PPAR γ , activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. *Arterioscler. Thromb. Vasc. Biol.* 2005;25(9):1897-1902
188. Cariou B., Van Harmelen K., Duran-Sandoval D., Van Dijk T., Grefhorst A., Bouchaert E., Fruchart JC., Gonzalez FJ., Kuipers F. Staels B. : Transient impairment of the adaptive response to fasting in FXR-deficient mice. *Febs Lett* 2005;579(19):4076-7080
189. Claudel T., Staels B., Kuipers F. : The farnesoid X receptor. A molecular link between bile acid and lipid and glucose metabolism. *Arterioscler. Thromb. Vasc. Biol.* 2005;25(10):2020-2030
190. Gizard F., Amant C., Barbier O., Bellosta S., Corsini A., Glineur C., Krimpenfort P., Percevault F., Sevestre H., Rochette J., Fruchart JC., Torpier G., Staels B. : PPAR α inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor gene p16^{INK4a}. *J. Clin. Invest.* 2005;115(11):3228-3238
191. Rigamonti E., Helin L., Lestavel S., Mutka AL., Lepore M., Fontaine C., Bouhrel MA., Bultel S., Fruchart JC., Ikonen E., Clavey V., Staels B., Chinetti-Gbaguidi G. : Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. *Circ Res* 2005,97(7):682-689
192. Pinelli A., Godio C., Laghezza A., Mitro N., Tortorella V., Fracchiolla G., Lavecchia A., Novellino E., Fruchart JC., Staels B., Crestani M., Liodice F. : Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPAR α and PPAR γ activity. *J Med Chem* 2005;48(17):5509-5519
193. Chinetti-Gbaguidi C., Rigamonti E., Helin L., Mutka AL., Lepore M., Fruchart JC., Clavey V., Ikonen E., Lestavel S., Staels B. : PPAR α controls cellular cholesterol trafficking in macrophages. *J Lipid Res* 2005;46(12):2717-2725

194. De Bosscher K., Vanden Berhe W., Beck IM., Van Molle W., Hennuyer N., Hapgood J., Libert C., Staels B., Louw A., Haegeman G. : A fully dissociated compound of plant origin for inflammatory gene repression. *Proc Natl Acad Sci USA* 2005;102(44):15827-15832
195. Gizard F., Robillard R., Gervois P., Faucompré A., Révillion F., Peyrat JP., Hum DW., Staels B. : Progesterone inhibits human breast cancer cell growth through transcriptional up-regulation of the cyclin-dependent kinase inhibitor p27^{kip1} gene. *Febs Lett.* 2005;579(25):5535-5541
196. Lie J., Lankhuizen IM., Gross B., Van Gent T., Van Haperen R., Scheek L., Staels B., De Crom R., Van Tol A. : Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein. *Biochim Biophys Acta.* 2005; *in press*
197. Bultel S., Fruchart JC., Ikonen E., Clavey V., Staels B., Chinetti-Gbaguidi G. : Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. *Circ Res* 2005;97(7):682-689
198. Schupp M., Clemenz M., Gineste R., Witt H., Janke J., Helleboid S., Hennuyer N., Ruiz P., Unger T., Staels B., Kintscher U. : Molecular characterization of new selective PPARgamma modulators with angiotensin receptor blocking activity. *Diabetes* 2005;54(12):3442-3452
199. Paumelle R., Blanquart C., Briand O., Barbier O., Duhem C., Woerly G., Percevault F., Fruchart JC., Dombrowicz D., Glineur C., Staels B. : Acute anti-inflammatory properties of statins involve PPAR α via inhibition of the PKC signalling pathway. *Circ Res* 2006;98:***-***
200. Duval C., Touche V., Tailleux A., Fruchart JC., Fievet C., Clavey V., Lestavel S., Staels B. : Niemann-pick C1 like 1 (NPC1L1) gene expression is down-regulated by LXR activators in the intestine. *Biochem Biophys Res Com* 2006;340(4):1259-1263
201. Shiri-Sverdlov R., Wouters K., Van Gorp PJ., Gijbels MJ., Noel B., Buffat L., Staels B., Maeda N., Van Bilsen M., Hofker MH. : Early diet-induced non alcoholic steatohepatitis in Apo E2 knock-in mice and its prevention by fibrates. *J. Hepatol in press*
202. Meisner F., Walcher D., Gizard F., Kapfer X., Huber R., Noak A., Sunder-Plassmann L., Bach H., Hombach V., Haug C., Bachem M., Koenig W., Staels B., Marx N. : Effect of rosiglitazone treatment on plaque inflammation and collagen content in non-diabetic patients *Arterioscler. Thromb. Vasc. Biol.* 2006; *in press*
203. Costet P., Cariou B., Lambert G., Lalanne F., Lardeux B., Jarnoux AL., Grefhorst A., Staels B., Krempf M. : Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element binding protein 1c. *J Biol Chem* 2006, *in press*
204. Zambon A., Gervois P., Pauletto P., Fruchart JC., Staels B. : Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR α activators : clinical and experimental evidence. *Arterioscler. Thromb. Vasc. Biol* 2006, *in press*
205. Brunham LR., Kruit JK., Iqbal J., Fievet C., Timmins JM., Pape TD., Coburn BA., Bissada N., Staels B., Groen AK., Hussain MM., Parks JS., Kuipers F., Hayden MR. : Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. *J Clin Invest* 2006; *in press*
206. Cariou B., Van Harmelen K., Duran-Sandoval D., Van Dijk T., Grefhorst A., Abdelkarim M., Caron S., Torpier G., Fruchart JC., Gonzalez F., Staels B. : The Farnesoid X Receptor modulates adiposity and peripheral insulin sensitivity in mice. *J Biol Chem* 2006, *in press*

207. Majali KA., Cooper MB., Staels B., Luc G., Taskinen MR., Betteridge DJ : The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. *Diabetologia* 2006 (21) : 1-11

REVIEW ARTICLES

1. Staels B., Saladin R., Auwerx J.: Contrôle hormonal des gènes impliqués dans le métabolisme lipoprotéique chez le rat. *Cah.Nutr.Diét.*, 1995;30:43-47
2. Auwerx J., Martin G., Guerre-Millo M., Staels B.: Transcription, adipocyte differentiation, and obesity. *J.Mol.Med.* 1996;74:347-352
3. Martin G., Staels B., Guerre-Millo M., Auwerx J.: Transcription, différenciation adipocytaire et obésité. *m/s* 1996;12:885-890
4. Guerre-Millo M., Saladin R., Staels B., Auwerx J.: Les facteurs régulateurs du gène *ob*. *m/s* 1996;12:383-385
5. De Vos P., Auwerx J., Staels B.: Hormonal control of appetite and energy expenditure. Regulation and function of leptin. *Eur.Hospital Manag.* 1996;3:56-57
6. Schoonjans K., Staels B., Auwerx J.: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. *Biochim.Biophys.Acta* 1996;1302:93-109
7. Auwerx J., Schoonjans K., Fruchart J.-C., Staels B.: Transcriptional control of triglyceride metabolism: fibrates change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. *Atherosclerosis*, 1996; 124:S29-S37
8. Schoonjans K., Staels B., Auwerx J.: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. *J.Lipid Res.* 1996;37:907-925
9. Saladin R., Staels B., Auwerx J., Briggs M.: Regulation of *ob* gene expression in rodents and human. *Horm.Metab.Res.* 1996;28:638-641
10. Guerre-Millo M., Staels B., Auwerx J.: New insights on obesity genes. *Diabetologia* 1996; 39:1528-1531
11. Lemberger T., Braissant O., Juge-Aubry C., Keller H., Saladin R., Staels B., Auwerx J., Burger A.G., Meier C.A., Wahli W.: PPAR tissue distribution and interactions with other hormone-signaling pathways. *Ann.N.Y. Acad.Sci.* 1996;804:231-251
12. Auwerx J., Schoonjans K., Fruchart J.-C., Staels B.: Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects. *J.Atheroscler.Thromb.* 1996;3:81-89
13. Gelman L., Staels B., Auwerx J.: Rôle des cofacteurs transcriptionnels dans la transduction des signaux hormonaux par les récepteurs nucléaires. *m/s* 1997; 13:961-970
14. Martin G., Shviro I., Staels B., Auwerx J.: Hyperlipidémie combinée familiale. *Annales d'Endocrinol. (Paris)* 1997;58:283-286

15. Staels B., Schoonjans K., Fruchart J.-C., Auwerx J.: The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct PPARs. *Biochimie* 1997;**79**:95-99
16. Staels B., Auwerx J.: Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones. *Curr.Pharmac.Design* 1997;**3**:1-14
17. Schoonjans K., Martin G., Staels B., Auwerx J.: Peroxisome proliferator activated receptors, orphans with ligands and functions. *Curr.Opin.Lipidol.* 1997;**8**:159-166
18. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.C.: The mechanism of action of fibrates on lipid and lipoprotein metabolism. *Circulation* 1998;**98**:2088-2093
19. Sirtori C.R., Lovati M.R., Manzoni C., Gianazza E., Bondioli A., Staels B., Auwerx J.: Reduction of serum cholesterol by soy proteins: clinical experience and potential molecular mechanisms. *Nutr.Metab.Cardiovasc.Dis.* 1998;**8**:334-340
20. Auwerx J., Staels B.: Leptin. *Lancet* 1998;**351**:737-742
21. Martin G., Schoonjans K., Staels B., Auwerx J.: PPAR γ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. *Atherosclerosis* 1998;**137**:S75-S80
22. Staels B., Auwerx J.: Regulation of apo A-I gene expression by fibrates. *Atherosclerosis* 1998;**137**:SS19-S23
23. Pineda Torra I., Gervois P., Staels B.: PPAR α in metabolic disease, inflammation, atherosclerosis and aging. *Curr.Opin.Lipidol.* 1999;**10**:151-159
24. Fruchart J.-C., Duriez P., Staels B.: Mode d'action moléculaire des fibrates. *J.Soc.Biol.* 1999;**193**:67-75
25. Fruchart J.-C., Chinetti G., Duriez P., Staels B.: Genes involved in lipoprotein metabolism, vascular inflammation and atherosclerosis are regulated by PPAR α activators. *Giornale della Arteriosclerosis* 1999;**24**:3-15
26. Fruchart J.-C., Duriez P., Staels B.: PPAR α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. *Curr.Opin.Lipidol.* 1999;**10**:245-257
27. Besnard S., Mariani J., Staels B., Tedgui A.: La mutation staggerer du récepteur nucléaire ROR α , ou comment un phénotype peut en cacher un autre. *m/s* 1999; **13**:1305-1307
28. Gervois P., Pineda I., Fruchart J.C., Staels B. : Regulation of lipid and lipoprotein metabolism by PPAR activators. *Clin. Chem. Lab. Med.* 2000;**38**(1): 3-11
29. Neve B., Fruchart J.C., Staels B. : Role of the Peroxisome Proliferator-Activated Receptors (PPARs) in atherosclerosis. *Biochem Pharmacol* 2000; **60**(8):1245-1250 – *Semper* 2001 N°248: 17-20 (Belgium)
30. Chinetti G., Fruchart J.-C., Staels B.: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. *Inflamm. Res.* 2000, (49) : 497-505

31. Delerive P., Fruchart J.C., Staels B. : Peroxisome proliferator activated receptors (PPARs) in inflammation control. *J.Endocrinol.* 2001, 169 : 453-459
32. Staels B.: Regulation of lipid and lipoprotein metabolism by retinoids. *J.Am.Acad.Dermatol.*, 2001;45 (5) : S158-S167
33. Lefebvre A.-M., Saladin R., Briggs M., Staels B., Auwerx J.: Régulation de l'expression du gène OB. *Diététique et Médecine* , in press Pas encore publié? Peux-tu verifier stp ?
34. Bocher V., Chinetti G., Fruchart J.C., Staels B. : Les peroxisome proliferator-activated receptors (PPARs) : des récepteurs nucléaires au carrefour entre métabolisme lipidique et inflammation. *Sang Thromb.Vaisseaux* 2001, n°2/13 : 82-88
35. Duez H., Fruchart J.C., Staels B. : PPARs in inflammation, atherosclerosis and thrombosis. *J.Cardiovasc.Risk.* 2001, 8 (4) : 187-194.
36. Fruchart J.C., Duriez P., Staels B. : The role of fibric acids in Atherosclerosis. *Current Atherosclerosis Reports* 2001, 3 (1) : 83-92
37. Staels B., Auwerx J., Fruchart J.C. : Molecular mechanisms of action of fenofibrate. Submitted Pas encore publié? Peux-tu verifier stp (avec MHD, sur Medline,...)
38. Chinetti G., Fruchart J.C., Staels B. : Peroxisome proliferator-activated receptors (PPARs) : nuclear receptors with functions in the vascular wall. *Z. Kardiol.*, 2001,90 : 125-132
39. Blanquart C., Fruchart J.C., Staels B. : Role of PPARs in the regulation of lipoprotein metabolism and atherosclerosis. *Médecine Thérapeutique Endocrinologie*, 2001, 3 n°2 PPARs : 26-32
40. Pilon A., Lestavel S., Chinetti G., Fruchart J.-C., Staels B., Clavey V. : Rôles de SR-BI et d'ABCA1 dans le métabolisme des HDL et implication dans le développement de l'athérosclérose. *Courrier de l'Arcol et de la SFA* 2001, n°2 : 67-73
41. Fruchart J.-C., Staels B., Duriez P. : "New conceptions in the mechanism of action of fibrates and prospective therapeutics in atherosclerosis". *Bull.Acad.Natle Méd.* 2001; 185, n°1 : 63-75
42. Lestavel S., Chinetti G., Bocher V., Fruchart J.C., Clavey V., Staels B. : PPARs (Peroxisome proliferator activated receptors) et paroi vasculaire : implications dans l'athérosclérose. *m/s* 2001 ; 17 : 637-642
43. Pilon A., Duez H., Fruchart J.C., Staels B. : Role of PPARs in inflammation, atherosclerosis and thrombosis. In press, Proceedings on PPARs (Florence) Pas encore publié? Peux-tu verifier stp ?
44. Pineda Torra I., Chinetti G., Duval C., Fruchart J.C., Staels B. : Peroxisome Proliferator-Activated Receptors : from transcriptional control to clinical practice. *Curr. Opin. Lipidol.* 2001; 12 : 245-254
45. Bocher V., Chinetti G., Fruchart J.C., Staels B. : Activateurs PPARs et régulation du métabolisme lipidique, de l'inflammation vasculaire et de l'athérosclérose. Flammarion *Médecine-Sciences - Journées de Diabetologie* 2001 ; 23-32
46. Staels B. : Commentary to Ricote and Glass "New roles for PPARs in cholesterol homeostasis". *Trends Pharmacol.Sci.*, 2001 : 22(9) : 444.

47. Fruchart J-C., Staels B., Duriez P.: PPARs, metabolic diseases and atherosclerosis. *Pharmacological Res.* 2001, 44 (5) : 345-352
48. Jarvis CI., Staels B., Brugg B., Lemaygre-Dubreuil Y., Tedgui A., Mariani J. : Age related phenotypes in the staggerer mouse expand the RORalpha nuclear receptor's role beyond the cerebellum. *Mol. Cell. Endocrinol.* 2002 (186) : 1-5
49. Staels B. : The clinical significance of PPAR α and γ agonism. *Br.J.Diab.Vasc.Dis.*, 2002, 2(Suppl 1) : S28-S31
50. Duval C., Chinetti G., Trottein F., Fruchart JC., Staels B. : The role of PPARs in Atherosclerosis. *Trends Mol. Med* 2002, 8(9) : 422-430
51. Bocher V., Chinetti G., Fruchart JC., Staels B. : Rôles des PPARs dans la régulation du métabolisme des lipides et le contrôle de l'inflammation. *J. Soc. Biol.* 2002, 196(1) : 47-52
52. Barbier O., Pineda-Torra I., Duguay Y., Blanquart C., Fruchart JC., Glineur C., Staels B. : Pleiotropic actions of PPARs in lipid metabolism and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 2002 : (22) 717-726
53. Staels B. : PPAR γ et Athérome. *Ann.Endocrinol.* 2002, 63(2) : 1S23-1S26
54. Bellosta S., Bernini F., Chinetti G., Cignarella A., Cullen P., Von Eckardstein A., Exley A., Freeth J., Goddard M., Hofker M., Kanters E., Kovanen P., Lordkowski S., Pentikäinen M., Printen J., Rauterberg J., Ritchie A., Staels B., Weitkamp B., De Winter M. : Macrophage function and stability of the atherosclerotic plaque – progress report of a European Project. *Nutr. Metab. Cardiovasc. Dis.* 2002, 12(1) : 3-11
55. Staels B. : Cardiovascular Biology : a cholesterol tether. *Nature* 2002 (417) : 699-701
56. Bocher V., Pineda-Torra I., Fruchart JC., Staels B. : PPARs : transcription factors controlling lipid and lipoprotein metabolism. *Ann. NY Acad. Sci.* 2002 (967) : 7-18
57. Millatt L., Bocher V., Fruchart JC., Staels B. : Liver X receptors (LXRs) and the control of cholesterol homeostasis : potential therapeutic targets for the treatment of atherosclerosis. *Biochim. Biophys. Acta* 2003, 1631 (2) : 107-118
58. Bocher V., Millatt L., Fruchart JC., Staels B. : Liver X receptors : new players in atherogenesis ?. *Cur. Opin. Lipidol.* 2003, 14(2) : 137-143
59. Cullen P., Baetta R., Bellosta S., Bernini F., Chinetti G., Cignarella A., Von Eckardstein A., Exley A., Goddard M., Hofker Marten H., Hurt-Camejo E., Kanters Markku, Rauterberg J., Ritchie A., Staels B., Weitkamp B., De Winther M. : Rupture of the atherosclerotic plaque : does a good animal model exist ? *Arterioscler. Thromb. Vasc. Biol.* 2003, 23(4) : 535 – 542
60. Bowyer D. Dallinga-Thie G., Von Eckardstein A., Hofker M., Jauhiainen M., Mooser V., Nimpf J. Rudling M., Staels B., Talmud P. : European Lipoprotein club : report on the 25th ELC annual conference. Tutzing, 9-12 Sept. 2002. *Atherosclerosis* 2003, 167(1) : 159-168
61. Blanquart C., Barbier O., Fruchart JC., Staels B., Glineur C. : PPARs : regulation of transcriptional activities and roles in inflammation. *J. Steroid Biochem. Mol. Biol.* 2003, 85(2-5) : 267-273

62. Tailleux A., Torpier G., Mezdour H., Fruchart JC., Staels B., Fievet C. : Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. *Trends Pharmacol. Sci.* 2003, 24(10) : 530-534
63. Duran-Sandoval D., Thomas AC., Bailleul B., Fruchart JC., Staels B. : Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development. *Méd. Sci* 2003, 19(8-9) : 819-825
64. Chinetti G., Fruchart JC., Staels B.: PPARs: new targets for the pharmacological modulation of macrophage gene expression and function. *Curr. Opin. Lipidol.* 2003, 14(5) : 459-468
65. Chinetti G., Fruchart JC., Staels B.: PPARs and inflammation: from basic science to clinical applications. *Int. J. Obesity* 2003, 27 : S41-S45
66. Thomas AC, Fruchart JC, Staels B.: Les PPAR α et γ et le métabolisme des lipides et du glucose. *Métab. Horm. Diabetes Nutr.* 2003, VII (5) :206-210
67. Vanden Berghe W., Vermeulen L., Delerive P., De Bosscher K., Staels B., Haegeman G. : A paradigm for gene regulation : inflammation, NF-kappaB and PPAR. *Adv. Exp. Med. Biol.* 2003, 544:181-196
68. Laitinen S., Staels B.: Potential roles of ROR α in cardiovascular endocrinology. *NURSA e-journal* 2003 Vol 1 (4) (<http://www.nursa.org/article.cfm?doi=10.1621/nrs.01011>)
69. Paumelle R., Duran-Sandoval D., Fruchart JC., Staels B. : PPAR α controlling HDL metabolism and Atherosclerosis. *International Congress Series – In Press*
70. Watts GF, Staels B. : Regulation of endothelial nitric oxide synthase by PPAR agonists : molecular and clinical perspectives. *Arterioscler.Thromb.Vasc.Biol.* 2004;24(4):619-621
71. Chinetti G., Staels B.: PPARs, macrophages and atherosclerosis. Commentary for the International Atherosclerosis Society (IAS) website (March 2004).
72. Hofker M., Calabresi L., Jauhiainen M., Nimpf J., Rudling M., Talmud P., Mooser V., Dalling-Thie G., Von Eckaerdstein A., Staels B., Karpe F., Kuipers F : European Lipoprotein Club, report on the 26th ELC annual conference, Tuzting 8-11/09/2003. *Atherosclerosis* 2004;173(1):125-134
73. Marx N., Duez H., Fruchart JC., Staels B. : PPARs and atherogenesis : regulators gene expression in vascular cells. *Circ. Res.* 2004;94(9):1168-1178
74. Duval C., Fruchart JC., Staels B. : PPAR α , fibrates, lipid metabolism and inflammation. *Arch. Mal. Coeur Vaiss.* 2004 ;97(6) :665-672
75. Bailleul B., Touvier T., Staels B. : Leptinorésistance et récepteur soluble de la leptine. *Metab. Horm. Diab. Nutr.* 2004, VII(2):84-90
76. Barbier O., Fontaine C., Fruchart JC., Staels B. : Genomic and non-genomic interactions of PPAR α with xenobiotic metabolizing enzymes. *Trends Endocrinol. Metabol.* 2004,15(7):324-330
77. Claudel T., Sturm E., Kuipers F., Staels B. : The farnesoid X receptor : a novel drug target ? *Expert Opinion on Investigational Drugs* 2004;13(9):1135-1148

78. Marx N., Duez H., Fruchart JC., Staels B. : PPARs and atherogenesis : regulators gene expression in vascular cells. *Circ. Res.* 2004;94(9):1168-1178
79. Gervois P., Fruchart JC., Staels B. : Inflammation, dyslipidaemia, diabetes and PPARs : pharmacological interest of dual PPAR α and PPAR γ agonists. *Int. J. Clin. Practice* 2004;58(Suppl 143):22-29
80. Kuipers F., Claudel T., Sturm E., Staels B. : The farnesoid X receptor (FXR) as modulator of bile acid metabolism. *Rev Endocr Metab Disord* 2004;5(4):319-326
81. Cariou B., Duran-Sandoval D., Kuipers F., Staels B. : FXR : a new player in glucose metabolism ? *Endocrinology* 2005,146(3):981-983
82. Duran-Sandoval D., Cariou B., Fruchart JC., Staels B. : Potential regulatory role of the FXR in the metabolic syndrome. *Biochimie* 2005,87:93-98
83. Laitinen S., Fontaine C., Fruchart JC., Staels B. : The role of the orphan receptor Rev-Erb α in adipocyte differentiation and function. *Biochimie* 2005,87:21-25
84. Staels B. : PPAR γ and atherosclerosis. *Curr Med Res Opin* 2005; (suppl 1):S13-S20
85. Chinetti-Gbaguidi G., Fruchart JC., Staels B. : Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis : new approaches to therapy. *Curr Opin Pharmacol* 2005,5(2):177-183
86. Froment P., Gizard F., Staels B., Dupont J., Monget P. : A role of PPAR γ in reproduction ? *Médecine/Sciences* 2005 ;21(5) :507-511
87. Staels B., Fruchart JC. : Therapeutic roles of PPAR agonists. *Diabetes* 2005;54(8):2460-2470
88. Staels B. : Glitazones and atherosclerosis. *Ann Endocrinol* 2005;66(2Pt2):1S24-31
89. Cariou B., Fruchart JC., Staels B. : Vascular protective effects of PPAR agonists. *Br J Diabetes Vasc Dis* 2005;5:126-132
90. Chinetti-Gbaguidi G., Fruchart JC., Staels B. : Pleiotropic effects of fibrates. *Curr Atheroscl Rep* 2005;7(5):396-401
91. Gross B., Fruchart JC., Staels B. : PPAR β/γ : a novel target for the reduction of atherosclerosis. *Drug Discovery Today : Therapeutic Strategies* 2005; in press
92. Staels B. : Fluid retention mediated by renal PPAR γ . *Cell Metab* 2005;2(2):77-78
93. Chinetti-Gbaguidi G., Fruchart JC., Staels B. : Therapeutical effects of PPAR agonists assessed by biomarker modulation. *Biomarkers* 2005,10(1):30-36
94. Staels B. : When the Clock stops ticking, metabolic syndrome explodes. *Nat Med* 2006,12(1):54-55
95. Chinetti-Gbaguidi G., Staels B. : Liver X receptors (LXRs) : transcriptional regulators of macrophage cholesterol metabolism. IAS commentary 2006.

96. Lefebvre P., Chinetti G., Fruchart J.C., Staels B. : Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. *J Clin Invest* 2006;116(3): *in press*
97. Froment P., Gizard F., Defever D., Staels B., Dupont J., Monget P. : PPARs in reproductive tissues : from gametogenesis to parturition. *Journal of Endocrinology* 2006, *in press*
98. Fievet C., Staels B. : Effects of PPAR γ ligands on atherosclerosis and cardiovascular disease. International Atherosclerosis Society Commentary 2006, on-line.

Chinetti-Gbaguidi G., Staels B. : Inflammation et maladies métaboliques et vasculaires : approches pharmacologiques.

BOOK CHAPTERS

1. Staels B., Auwerx J.: Hormonal control of genes involved in lipoprotein metabolism in the rat. In *Hormones in Lipoprotein Metabolism* (A.Steinmetz, J.Schneider, H.Kaffarnik, eds.), pp.9-15, Springer Verlag, 1993.
2. Auwerx J., Schoonjans K., Staels B.: Regulation of liver lipoprotein lipase gene expression. In *Atherosclerosis X* (F.P.Woodford, J.Davignon, A.Sniderman, eds.), pp241-245, Elsevier Science B.V., 1995
3. Fruchart J.-C., Clavey V., Luc G., Dallongeville J., Staels B., Auwerx J.: Apolipoprotein C-III, an important player in lipoprotein metabolism. In *Drugs Affecting Lipid metabolism* (A.M.Gotto Jr., R.Paoletti, L.C.Smith, A.L.Catapano, A.S.Jackson, eds.), pp.631-638, Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1996
4. Staels B., Fruchart J.-C., Auwerx J.: Fatty acids as transcriptional regulators of the lipoprotein lipase and apo C-III genes: consequences for plasma triglyceride metabolism. In *Omega-3 Lipoproteins and Atherosclerosis* (J.Davignon, J.C.Fruchart, J.M.Ordovas, eds.), pp.41-48, John Libbey Eurotext, Paris, 1996
5. Staels B., Fruchart J.-C., Auwerx J.: Role of PPAR in the regulation of high density lipoprotein metabolism. In *Biologie Prospective* (M.-M.Galteau, P.Delwaide, G.Siest, J.Henny, eds.), pp135-140, John Libbey Eurotext, Paris, 1997
6. Auwerx J., Staels B., Saladin R., Briggs M.R.: Leptin. In *Human cytokines Vol.III* (Aggarwal, ed.), pp189-206, Blackwell Science Inc., 1998
7. Staels B., Auwerx J., Fruchart J.-C.: Molecular mechanisms of action of fenofibrate. In *Atherosclerosis XI* (B.Jacotot, D.Mathé, J.-C.Fruchart, eds.), pp249-257, Elsevier Science B.V., 1998
8. Martin G., Schoonjans K., Staels B., Auwerx J.: PPAR activators improve glucose homeostasis by changing fatty acid partitioning. In *Atherosclerosis XI*, pp35-47, Elsevier Science B.V., 1998
9. Duriez P., Staels B., Fruchart J.C. : Le PPAR α – Le rôle de ses activateurs dans la régulation de l'expression des gènes impliqués dans le métabolisme des lipoprotéines, l'inflammation vasculaire et l'athérosclérose. *Pasteur Institute Annual Book*, pp 89-106, Elsevier Science, 2000
10. Staels B.: The PPAR system and regulation of lipoprotein metabolism. In *Lipids and Vascular Disease: Current Issues* (D.J.Betteridge, ed.), pp_, Martin Dunitz Publ., 2000, Ch. 3 – pp27-37

11. Bouly M., Staels B. : Mécanismes d'action des fibrates, activateurs du PPAR α , sur le métabolisme des lipoprotéines et l'inflammation vasculaire. *Statines et Fibrates – Modes d'action moléculaires dans la prévention des maladies cardiovasculaires*, pp 5-38, John Libbey Eurotext, 2000
12. Bocher V., Chinetti G., Fruchart JC., Staels B. : Activateurs PPARs et régulation du métabolisme lipidique, de l'inflammation vasculaire et de l'athérosclérose. *Journées de Diabétologie 2001*, pp 23-32
13. Staels B., Jean-Charles Fruchart J.C., Auwerx J.: Role of PPAR in the regulation of high density lipoprotein metabolism. In *Comptes-Rendus du IX Colloque International de Pont-à-Mousson Eurobiologie*, John Libbey Eurotext, Paris, in press
14. Duguay Y., Duriez P., Fruchart J-C., Staels B. : “Régulation transcriptionnelle du métabolisme lipidique par les statines et fibrates”. *Athérosclérose : Physiopathologie, Diagnostics et Thérapeutiques*, 2001 (1) : in press Pas encore publié ? Peux-tu verifier stp ?
15. Bocher V. Pineda Torra I., Fruchart J.-C., Staels B.: PPARs : Transcription factors controlling lipid and lipoprotein metabolism. *Ann. N.Y. Acad. Sci.* 2002, 967 : 7-18
16. Pilon A., Duez H., Fruchart JC., Staels B. : Role of PPARs in inflammation, atherosclerosis and thrombosis. *PPARs : from basic science to clinical applications 2002*, 18 : 25-34; Kluwer Academic Publishers
17. Fruchart JC., Staels B., Duriez P.: PPAR α , lipoprotein metabolism, metabolic diseases, and atherosclerosis. *PPARs : from basic science to clinical applications 2002*, 18 : 63-79; Kluwer Academic Publishers
18. Fruchart JC., Staels B., Duriez P. : PPAR α in lipid lipoprotein metabolism, vascular inflammation and atherosclerosis. *Atherosclerosis, Hypertension and Diabetes 2003*; Kluwer Academic Publishers
19. Fontaine C., Duval C., Barbier O., Chinetti G., Fruchart JC., Staels B. : PPARs and Atherosclerosis. *Advances in Molecular and Cell Biology (Lipobiology) 2004*,33 :543-560 Elsevier Science B.V.
20. Duran-Sandoval D., Fruchart JC., Staels B. : PPAR agonists in the treatment of the metabolic syndrome and type 2 diabetes. *Lipids and Atherosclerosis 2003*, 3 : 37-58 (edited by Allan Gaw and James Shepherd – MD Martin Dunitz)
21. Paumelle R., Duran-Sandoval D., Fruchart JC., Staels B. : PPAR α controlling HDL metabolism and atherosclerosis. *Atherosclerosis XIII – International Congress Series 1262 (2004)*, 215-219. Elsevier Science
22. Blanquart C., Fruchart JC., Staels B., Glineur C. : PPAR α , un récepteur nucléaire impliqué dans la régulation du métabolisme des lipides et des lipoprotéines ainsi que dans la réponse inflammatoire . *Flammarion Médecine Sciences – Actualités Néphrologiques 2004*, p.19-31.
23. Claudel T., Sturm E., Staels B., Kuipers F. : FXR: the molecular link between bile acid and lipid metabolism. *Advances in Translational Medical Science : Lipids and Atherosclerosis 2005 – CJ Packard and D. Rader, Chapter 7: 69-80*
24. Robillard R., Fontaine C., Chinetti G., Fruchart JC, Staels B. : Fibrates. *Handbook of Experimental Pharmacology ‘Atherosclerosis : Diet and Drugs’ 2005*;170:389-406

25. Duez H., Fruchart JC., Staels B. : PPARS in Atherosclerosis. Nutritional Genomics edited by Reginal Brigelius-Flohé & Hans-Georg Joost, 2006, Part II (Ch.9) : 159-179

Duran-Sandoval D., Claudel T., Fruchart JC., Staels B. : Control of HDL metabolism by nuclear receptors. HDL and Coronary Heart Disease. 2003

Gervois P, Fruchart JC, Staels B: Role of PPARs in cardiovascular diseases. Book “Cellular dysfunction in Atherosclerosis and Diabetes – Reports from Bench to Bedside. *In press*

PUBLISHED ABSTRACTS

1. - Staels B., van Tol A., Chan L., Verhoeven G., Auwerx J.: Differential expression of potential ligands for the HDL-receptor. *Circulation*, 1990;**82**:III-533
2. - Staels B., van Tol A., Chan L., Verhoeven G., Auwerx J.: Differential expression of potential ligands for the HDL-receptor. *Arteriosclerosis*, 1990;**10**:779a
3. - Auwerx J., Staels B., Szpirer J., Szpirer C., Verhoeven G., Deeb S.: Developmental regulation and extinction of liver lipoprotein lipase mRNA. *Arteriosclerosis*, 1990;**10**:826a
4. - Staels B., van Tol A., Chan L., Verhoeven G., Auwerx J.: Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. *Regard sur la Biochimie*, 1991;**3**:11
5. - Schoonjans K., Devos P., Staels B., Verhoeven G., Auwerx J.: Developmental extinction of liver lipoprotein lipase mRNA expression is regulated by an NF-1 like site. *Circulation*, 1993;**88**:I-420
6. - Staels B., Berthou L., Branellec D., Bush R.C., Foster M.L., Fruchart J.-C., Denèfle P.: Differential regulation of hepatic apo A-I and apo A-II gene expression by retinoic acid. *Arterioscler.Thromb.*, 1993;**Suppl.121**
7. - Schoonjans K., Devos P., Staels B., Verhoeven G., Auwerx J.: Developmental extinction of liver lipoprotein lipase mRNA expression is regulated by an NF-1 like site. *Arterioscler.Thromb.*, 1993;**Suppl.34**
8. - Branellec D., Berthou L., Staels B., Saldicco I., Parrott D., Fruchart J.-C., Denèfle P.: Opposite in vitro and in vivo regulation of hepatic apo A-I gene expression by retinoic acid. *J.Cell.Biochem.*; 1994; **Suppl.18A** : 277
9. - Auwerx J., Schoonjans K., Vu Dac N., Staels B.: Control of gene expression by hypolipidemic fibrates and nutritional factors, a coordinating role for PPAR. *J.Endocrinol.*, 1994;**140**:S-6
10. - Schoonjans K., Yamamoto T., Wahli W., Fruchart J.-C., Grimaldi P., Auwerx J., Staels B.: Induction of Acyl-Coenzyme A synthetase (ACS) gene expression by fibrates is mediated by a PPAR-responsive element in the 1C promoter of the ACS gene. *Circulation*, 1994;**90**:I-571
11. - Bossu J.-P., Chartier F.L., Vu Dac N., Fruchart J.-C., Staels B., Auwerx J., Laine B.: Characterization of a negative regulatory activity in the first intron of the human apolipoprotein A II gene. *Circulation*, 1994;**90**:I-571

12. - Schoonjans K., Yamamoto T., Wahli W., Fruchart J.-C., Grimaldi P., Auwerx J., Staels B.: Induction of Acyl-Coenzyme A synthetase (ACS) gene expression by fibrates is mediated by a PPAR-responsive element in the 1C promoter of the ACS gene. *Arterioscler.Thromb.*, 1994;**Suppl**.p.42
13. - Bossu J.-P., Chartier F.L., Vu Dac N., Fruchart J.-C., Staels B., Auwerx J., Laine B.: Characterization of a negative regulatory activity in the first intron of the human apolipoprotein A II gene. *Arterioscler.Thromb.*, 1994;**Suppl**.p.42
14. - Staels B., Saladin R., Vu-Dac N., Fruchart J.-C., Auwerx J.: Tissue-specific down-regulation of apo C-III gene expression by fibrates. *Arterioscler.Thromb.*, 1994;**Suppl**.p.123
15. - Berthou L., Staels B., Branellec D., Denèfle P.: Regulation of apolipoprotein gene expression by fibrates in primary culture of adult rat hepatocytes. *Arterioscler.Thromb.*, 1993;**Suppl**.p.86
16. - Berthou L., Duverger N., Cuiiné S., Berthelot K., Attenot F., Staels B., Fruchart J.-C., Rubin E.M., Denèfle P., Branellec D.: Human apo A-I transgenic mice as a pharmacological tool. *Arterioscler.Thromb.*, 1993;**Suppl**.p.89
17. - Schoonjans K., Staels B., Yamamoto T., Wahli W., Grimaldi P., Auwerx J.: Induction of the acyl-coenzyme A synthetase (ACS) gene expression by fibrates is mediated by a PPAR-responsive element in the 1C promoter of the ACS gene. *Atherosclerosis*, 1994;**109n°1,2**:106
18. - Schoonjans K., Devos P., Staels B., Auwerx J.: Developmental extinction of liver lipoprotein lipase mRNA expression is regulated by an NF-1 like site. *Atherosclerosis*, 1994;**109n°1,2**:85
19. - Hoogerbrugge N., Jansen H., Staels B., Kloet L.T., Birkenhäger J.C.: Growth hormone normalizes LDL-receptor quantity, but not LDL clearance in hypothyroid rats. *Atherosclerosis*, 1994;**109n°1,2**:117
20. - Staels B., Vu-Dac N., Saladin R., Fruchart J.-C., Auwerx J.: Tissue-specific down-regulation of apo C-III gene expression by fibrates. *Atherosclerosis*, 1994;**109n°1,2**:139
21. - Schoonjans K., Mahfoudi A., Wahli W., Yamamoto T., Grimaldi P., Auwerx J., Staels B.: Induction of Acyl-Coenzyme A synthetase expression by fibrates and fatty acids is mediated through activation of the peroxisome proliferator activated receptor. *64th European Atherosclerosis*, 1995;**115(Suppl.)**:S9
22. - Berthou L., Duverger N., Emmanuel F., Auwerx J., Fruchart J.-C., Denèfle P., Staels B., Branellec D.: Opposite regulation of human versus mouse apo A-I by fibrates in human transgenic mice. *Circulation*, 1995;**92(Suppl.I)**:I-105-106
23. - Staels B., Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.-C., Auwerx J.: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. *Circulation*, 1995;**92(Suppl.I)**:I-291
24. - Schoonjans K., Staels B., Deeb S., Auwerx J.: Fibrates and fatty acids induce lipoprotein lipase gene expression via the peroxisome proliferator activated receptor. *Circulation*, 1995;**92(Suppl.I)**:I-495
25. - Staels B., Fruchart J.-C., Auwerx J.: Gene-environment interactions: pharmacological and nutritional control of apo A-I and apo A-II gene regulation. *m/s* 1996;**12**:11
26. - Staels B.: Regulation of apo A-I gene expression by fibrates. *Atherosclerosis*, 1997;**130(Suppl.)**:S5

27. - Auwerx J., Staels B., Fruchart J.C.: Clinical importance of new insights into the mechanism of activation of fibrates. *Atherosclerosis*, 1997;**130(Suppl.)**:S23
28. - Berge R., Froyland L., Kryvi H., Auwerx J., Staels B., Madsen L.: The mitochondrion is the principal target for nutritional and pharmacological regulation of triglyceride metabolism. *Atherosclerosis* 1997;**134**:53
29. - Lefebvre A.-M., Peinado-Onsurbe J., I. Leitersdorf, Briggs M.R., Paterniti J.R., Fruchart J.-C., Fievet C., Auwerx J., Staels B.: Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. *Atherosclerosis* 1997;**134**:57
30. - Madsen L., Froyland L., Staels B., Berge R.: The underlying mechanism of the hypolipidemic effect of 3-thia fatty acids. *Atherosclerosis* 1997;**134**:58
31. - Neele D.M., Buytenhek R., Staels B., Dallongeville J., Wallnöfer A.E., Kooistra T., Princen H.M.G.: Effects of oral isotretinoin (13-cis retinoic acid) on lipoprotein(a) and HDL subclasses LpA-I and LpA-I:A-II in healthy volunteers. *Atherosclerosis* 1997;**134**:145
32. - Martin G., Schoonjans K., Lefebvre A.-M., Staels B., Auwerx J.: Coordinate regulation of the expression of the fatty acid transporter protein (FATP) and acyl CoA synthetase (ACS) genes by PPAR α and PPAR γ activators. *Atherosclerosis* 1997;**134**:351
33. - Martin G., Pilon A., Albert C., Vallé M., Hum D.W., Fruchart J.C., Auwerx J., Clavey V., Staels B.: HDL (high density lipoprotein) and LDL (low density lipoprotein) receptors regulation in human adrenal cortex. *Atherosclerosis* 1997;**134**:360
34. - Staels B.: Transcription factor genes controlling high density lipoprotein metabolism. *Atherosclerosis* 1997;**134**:374
35. - Hennuyer N., Peters J.M., Staels B., Fievet C., Gonzalez F.J., Auwerx J.: Role of the peroxisome proliferator-activated receptor (PPAR) in HDL metabolism - Insights from studies with PPAR α -deficient mice. *Circulation* 1997;**96**:I-661
36. - Hennuyer N., Poulain P., Madsen L., Berge R., Houdebine L.-M., Branellec D., Fruchart J.-C., Auwerx J., Fievet C., Duverger N., Staels B.: The beneficial effects of fibrates on high density lipoprotein metabolism occur independent of any peroxisome proliferative response. *Circulation* 1997;**96**:I-662
37. - Kockx M, Peters J.M., Gonzalez F.J., Princen H.M.G., Kooistra T., Staels B.: Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor- α . *Circulation* 1998;**98**:I-124
38. - Gervois P., Vu-Dac N., Chopin-Delannoy S., Fadel A., Kosykh V., Bonnelye E., Martin G., Schoonjans K., Fruchart J.-C., Laudet V., Staels B.: Fibrates repress rat apo A-I gene expression by increasing Rev-erba expression via PPAR α interacting with a novel PPAR response element. *Circulation* 1998;**98**:I-125
39. - Delerive P., Martin F., Chinetti G., Trottein F., Fruchart J.-C., Duriez P., Staels B.: PPAR activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells. *Circulation* 1998;**98**:I-406
40. - Duez H., Mansen A., Fruchart J.-C., Vennstrom B., Fievet C., Staels B.: Rev-erba: a nuclear receptor with a role in lipoprotein metabolism. *Circulation* 1998;**98**:I-449

41. - Flavell D.M., Pineda Torra I., Jamshidi Y., Evans D., Syvanne M., Taskinen M.-R., Talmud P.J., Humphries S.E., Staels B.: Variation in the peroxisome proliferator-activated receptor alpha gene is associated with plasma lipid concentrations, response to gemfibrozil and progression of atherosclerosis in coronary artery bypass graft patients. *Circulation* 1998;**98**:I-532
42. - Staels B.: PPARs, the metabolic syndrome and atherosclerosis. *Biol.Chem.* 1999;380:S130
43. - Staels B.: Nuclear receptors as targets to modulate HDL levels. *Atherosclerosis* 1999;**46Suppl.1**:S15
44. - Mallat Z., Besnard S., Duriez M., Deleuze V., Emmanuel F., Bureau M.F., Duez H., Fievet C., Staels B., Duverger N., Scherman D., Tedgui A.: Protective role of interleukin-10 in atherosclerosis. *Circulation* 1999;**100**:I-43
45. - Raspé E., Duez H., Gervois P., Fievet C., Fruchart J.-C., Mariani J., Staels B.: Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor ROR α . *Circulation* 1999;**100**:I-137
46. - Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Tedgui A., Fruchart J.-C., Haegeman G., Staels B.: PPAR α : a negative regulator of the vascular inflammatory response. *Circulation* 1999;**100**:I-355
47. - Dallongeville J., Baugé E., Tailleux A., Fruchart J.-C., Staels B.: Fish oil decreases lipid levels independently of PPAR alpha. *Circulation* 1999;**100**:I-403
48. - Briand O., Martin-Nizard F., Delerive P., Lestavel S., Fruchart J.-C., Staels B., Clavey V., Duriez P.: Peroxisome proliferator-activated receptor activators inhibit HDL and apolipoprotein A-I induced ET-1 secretion and increase apo A-I induced inhibition of endothelial nitric oxide synthase activity in endothelial cells. *Circulation* 1999;**100**:I-416
49. - Post S.M., Staels B., de Fabiani E., Chiang J.Y.L., Princen H.M.G., Crestani M.: Fibrates suppress bile acid synthesis via PPAR α -mediated down-regulation of cholesterol 7 α -hydroxylase and sterol 27-hydroxylase gene expression. *Circulation* 1999;**100**:I-686
50. - Kuipers F., Bloks V., Wolters H., Voshol P.J., Staels B.: Altered hepatic cholesterol metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. *Circulation* 1999;**100**:I-687
51. - Gervois P., Kockx M., Kooistra T., Fruchart J.-C., Staels B.: Fibrates suppress IL-6-induced human fibrinogen-beta expression through a cross talk between STAT3, C/EBPbeta and PPARalpha signalling pathways. *Circulation* 1999;**100**:I-849
52. - Post S.M., Staels B., de Fabiani E., Chiang J.Y.L., Princen H.M.G., Crestani M.: Fibrates suppress bile acid synthesis via PPAR α -mediated down-regulation of cholesterol 7 α -hydroxylase and sterol 27-hydroxylase gene expression. *Atherosclerosis* 1999;**144**:S23
53. - Delhon A., Junquero D., Pilon A., Carilla-Durand E., Patoiseau J.-F., Tarayre J.-P., Clavey V., Staels B., Fruchart J.-C., Colpaert F.C.: Effects of F12511, a potent ACAT inhibitor, on human adrenocortical cells in culture. *Atherosclerosis* 1999;**144**:S28
54. - Roevens P., Heeres J., Meerpoel L., Dupont A., Borghys H., Lammens L., Auwerx J., Staels B., de Chaffoy de Courcelles: Hypolipidemic effects of R103757, a potent stereoselective inhibitor of microsomal triglyceride transfer protein (MTP). *Atherosclerosis* 1999;**144**:S38

55. - Gbaguidi F., Chinetti G., Griglio S., Antonucci M., Fruchart J.-C., Chapman J., Najib J., Staels B.: Regulation of CLA-1 by activators of peroxisome proliferator-activated receptors. *Atherosclerosis* 1999;**144**:S112
56. - Griglio S., Gbaguidi F.G., Chinetti G., Milosavljevic D., Antonucci M., Najib J., Fruchart J.-C., Chapman J., Staels B.: Regulation of macrophage lipoprotein lipase expression by activators of peroxisome proliferator-activated receptors. *Atherosclerosis* 1999;**144**:S146
57. – Staels B. : Nuclear transcription factors : new opportunities for lipid lowering. *Proc.Nutr.Soc.* 2000;**59**:p433
58. – Delerive Ph., Furman C., Teissier E., Fruchart JC., Duriez P., Staels B. : Oxidized phospholipids activate PPAR α in a phospholipase A2-dependent manner. *Atherosclerosis* 2000; **151**-1:P60
59. – Staels B. : PPARs : Fatty acid-activated receptors controlling lipid metabolism and inflammation. *Atherosclerosis* 2000; **151**-1:P86
60. – Dallongeville J., Raspé E., Baugé E., Fruchart JC., Staels B. : Possible role of SREBP1c in fish oil-mediated regulation of APO C-III gene expression. *Atherosclerosis* 2000; **151**-1:P86
61. – Jaboureck O., Six I., Deplancke D., Caillez A., Fruchart JC., Staels B., Duriez P., Bordet R. : PPAR-alpha activator (fenofibrate) restores endothelium responses in spontaneous hypertensive rat. *Atherosclerosis* 2000; **151**-1:P203
62. – Chinetti G., Gbaguidi F., Lestavel S., Milosavljevic D., Chapman J., Najib J., Fruchart JC., Staels B. : PPARs regulate genes involved in cholesterol homeostasis in human monocyte/macrophages. *Atherosclerosis* 2000; **151**-1:P290
63. – Pineda Torra I., Fruchart JC., Staels B. : Structure and promoter analysis of the human PPAR α gene. *Atherosclerosis* 2000; **151**-1:P290
64. – Staels B. : Transcription factors as regulators of HDL metabolism. *Atherosclerosis* 2000; 150 Supp.2:I15
65. – Pineda Torra I., Fruchart JC., Staels B. : PPARs and Atherosclerosis. *Lipoprotein Metabolism and Atherogenesis* 2000; Ch. 3 – P88
66. – Staels B. : Tissue factor is inhibited by PPAR α agonists in monocytic cells. *American Society of Haematology*
67. – Duez H., Poulain P., Fievet C., Fruchart JC., Staels B. : Peroxisome proliferator activated receptor α (PPAR α) is required for the in vivo regulation of human Apo AI gene expression by fibrates. *Circulation* 2000, 102 :18 – 214
68. – Furman C., Gervois P., Delerive P., Martin-Nizard F., Fruchart JC., Duriez P., Staels B., Teissier E. : Oxidized LDL, Phospholipid Component of Oxidized-LDL and PPARs activators increase the catalase gene transcription and its expression in different human and bovine vascular cells. *Circulation* 2000, 102 :18 – 587
69. – Martin G., Duez H., Berezowski V., Poulain P., Kosydh V., Fruchart JC., Staels B. : Statins induce hepatic human apolipoprotein A-I gene in hepatoma cells via activation of peroxisome proliferator activated receptor α . *Circulation* 2000, 102 :18 – 587

70. – Vu-Dac N., Dubois G., Gervois P., Fruchart JC., Laine B., Staels B. : Regulation of human Apo-AII promoter by the orphan nuclear receptor ROR- α is mediated through PPAR- α acting as a docking factor. *Circulation* 2000, 102 :18 – 587
71. – Gevois P., Kockx M., Fruchart JC., Kooistra T., Staels B. : Molecular mechanism of negative regulation of human fibrinogen by fibrates : titration of transcriptional intermediary factor TIF2 by PPAR- α . *Circulation* 2000, 102 :18 – 587
72. – Chinetti G., Lestavel S., Remaley A., Neve B., Pineda Torra I., Minnich A., Jaye M., Duverger N., Brewer HB., Fruchart JC., Clavey V., Staels B. : PPAR α and PPAR γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABC-1 pathway. *Circulation* 2000, 102 :18 – 587
73. – Deplanque D., Gele P., Bouly M., Six I., Teissier E., Fruchart JC., Staels B., Duriez P., Bordet R. : Increase in brain superoxide dismutase as a potential mechanism of peroxisome proliferator activated receptor alpha activator induced brain ischemic tolerance. *Circulation* 2000, 102 :18 – 587
74. Staels B. : PPARs : Fatty acid-activated receptors controlling lipid metabolism and inflammation. *Atherosclerosis XII*, 2000, p.185
75. Bouly M., Lagrost L., Staels B., Fruchart JC., Luc G. : In vivo induction of HDL size enlargement by fenofibrate is dependant on Phospholipid transfer protein (PLTP). *Archive des Maladies du Cœur et des Vaisseaux*, 2001 V.94 (4) : p. 354
76. Blanquart C., Barbier O., Fruchart JC, Staels B., Glineur C. : Le récepteur nucléaire PPAR α est dégradé par les protéasomes de manière ligand dépendant. *Archive des Maladies du Cœur et des Vaisseaux*, 2001 V.94 (4) : p. 385
77. Pineda-Torra I., Fruchart JC, Staels B. : Fibrates negatively modulate PPAR α expression in human hepatocytes. *Archive des Maladies du Cœur et des Vaisseaux*, 2001 V.94 (4) : p. 385
78. Bouly M., Masson D., Gross B., Jiang XC., Fievet C., Castro G., Tall AR., Fruchart JC., Staels B., Lagrost L., Luc G. : Induction of the plasma phospholipid transfer protein (PLTP) gene accounts for the HDL enlargement in mice treated with fenofibrate . Lack of HDL size distribution in treated PLTP-deficient mice. *Atherosclerosis* 2001, 2(2) : p.71
79. Lestavel S., Chinetti G., Barbeau R., Fruchart JC., Clavey V., Staels B. : Cholesterol homeostasis is controlled by PPARalpha in human macrophages. *Atherosclerosis* 2001, 2(162) : p.86
80. B.Staels : PPAR α and insulin resistance. *Hong Kong Medical Journal* 2001, 7 (4) : PL2
81. Raspé E., Mautino G., Duez H., Fruchart JC., Staels B. : Transcriptional regulation of Apolipoprotein C-III gene expression by the orphan nuclear receptor Reverb α . *Circulation* 2001Supp. II –15, 104 (17) : 65
82. Chinetti G., Lestavel S., Fruchart JC., Clavey V., Staels B. : PPAR α controls cholesterol homeostasis in human monocyte-derived macrophages. *Circulation Supp. II* 2001,104 (17) Suppl II-233 : 1124
83. Duez H., Chao YS., Poulain P., Fievet C., Fruchart JC., Wright SD., Staels B. : Fenofibrate treatment reduces lesion size and aortic cholesterol content in human apo A-I transgenic X apo E-deficient and apo E-deficient mice. *Circulation Supp. II* 2001,104 (17) Suppl II –234 : 1129

84. Singaraja R., Bocher V., James ER., Clee SM., Zhang LH., Kwok A., Bissada N., Chang YZ., Liu G., Wellington CL., Fievet C. Staels B., Hayden M. : Increased HDL-C and apo A-I dependent efflux modulated by LXREs in human ABCA1 BAC transgenic mice. *Circulation Supp. II-290*; 2001,104 (17) : 1395
85. Claudel T., Duez H., Pineda-Torra I., Fruchart JC., Staels B. : Bile acids suppress human apolipoprotein A-I gene expression via a negative response element for the nuclear receptor FXR. *Circulation Supp. II 2001,104 (17) Suppl II – 291* : 1399
86. Staels B. : Transcription factors controlling lipid and lipoprotein metabolism. *CPL 2001, 110 (2)* : 98
87. Dallinga-Thie G., Bowyer D., Dieplinger H., Funke H., Hofker M., Jauhiainen M., Nimpf J., Staels B., Talmud P., Tarugi P. : European Lipoprotein Club – Report of the 24th ELC annual conference, Tutzing, 10-13 Sept. 2001. *Atherosclerosis 2002 (162)* : 439-447
88. Kitsberg D., Alkalay I., Szafer F., Meir K., Rosen H., Shpizen S., Ben Avi L., Staels B., Fievet C., Meiner V., Bjorkhem I., Leitersdorf E. : Human sterol 27-hydroxylase (CYP27) overexpression transgenic mouse model. Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis. *Atherosclerosis 2002 Suppl 3, Abstr 456, p 164*
89. P. SCHAEFFER, G. MARTIN, F. DOL, A.M. MARES, V. BEREZOWSKI, B. STAELS, D.W. HUM, J.M. HERBERT: Effect of the ATI angiotension II receptor antagonist irbesartan on lesion progression and chemokine expression in apo E deficient mice. *Atherosclerosis 2002 Supplements, 3, Abstr 625, p.201.*
90. P. GERVOIS, N. VU-DAC, H. JAKEL, M. NOWAK, B. STAELS, L.A. PENNACCHIO, E.M. RUBIN, J. FRUCHART, J.C. FRUCHART: Apolipoprotein A-V is a crucial determinant of plasma triglyceride levels highly responsive to PPAR α activators. *Circulation 2002, 106/19 Suppl.II-301, 1507.*
91. R.R. SINGARAJA, C. FIEVET, G. CASTRO, E. JAMES, S. CLEE, N. HENNUYER, J. CHOY, N. BISSADA, B. McMANUS, B. STAELS, M.R. HAYDEN : Increased HDL and changes in lipoprotein composition are associated with increased efflux and atheroprotection in an ABCA1 BAC transgenic mouse model. *Circulation 2002, 106/19 Suppl.II-219, 1105.*
92. E. TEISSIER, G. CHINETTI, B. STAELS : PPAR α but not PPAR γ agonists induce generation of hydrogen peroxide in human macrophages. *Circulation 2002, 106/19 Suppl.II-261, 1312.*
93. P.FROMENT, S.FABRE, C.PISSELET, D.MONNIAUX, B.STAELS, P.MONGET : Rôle des PPAR gamma dans la fonction ovarienne. *Annales d'Endocrinologie 2002, 63(4) : C012.*
94. P.GELE, D.DEPLANQUE, I.SIX, S.NION, JC FRUCHART, R.CECHELLI, B.STAELS, P.DURIEZ, R.BORDET : Prophylactic PPARalpha activation decreases brain injury after transient ischemia in mice. *Fundamental and Clinical Pharmacology 2003, 17 : 227-229*
95. B.STAELS : Nuclear receptors in metabolic control. *Endocrine Abstracts 2003, Vol. 5 : S22*
96. NM. MORTON, JM. PATERSON, H.MASUZAKI, MC HOLMES, B.STAELS, C.FIEVET, BR WALKER, J.FLIER, JJ.MULLINS, JR. SECKL : Reduced intra-adipose glucocorticoid regeneration : a novel adaptive response to, and therapy for the metabolic syndrome. *Endocrine Abstracts 2003, Vol. 5 : S23*
97. B.STAELS : Nuclear receptors controlling the metabolic syndrome and atherosclerosis. *Atherosclerosis 2003; 4(2) Supp.: p.92*

98. L.MILLATT, K.BERTRAND, R.DARTEIL, P.VERWAERDE, DW.HUM, N.PROVOST, P.POULAIN, Z.MAJD, S.HELLEBOID, JF.DELHOMEL, R.BORDET, J.FRUCHART, B.STAELS, JC.FRUCHART : A novel family of compounds with beneficial effects in mouse models of dyslipidemia and ischemic stroke. *Atherosclerosis* 2003; 4(2) Supp.: p.156
99. L.MILLATT, R.DARTEIL, K.BERTRAND, P.VERWAERDE, DW.HUM, E.RASPE, P.POULAIN, Z.MAJD, S.HELLEBOID, E.BOUHEY, R.BORDET, J.FRUCHART, B.STAELS, JC.FRUCHART : GFT14, a novel compound with hypolipidemic and neuroprotective properties. *Atherosclerosis* 2003; 4(2) Supp.: p.241
100. M.NOWAK, A HELLEBOID-CHAPMAN, H.JAKEL, C.ROMMENS, E.BAUGE, P.GERVOIS, N.VU-DAC, G.MARTIN, D.DURAN-SANDOVAL, B.STAELS, MR TASKINEN, L.PENNACCHIO, E.RUBIN, J.FRUCHART-NAJIB, JC.FRUCHART : Transcriptional regulation of the apolipoprotein A5 gene by insulin. *Atherosclerosis* 2003; 4(2) Supp.: p.245
101. B.STAELS : Perspective targets in the treatment of the metabolic syndrome. *International Journal of Obesity* 2004;28(1) : S25
102. HM.PRINCEN, GROENENDIJK M., POST S., FIEVET C., STAELS B. : Deficient bile acid synthesis in hyperlipidemic mice enhances HDL cholesterol via increased hepatic ABCA1 activity. *Circulation* 2004;110(17):1302
103. F.GIZARD, C.AMANT, O.BARBIER, F.PERCEVAULT, A.CORSINI, C.GLINEUR, FRUCHART JC, G.TORPIER, B.STAELS : PPAR α inhibits vascular smooth muscle cell proliferation through trans-activation of the gene tumor suppressor p16^{INK4a}. *Circulation* 2004;110(17):1326
104. R.S.Sverdlov-Shiri, K.Wouters, PJJ Van Gorp, MJJ Gijbels, B.Staels, M. Van Bilsen, MH. Hofker : The apoE2 knock-in mouse as a model for type III hyperlipidemia and steatohepatitis. *Atherosclerosis* 2005;6(1)Suppl:10
105. B.Staels : PPARs as targets for anti-atherosclerotic therapies. *Atherosclerosis* 2005;6(1)Suppl:95
106. T.Claudel, BM.Elzinga, V.Bloks, B.Staels, PJ. Voshol, F.Kuipers : Role of farnesoid X receptor (FXR) in control of plasma lipid levels. *Atherosclerosis* 2005;6(1)Suppl:95
107. A.Tailleux, F.Lalloyer, S.Lestavel, G.Torpier, S.Yous, JC.Fruchart, B.Staels, C.Fievet : Atheroprotective effect of the rexinoid targeting in a murine model of atherosclerosis. *Atherosclerosis* 2005;6(1)Suppl:96
108. F.Lalloyer, F.Percevault, G.Torpier, JC.Fruchart, F.Kuipers, C.Fievet, B.Staels : PPAR α deficiency aggravates diabetes in OB/OB mice. *Atherosclerosis* 2005;6(1)Suppl:97
109. S.Lestavel, C.Duval, V.Touche, A.Tailleux, V.Carriere, JC.Fruchart, B.Staels, V.Clavey : Regulation of genes encoding intestinal cholesterol transporters by nuclear receptors in human CaCo-2/TC7 enterocytes. *Atherosclerosis* 2005;6(1)Suppl:97
110. Clemenz M., Schupp M., Frost N., Unger T., Staels B., Kintscher U. : The AT1 receptor blocker telmisartan is a partial PPAR α agonist. *Int J Obesity* 2005;29(3):P007

INVITED LECTURES

1. "Transcriptional control of triglyceride metabolism: fibrates regulate the LPL and apo C-III genes through the nuclear receptor PPAR"; Euroconférences 95, Contribution de la Biologie Moléculaire à la Découverte de Médicaments, Prés.G.Feuerstein & E.-E.Baulieu, avril 6 1995, Institut Pasteur, Paris, France
2. "Régulation des gènes du métabolisme des lipoprotéines par les fibrates: rôle du facteur de transcription PPAR"; july 7 1995, Centre du Médicament, U.R.A.597 (G.Siest), Faculté des Sciences Pharmaceutiques et Biologiques, Université Henri Poincaré-Nancy I, Nancy, France
3. "Fatty acids as transcriptional regulators of genes involved in lipoprotein metabolism"; International Symposium " ω -3, Lipoproteins and Atherosclerosis"; 13-15/10/95, Granada, Spain
4. "Regulation of genes involved in lipoprotein metabolism by fibrates: role of the transcription factor PPAR"; november 17 1995, Department of Atherosclerosis Pharmacology (R.Newton), Parke-Davis, Ann Arbor, MI, USA
5. "Nutritional and pharmacological control of genes involved in lipoprotein metabolism: role of the transcription factor PPAR"; january 4 1996, Department of Cardiovascular Pharmacology (G.Feuerstein), Smith-Kline Beecham R&D, Philadelphia, PA, U.S.A.
6. "Regulation of lipoprotein lipase expression"; april 27 1996, Round Table on Chylomicron Catabolism - Lipases and Receptors (U.Beisiegel), Hamburg, Germany
7. "Gene-environment interactions: pharmacological and nutritional control of apo A-I and A-II gene regulation"; september 29-october 3 1996, IX Colloque International de Pont-à-Mousson Eurobiologie (K.Berg), France
8. "PPARs et métabolisme des lipides et lipoprotéines"; november 8 1996, DEA Microbiologie, Enzymologie et Nutrition (Module Interactions Cellulaires et Moléculaires) (M.Dauca), Univ. de Nancy I
9. "Régulation de la leptine. Différenciation de l'adipocyte"; november 28 1996; DU de Nutrition Humaine de Diététique et de Diététique Thérapeutique (Module de Physiologie de la Nutrition) (O.Ziegler), Faculté de Médecine de Nancy
10. "Role of PPAR in the regulation of high density lipoprotein metabolism"; Euroconférences 96, Nouvelles perspectives sur l'athérosclérose, Prés.J.C.Fruchart & P.Denèfle, december 6 1996, Institut Pasteur, Paris, France
11. "Nutritional regulation of genes"; december 11 1996; Karolinska Institute (F.Karpe), Stockholm, Sweden
12. "Rôle des PPARs dans la régulation des gènes du métabolisme des lipides et des lipoprotéines"; Séminaire URA CNRS 1283 (P.Benlian), february 11 1997, Paris, France
13. "Régulation par des facteurs nutritionnels et pharmacologiques de l'expression des gènes des apolipoprotéines"; DEA de Nutrition et Sciences des Aliments (Option Nutrition: Aspects métaboliques, cellulaires et moléculaires) (A.Mazur), Univ. Blaise Pascal & Univ. d'Auvergne, march 14 1997, Saint Genès Champanelle, France
14. "PPAR system - implications for therapy of mixed lipaemia"; march 18 1997, British Hyperlipidemia Association International Workshop Mixed Lipaemia, Royal College of Physicians, London
15. "Regulation of apo A-I gene expression by fibrates"; Plenary Session, may 8 1997, 68th Meeting of the European Atherosclerosis Society on Molecular Cell Biology & Atherogenesis, Brugge, Belgium
16. "Biologie moléculaire de la différenciation adipocytaire"; le 9 may 1997, IXème Séminaire Pédagogique, Association Nationale des Professeurs et Maîtres de Conférences Biochimistes des Facultés de Médecine de France (Prof.H.H.Floch), 7-10 may 1997, Port aux Rocs - Le Croisic, France
17. "Control of apo A-I and apo A-II gene expression"; october 4 1997, XIth International Symposium on Atherosclerosis Satellite Symposium: Reverse Cholesterol Transport (J.C.Fruchart & H.B.Brewer), Lille
18. "Identification and characterization of a human PPAR α splice variant with recessive negative activity"; october 13 1997, 9th International CBT Symposium on Nuclear Steroid and Orphan Receptors, Huddinge, Sweden
19. "PPARs: mediators of fibrate action on lipoprotein metabolism"; Symposium on Molecular mechanisms in lipid and lipoprotein metabolism, 25th Silver Jubilee Meeting of FEBS, july 5-10, 1998, Copenhagen, Denmark
20. "Système d'expression inductible: application à la thérapie génique"; november 18 1997, Journées Scientifiques Bio Avenir 1997, Paris, France
21. "PPARs: regulators of lipid and lipoprotein metabolism"; Seminar Dept. Molecular Biology, Univ. Gent (G.Haegeman), december 15 1997, Gent, Belgium
22. "PPARs et métabolisme des lipoprotéines"; Club des Jeunes Lipidologues, november 1997, Lille, France
23. "Fibrates: acides gras 'frauduleux' qui régulent le métabolisme des lipoprotéines par le récepteur nucléaire PPAR"; Symposium Albert Calmette, Institut Pasteur de Lille, januari 13 1998, Lille, France
24. "PPARs"; Assemblée Générale du Club des Jeunes Lipidologues, january 16 1998, Dijon, France
25. "Transcription factor genes controlling high density lipoprotein metabolism"; 1er Mini-Colloque International 'Facteurs de Transcription et Régulation de l'Expression des Gènes comme Cibles Thérapeutiques', januari 30 1998, Luxembourg, Luxembourg
26. "PPARs and atherosclerosis"; february 20 1998, Division of Cardiovascular Genetics, The Rayne Institute, London
27. "Transcription factor genes controlling high density lipoprotein metabolism"; Union de Sociétés Suisses de Biologie Expérimentale, march 5-6 1998, Lausanne, Switzerland
28. "PPARs and atherosclerosis"; march 11 1998, British Hyperlipidemia Association Workshop 'Transport Mechanisms in Lipid and Lipoprotein Metabolism', Royal College of Surgeons, London
29. "PPARs and atherosclerosis"; march 27 1998, Division of Endocrinology and Diabetes, Vanderbilt University Medical Center, Nashville, USA
30. "Rôle des facteurs nucléaires dans l'athérosclérose"; april 23 1998, Dynamique Cardiocirculatoire - Biologie de la Paroi Vasculaire, INSERM U.141, Hôp. Lariboisière, Paris

31. "PPARs: regulators of lipid metabolism and inflammation with a function at the vascular wall"; 70th Congress of the European Atherosclerosis Society, September 6-9, 1998, Geneva, Switzerland
32. "Hormonal and Pharmacological Regulation of Apolipoprotein Gene Expression"; september 21 1998, Biochimie Cardiovasculaire, Synthelabo Recherche, Paris, France
33. "Fibrates: hypolipidemic drugs with an action at the vascular wall" september 28-october 1 1998, 21st European Lipoprotein Club Meeting, Tutzing, Germany
34. "Mechanism of action of fenofibrate" october 2 1998, XI Congreso Nacional de la Sociedad Espanola de Atherosclerosis, Cadiz, Spain
35. "Regulations of lipid metabolism by PPARs"; Symposium: Insuline-resistentie, dyslipidemie en hart- en vaatziekten. October 9 1998, Academisch Ziekenhuis Groningen, The Netherlands
36. "Molecular mechanisms of action of omega-3 fatty acids" Consensus symposium 'Atherothrombosis and Triglycerides' october 29 1998, Paris, France
37. "PPARs modulators of fibrate action on lipid metabolism and inflammation" november 26 1998, Dépt. d'Endocrinologie, Erasmus Universiteit Rotterdam, The Netherlands
38. "Rôle des récepteurs nucléaires" november 30 1998, Stages de Formation du GRRC 'Athérosclérose: Physiopathologie, Modèles expérimentaux, Clinique', Le Vésinet, France
39. "PPAR α and its role in atherogenesis"; Japan Intractable Diseases Research Foundation' International Symposium on Lipoprotein Metabolism and Atherosclerosis, december 3-5 1998, Kyoto, Japan
40. "PPAR α activateurs, inflammation et paroi artérielle"; december 8 1998, Journées annuelle des Centres Clinico Biologiques des Lipides, Paris, France
41. "De PPARs verder ontrafeld?" december 14 1998, Dept.Endocrinology/Diabetology, Universitair Ziekenhuis Antwerpen, Belgium
42. "Mechanisms by which PPAR γ and α agonists affect insulin sensitivity and lipid metabolism"; april 14-16 1999, SmithKlineBeecham Research Symposium The Insulin Resistance Syndrome: Molecular mechanisms linking obesity, diabetes and cardiovascular disease. Cambridge, U.K.
43. "Contribution des fibrates"; april 24 1999, 10th Annual Meeting of the Club de Lipidologie du Québec, Québec, Canada
44. "PPAR α and Syndrome X" april 28-may 2 1999, Keystone Symposium on "The PPARs: Transcriptional links to Obesity, Diabetes and Cardiovascular Disease", Lake Tahoe, USA
45. "Applications de la génomique fonctionnelle dans l'athérosclérose" may 7 1999, Colloque Mastère en Drug Design/DEA Biologie Cellulaire et Moléculaire, Louvain-la-Neuve, Belgique
46. « Anti-inflammatory actions of PPAR α in atherosclerosis », EMBO Workshop 'Structure and function of Nuclear Receptors' ; May 25-27, 1999, Villefranche-sur-mer, France.
47. "Récepteurs nucléaires et athérosclérose"; may 28 1999, Journées Franco-Belges de Pharmacochimie 'De la conception à la réalisation en pharmacochimie' Liège, Belgium
48. "Nuclear receptors and the metabolic syndrome"; may 31 1999, GESA 28, Obernai, France
49. "PPARs: modulateurs des facteurs de risque pour l'athérosclérose"; june 11 1999, 1st Annual Meeting of the Société Française d'Athérosclérose, Arcachon, France
50. « Mechanisms by which PPAR activators affect insulin sensitivity and lipid metabolism » ; 4th International Clore symposium – Obesity and NIDDM, June 30-July 2 1999, Buckingham, England.
51. "PPARs, the Metabolic Syndrome and Atherosclerosis"; september 5-8 1999, Annual Fall Meeting of the GBM, Hamburg, Germany
52. "PPARalpha activators regulate genes controlling HDL metabolism"; september 18 1999, IAS Workshop on HDL metabolism, Gent, Belgium
53. "PPARs, inflammation and atherosclerosis"; september 30-october 2 1999, 3rd Japan-Europe Joint Forum on Atherosclerosis Research, Ise, Japan
54. "Nuclear transcription factors: new opportunities for lipid lowering"; october 5-6 1999, Joint Meeting Nut-Soc, BHA, ASO, RSM Lipid Forum, 'Reducing CHD risk: a multifactorial approach', Royal College of Physicians, London, England.
55. "PPARs, inflammation and atherosclerosis"; september 30-october 2 1999, 3rd Japan-Europe Joint Forum on Atherosclerosis Research, Ise, Japan
56. "Apports de la biologie moléculaire et cellulaire à la connaissance de la physiologie de l'adipocyte"; october 10 1999, 45th Journée Pharmaceutique du Nord, 'La Surcharge Ponderale', Lille, France
57. "Peroxisome proliferator-activated receptors: nuclear receptors at the cross-roads between lipid metabolism and inflammation"; november 3 1999, Merck, Rahway, USA
58. "Peroxisome proliferator-activated receptors: nuclear receptors at the cross-roads between lipid metabolism and inflammation"; november 4 1999, Dupont Pharma, Wilmington, USA
59. "Peroxisome proliferator-activated receptors and the regulation of inflammation"; november 5 1999, American Society of Nephrology Annual Meeting, Basic Science Symposium, Miami, USA
60. "The PPAR system in the regulation of energy homeostasis and metabolic disorders"; Euroconférences 99, Obesity, Genetics, Pathophysiology and Therapeutics on the Eve of a Major Conceptual Revolution, Prés.J.Caro, P.Froguel, J.Licinio, M.McCamish, B.B.Vargaftig, november 25-27 1999, Institut Pasteur, Paris, France
61. "Control of insulin resistance and inflammation by PPARalpha"; 10th International Dresden Symposium on Lipoproteins and Atherosclerosis, december 9-11 1999, Dresden, Germany

62. "Role of fatty acids in insulin resistance : the glucose fatty acid cycle revisited"; Endocrinology and metabolism discussion symposium, December 13-14, 1999, Oxford, England.
63. "Transcription factors controlling lipid metabolism as a therapeutic target"; International Meeting on 'Signal Transduction Pathways and Regulation of Gene Expression as Therapeutic Targets', januari 26-29 2000, Luxembourg, Luxembourg
64. "Nuclear receptors as targets to modulate HDL levels"; International Symposium on 'Basic aspects of HDL metabolism and disease prevention', 2000 EAS workshop, April 7-9 2000, Istanbul, Turkey.
65. "PPAR γ and Insulineresistentie "; 12th International De Dagen 2000, April 26-28, Koningshof Veldhoven, The Netherlands.
66. "PPAR γ en thiazolidines, (patho)fysiologie"; 12th International De Dagen 2000, April 26-28, Koningshof Veldhoven, The Netherlands
67. "The PPAR family of nuclear receptors"; First Liverpool Symposium on type 2 Diabetes, May 3-5, 2000, Liverpool, UK.
68. "PPAR regulated genes involved in macrophage lipid homeostasis"; EU-Biomed 2, May 4-7, 2000, London, UK.
69. "Role of the PPAR system in atherosclerosis"; 2nd scientific workshop on Biology of Vascular Calcification, May 25-26, 2000, Lutherstadt Wittenberg, Germany.
70. "PPARs : Nuclear Receptor Controlling Vascular Inflammation"; 32th annual meeting of Japan Atherosclerosis Society, June 1-2, 2000, Tokyo, Japan.
71. "Regulation of HDL metabolism by fenofibrate through PPAR α "; International Luncheon Symposium on Atherosclerosis Research – present and future, June 1-2, 2000, Tokyo, Japan.
72. "Peroxisome proliferator-activated receptors (PPARs) : nuclear receptors at the crossroads between lipid metabolism and inflammation"; 4th Dutch Endo-Neuro Meeting, Plenary Session, June 6, 2000, Doorwerth, The Netherlands.
73. "PPAR regulation of lipoprotein metabolism"; American Diabetes Association's 60th scientific sessions, symposium session – PPAR transcription factors and complications of diabetes -, June 9-13, 2000; San Antonio, Texas, USA.
74. "Fatty acid-activated receptors controlling lipid metabolism and inflammation"; XII International Symposium on Atherosclerosis, June 25-29, 2000; Stockholm, Sweden.
75. "Role of HDL in cell signalling"; XII International Symposium on Atherosclerosis, July 2, 2000; Helsinki, Finland.
76. "PPARs : nuclear receptors at the crossroads between lipid metabolism and inflammation"; International Symposium of CBT and Eurosterone on Nuclear Receptors in Health and Disease, Sept. 24-27,2000, Huddinge, Sweden
77. "PPARalpha, lipoproteines et athérosclérose"; 2nd Congress of SMEDIAN, Oct. 19-22,2000, Tanger, Maroc
78. "Chairman Session", AHA Congress, Nov. 15, 2000, New Orleans, Louisiana, USA.
79. "Regulation of lipoprotein metabolism and atherosclerosis"; HDL and Cardiovascular Disease : Therapeutic Implications – Dec. 15, 2000, University of Milan, Institute of Pharmacological Sciences, Italy.
80. "Control of HDL Metabolism by PPARs"; Accessing HDL as a risk factor in coronary heart disease- Working Group Meeting, Hyatt Regency Scottsdale, Arizona, USA, January 12-13, 2001.
81. "Transcription factors as regulators of HDL metabolism" – HDL cholesterol, metabolic pathways and drug development – 11-13 February 2001, Boston, USA
82. "Metabolic and inflammation control by PPAR α " – The 2001 Deuel Conference on Lipids, March 6-9, 2001 – Dana Point, California, USA
83. "Les glitazones, mécanismes d'action" – Alfediam congress on Diabete, March 27-31, 2001 – Montpellier, France
84. « Clinical significance of PPARgamma and alpha agonism in disease : an update on pioglitazone research ». 1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy.
85. " PPARalpha and the metabolic syndrome" - 1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy.
86. "PPARs, nuclear receptors controlling the metabolic syndrome and atherosclerosis" – The 44th annual scientific meeting of Japan Diabetes Society – April 16, 2001 – Kyoto, Japan.
87. "Role of PPARs in Vascular Disease" – VISN17 Research Conference : role of lipids in cardiovascular disease in diabetes and aging – April 20, 2001, Dallas, USA.
88. "PPAR α : another anti-inflammatory PPAR" – Euroconferences Pasteur Institute on Inflammation : between lesion and resolution, April 25, 2001 – Paris, France.
89. "Les activateurs de PPARalpha et la régulation du métabolisme des lipoprotéines, de l'inflammation vasculaire et de l'athérosclérose" – 42^{ème} Journées Annuelles de Diabétologie de l'Hôtel Dieu, May 10-12, 2001, Paris, France.
90. « PPARs : nuclear receptors on the crossroads of lipid metabolism and inflammation control" - (plenary session) 72nd European Atherosclerosis Society Congress, 20-23 May 2001, Glasgow, UK.
91. "Transcription factors controlling lipid and lipoprotein metabolism" – 42nd International Conference on the Bioscience of Lipids, 5-9 June 2001, Bergen, Norway
92. "PPAR regulation of lipid metabolism and energy homeostasis" – (plenary session) 4th International Smolenice Insulin Symposium on Lipids and Insulin Resistance, 30 August 2001, Bratislava, Slovak Republik.
93. "Nutrients, transcriptions factors and the prevention of diseases" – VLAG masterclass on Nutrient gene interactions, 6-7 September 2001 University of Wageningen, Maastricht, The Netherlands
94. "Nuclear receptors controlling lipid metabolism and inflammation in the vascular wall" – ELC 24th Annual Conference, 10-13 September 2001, Tutzing, Germany.
95. "Treatment of low HDL levels" – IAS workshop on Receptor-mediated regulation of HDL in Atherosclerosis, 4-6 October 2001, Gent, Belgium.
96. "PPARs, nuclear targets for the treatment of the metabolic syndrome" – Wellcome Trust Cardiovascular Research Initiative Seminar – October 30, 2001, Edinburgh, UK

97. "Clinical significance of PPAR γ and PPAR α agonism in diseases – an update" – 3rd Annual Endocrine Specialist Symposium, 2 November 2001, Snekkersten, Denmark
98. "The clinical significance of PPAR α and γ agonism" – Takeda meeting on Thiazolidinediones, the promises and the facts, 10 November 2001, Marbella, Spain
99. "PPARs and lipoprotein metabolism" – AHA Scientific Sessions, 12 November 2001, Anaheim, California, USA
100. "PPARs – Metabolic Syndrome and Atherosclerosis" – GPRPV meeting, 29 November 2001, Paris, France
101. "PPAR α and insulin resistance" – 2nd International Huaxia Congress of Endocrinology", 14-17 December 2001, Hong Kong, China
102. "Nuclear receptors as targets in the pharmacology" – Symposium La sécurité des médicaments en milieu hospitalier, 31 January 2002, Kursaal Bern, Switzerland
103. "PPAR α , metabolic control and inflammation" – European Conference Center, 2 Feb. 2002, Kirchberg Luxembourg.
104. "PPAR γ in reverse cholesterol transport" – 46th Annual meeting of the German Society of Endocrinology, Feb 28- March 1st 2002, Göttingen, Germany
105. "Thiazolidinediones : mode of action and the clinical significance of PPAR α and γ agonism" – Actos regional medical congress on diabetes – a cardiovascular disease ? the role of thiazolidinediones, March 1st 2002, Madrid, Spain
106. "Fibrates" – Korea Society of Lipid and Atherosclerosis, March 7-9, 2002, Seoul, Korea.
107. "Nuclear receptors as targets for the treatment of atherosclerosis and the metabolic syndrome" – Congress of Metabolic syndrome and Atherosclerosis, March 27-29, 2002, Lille, France
108. "PPARs : modulators of the metabolic syndrome". Pontificia Universidad Catolica - Facultad de Ciencias Biologicas – April 1-3, 2002 Santiago, Chile
109. "Regulation of Apolipoprotein AI synthesis" - 36th Annual Scientific Meeting of the European Society for Clinical Investigation – April 11th, 2002, Brussels, Belgium
110. « PPAR receptors at the cross-roads between lipid metabolism and inflammation » - 2nd European Conference on "Management of Coronary Heart Disease" – April 13-15, 2002, Nice, France
111. "PPARs : nuclear receptors at the crossroads of inflammation and metabolic control". Congress of the Dutch Society for Clinical Chemistry – NVKC meeting April 25, 2002, Lunteren, The Netherlands.
112. "The role of PPARs in Atherosclerosis". American Association of Clinical Endocrinologists, NDEI Annual Meeting on PPARs and their relevance to clinical practice – May 1st, 2002, Chicago, USA
113. "The clinical significance of PPAR α and γ agonism" – The First European Actos Symposium on Pioglitazone, new approaches to vascular diseases in type 2 diabetes", May 17-19, 2002, Prague, Tchécoslovaquie.
114. "Modulation of TG metabolism by nuclear receptors" – 6th International Symposium on Global Risk Heart Disease and Stroke : Assessment, Prevention and Treatment", June 12-14, 2002, Florence, Italy
115. "Rôles des récepteurs PPARs dans le contrôle de l'homéostasie lipidique et glucidique » - 28^{èmes} rencontres internationales de chimie thérapeutique, July 4, 2002, Rennes, France
116. « PPAR α and Atherosclerosis » - 34th annual meeting of the Japan Atherosclerosis Society », July 18-19, 2002, Kobe, Japan
117. "PPAR α , fibrate and HDL metabolism : from science to clinical benefits" - 34th annual meeting of the Japan Atherosclerosis Society », July 18-19, 2002, Kobe, Japan
118. "PPARs, lipids and atherosclerosis" – ESC PPAR and Cardiovascular Disease – August 30th, 2002, Berlin, Germany.
119. "Decreasing resistance through dual PPAR γ and α activation" - EASD Symposium : Tools for metabolic control, today and tomorrow – Sept. 1st, 2002, Budapest, Hungary
120. "Nuclear Hormone Receptors in Atherosclerosis " – British Atherosclerosis Society – Autumn meeting, Sept. 19-20, 2002, Cambridge, UK
121. "PPARs and the metabolic syndrome" - ADS-ADEA Annual Scientific Meeting in Adelaide – Sept. 21- Oct. 1, 2002, Adelaide, Australia
122. "PPARs and the atherogenic lipid triad of the metabolic syndrome" - ADS-ADEA Annual Scientific Meeting in Adelaide – Sept. 21- Oct. 1, 2002, Adelaide, Australia
123. « Nuclear receptors controlling the metabolic syndrome » - VIII European Symposium on Metabolism – Oct 3-7, 2002, Padova, Italy
124. « Nuclear receptors controlling lipid and lipoprotein metabolism » - The romanian Academy Institute of Cellular Biology and Pathology « Nicolae Simionescu" Workshop "Cardiovascular Dysfunctions in Hyperlipidemia and Diabetes" – Oct 10-12, 2002 Bucharest, Romania
125. "New therapeutic pathways in the fields of preventive cardiology and metabolic disease" – 6th French Biotechnology Crossroads, Oct. 15-16, 2002 Lille, France
126. "Control of the metabolic syndrome by PPARs" - International Congress on Hormonal Steroids and Hormones and Cancer – Oct. 21-25, 2002 Fukuoka, Japan
127. "Clinical significance of PPAR γ and α agonism" - Thiazolidinedione Conference on Oct. 26-27, Tokyo, Japan
«PPARs and inflammation » - 4th annual symposium DB Brown Research Chair on Obesity Complications of obesity : the inflammation link' Nov. 14-16, 2002 Québec, Canada
128. « PPARs : at the interface of lipid metabolism » - NDEI PPARs : at the interface of type 2 diabetes and atherosclerosis Nov. 17, 2002 Chicago, USA
129. ""Pharmacologie moléculaire des fibrates et des thiazolididiones" – 48^{èmes} Journées Pharmaceutiques du Nord Dec. 1st, 2002 – Lille, France.

130. « PPARs and the metabolic syndrome » - 4th International Think Tank “The metabolic syndrome : the new world-wide epidemic” Dec. 13-15, 2002 Nice France
131. “PPARs at the crossroads of lipid metabolism and inflammation control” – Kestone Symposia, Feb. 4-9, 2003 - Colorado, USA
132. “PPAR α agonists : from molecular mechanism to clinical implications in low HDL-C and the metabolic syndrome” (plenary lecture) – Annual meeting of the Taiwan Endocrinology Society, March 12-15, 2003 – Taiwan, Japan
133. “Modulation of the PPAR α signalling pathway : relevance for the metabolic syndrome and atherosclerosis” – 2nd International Symposium on PPARs : from basic science to clinical applications, March 18-22, 2003 – Florence Italy
134. “Nuclear receptors in metabolic control” – 22nd Joint meeting of the British Endocrine Societies – March 24-26, 2003 – Glasgow, UK
135. “PPAR α/γ co-ligands and SPPARMS” – Alfediam congress, March 26-27, 2003 – Bordeaux, France
136. “PPARs and the metabolic syndrome” – 7th Annual Congress of the French Society of Pharmacology – April 14-16, 2003 – Lille France
137. “PPARs and lipid metabolism” – 6th European Congress of Endocrinology – April 26-30, 2003 – Lyon, France
138. “PPARs and the metabolic syndrome” – Congress of the Spanish Society of Atherosclerosis – May 14-15, 2003 – Malaga, Spain
139. “PPARs and vascular inflammation” – IBC’s Drug Discovery for Inflammation Disease” – June 2-4, 2003 – Washington, USA
140. “PPARs ligand” – Hear Failure / ISHR – ES 2003 – June 21-22, 2003 – Strasbourg, France
141. “ Nuclear receptors controlling the metabolic syndrome and atherosclerosis” 19^{ème} Ernst Klenk Symposium – July 6-8, 2003 – Cologne, Germany
142. “ Adipocyte differentiation : PPARs and PPAR agonists” – Int.Symp. on Triglycerides, Metabolic Syndrome and Cardiovascular Disease, July 10-13, 2003, New York USA
143. “Future directions : new metabolic targets for the prevention and treatment of atherosclerosis” - Int.Symp. on Triglycerides, Metabolic Syndrome and Cardiovascular Disease, July 10-13, 2003, New York USA
144. “Pleiotropic effects of glitazones” – 18th Int. Diabetes Federation Congress, August 22-29, 2003, Paris France
145. “Regulation of lipid homeostasis by PPARs” – Nobel Conference (Transcriptional control of lipid homeostasis), August 25-27, 2003, Huddinge, Sweden
146. “Récepteurs nucléaires et athérosclérose” – 1er congrès de Lipidomique, Sept. 5, 2003, Paris France
147. « Current and new metabolic targets for the prevention and treatment of atherosclerosis” – 13th Int. Symposium on Atherosclerosis, Sept 27- Oct 3, 2003, Kyoto, Japan
148. “Emerging role of PPAR agonists with both alpha and gamma receptor activity” - 13th Int. Symposium on Atherosclerosis, Sept 27- Oct 3, 2003, Kyoto, Japan
149. “Nuclear receptors controlling the metabolic syndrome and atherosclerosis” - 13th Int. Symposium on Atherosclerosis, Sept 27- Oct 3, 2003, Kyoto, Japan
150. “PPARs as therapeutic targets” – 13th Int. Symposium on Atherosclerosis – Satellite Symposium Tokyo Bay, Oct. 3-6, 2003, Tokyo, Japan
151. “PPARs and Atherosclerosis” – 8th Annual Meeting of the European Council for Blood Pressure and Cardiovascular Research”, Oct. 10, 2003, Seeheim, Germany
152. “Linking PPARs to metabolic, inflammatory and energy control in relation to ageing” – Future Forum Conference, Oct. 24, 2003, Amsterdam, The Netherlands
153. “Le rôle des PPARs dans la régulation de l’inflammation de la paroi artérielle » - 3rd congress of Société Francophone de Transplantation, Nov. 27-28, 2003, Paris, France.
154. « Le point de vue du fondamentaliste » Session Foie et Diabète – Stéatose Hépatique. 5th Symposium de Diabétologie Franco-Suisse, Zermatt Switzerland, January 15-18, 2004
155. « Les récepteurs nucléaires de la famille des PPARs : cibles thérapeutiques pour la régulation du métabolisme lipidique » . 5^{ème} cours intensif Alfediam, Paris, France, February 6-8, 2004
156. « Beyond lipid targets : regulation of non lipid parameters by PPAR α – from molecular mechanisms to clinical practice management ». 12th International workshop in Cardiovascular Disease, Dijon, France, February 13-15, 2004
157. “Scientific update on hormone nuclear receptor” – University Health Network Lipid Research Group and Robarts Institute Research Rounds in Toronto, Canada – March 2-3, 2004.
158. “Nuclear receptors – from basic science to clinical applications – Toronto General Hospital, Cardiology research rounds and St Michaels Hospital Cardiovascular Research Group; and St Joseph’s Grand Rounds in Toronto, Canada – March 2-3, 2004.
159. “Molecular and Clinical Advances in the Control of Intestinal Cholesterol Absorption” – Vascular Research Group in Hamilton – Canada March 4, 2004
160. “Nuclear receptors – from basic science to clinical applications – Endocrinology Rounds, University of Calgary, Canada – March 10, 2004.
161. “New insights into diabetes and atherosclerosis – Endocrinology rounds, University of Montreal, Canada – March 12, 2004.
162. “PPAR agonists and atherosclerosis” - Symposium on PPAR agonists and Metabolic Regulation, Biomedicum Helsinki – Finland - March 29, 2004
163. « PPAR γ/δ » - ADA Research Symposium on Integrative Role of Fatty Acids in Metabolic Regulation : Implications for Obesity and Diabetes – Boston, USA - April 2nd, 2004.

164. "Nuclear receptors controlling glucose and Lipid metabolism" 74th EAS congress - Plenary lecture - Session on Diabetes, HDL and Triglycerides – Seville, Spain, April 19th, 2004
165. "Molecular Mechanism" Post EAS congress satellite – Malaga, Spain, April 20th, 2004
166. "Pleiotropic actions of PPAR on inflammation and atherosclerosis". Necker Seminar in Nephrology – Paris, France – April 26, 2004
167. "Inflammation, diabetes and PPARs" – Future Forum Conference – Barcelona, Spain – May 17, 2004.
168. « Insulin resistance and cardiovascular risk in diabetes » - Metabolic syndrome, type II diabetes and atherosclerosis Congress, Marrakech, Morocco – May 19, 2004.
169. "PPARs : their endogenous and exogenous ligands and the metabolic syndrome" – First International Cardiovascular Research Conference, Marrakech, Morocco – May 19, 2004
170. "Perspective targets in the treatment of metabolic syndrome" – 13th European Congress on Obesity, Prague Czech Republic – May 29, 2004.
171. "Molecular and Clinical Advances in the Control of Intestinal Cholesterol Absorption: a Focus on PPARs, Statins and Ezetimibe" – ASEANZ, Perth, Australia – June 3rd, 2004.
172. "Nuclear receptors - Curiosity for cell biologists or pharmacologic breakthrough for clinicians" – Melbourne, Australia – June 6th, 2004.
173. Chairman of the Session "Nuclear receptors and Coregulators" – 1st Paul Hamel Conference, Monaco - June 7th 2004.
174. "PPARs : from basic science to clinical application" : Taiwanese Lipid. And Atheroscl. Soc. – Taipei, Japan – June 25, 2004
175. « Nuclear receptors, diabetes mellitus and cardiovascular disease » - Heart UK 18th Annual Medial and Scientific Meeting : Lipids and diabetes, current concepts. – Bath UK, July 1st, 2004.
176. "Bile acid receptors" – International congress of Endocrinology - Lisbonne, Portugal, Sept. 2-4, 2004
177. "Insulin resistance at the vascular level and endothelial dysfunction : mechanisms and potential for modulation – 40th EASD, Munich, Germany, Sept 7, 2004
178. "The protein kinase C signalling pathway regulates a molecular switch between transactivation and transrepression activity of PPARalpha – 27th ELC meeting, Tutzing, Germany, Sept.8, 2004
179. "PPARs and human diseases" – CASCADE Summer school on Nuclear Hormone Receptors, ENS Lyon, France, Sept. 13, 2004
180. "Metabolic and pleiotropic cardioprotective activities of PPARalpha and gamma" – International symposium on the occasion of the 65th birthday of Pr. Klaus-Henning Usadel – Nuclera receptors in endocrinology, diabetes and metabolism, Frankfurt, Germany, Oct. 6, 2004
181. "Control of reverse cholesterol transport and atherosclerosis by the nuclear receptors PPARalpha and FXR – HDL summit meeting, Paris, France, Oct. 14, 2004
182. "Glitazones et athérosclérose" – 4^{ème} journées d'Actualité en Diabétologie – Paris, Oct. 15, 2004
183. « Activating the PPAR receptors – Basic science and clinical ramifications » - DALM meeting, Venise, Italy – Oct. 25, 2004
184. "Macrophages" – AHA New Orleans, USA – Nov. 7, 2004
185. "PPARs and atherosclerosis" – National Network for Cardiovascular Research, Goteborg, Sweden – Nov 19, 2004
186. "The evolving role of PPARalpha in lipid metabolism and treatment of lipid disorders" – 1st Congress of Hellenic Atherosclerosis Society, Athens, Greece – Dec. 3, 2004
187. "Relation between protein kinase C and PPAR in the control of inflammation" – WCFS Food Summit meeting, Wageningen, The Netherlands – Dec. 10, 2004
188. "Molecular mechanism" – 6th International Think Tank", Paris, France – Dec. 11, 2004
189. "Nuclear hormone receptors" – EVGN meeting, Cambridge, UK – Dec. 13, 2004
190. "PPARs and the metabolic syndrome" – Plenary Session – 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.
191. "Preclinical analysis of PPARalpha agonist action on diabetes and the metabolic syndrome" – 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 21, 2005.
192. "PPARalpha, the metabolic syndrome and atherosclerosis" – Kestone Symposia, Wisthler, Canada – April 15-17, 2005.
193. "PPARs as targets for anti-atherosclerosis therapies" – 75th EAS, Prague, Czeck Republic – April 24-26, 2005
194. " Molecular mechanisms of metabolic liver diseases" – 40th annual meeting of the German Diabetes Association, Berlin, Germany, May 5, 2005
195. "Metabolic syndrome, HDL and its modulation by PPARalpha agonists" – 18th Congress of the Spanish Atherosclerosis Society, La Coruña, Spain, May 6, 2005.
196. "PPAR agonists : targeting insulin resistance and atherosclerosis in the obese – 14th European Congress on Obesity, Athens, Greece, June 1-4, 2005.
197. "Rôle des agonistes de PPARgamma dans le contrôle du diabète et le risque cardiovasculaire associé. 2nd Annual Congress of the NSFA, Biarritz, France – June 9-11, 2005.
198. "Endothelial dysfunction in diabetes" – ADA, San Diego, USA – June 11-17, 2005.
199. « Signal transduction pathways and atherosclerosis ». EVGN meeting, Maastricht, The Netherlands – July 7, 2005
200. "Nuclear receptors modulating the metabolic syndrome : focus on PPARalpha and FXR. 2nd Int. Sympo on Triglycerides and HDL : Role in cardiovascular disease and the metabolic syndrome – New York, USA – July 14-17, 2005.
201. "Glucose and lipid metabolism" – ESC congress, Stockholm, Sweden – Sept. 5-9, 2005.
202. "Récepteurs nucléaires et modulation des lipides" – Symposium CHU Tivoli, Belgium – Sept 24, 2005

203. « PPARs and the metabolic syndrome » - 1st International CCR Symposium, Berlin, Germany – Oct. 21-22, 2005
204. “Nuclear Receptors, the metabolic syndrome and atherosclerosis” – 4th International Symposium on Obesity and Hypertension, Berlin, Germany – Oct. 27-29, 2005
205. “Nuclear receptors as pharmaceutical targets” – European Biotech crossroads, Lille, France – Nov. 28-30, 2005
206. “Metabolic and vascular control of atherosclerosis by nuclear receptors” – 21st Ernst Klenk Symposium in Molecular Medicine, Cologne, Germany – Dec. 2-3, 2005
207. “Metabolic syndrome and PPARs” – 2nd Metabolic Syndrome Seminar, Tokyo, Japan, Jan. 21, 2006.
208. “Agonistes PPAR” – 9^{èmes} rencontres franco-américaines d’Endocrinologie – Paris, France, Feb. 2, 2006.
209. “PPAR agonists in the prevention of vascular disease in the diabetic patients” – 5th Genoa Meeting on Hypertension, Diabetes and Renal Diseases – Genoa, Italy, Feb. 23, 2006.
- 210.

MEETING PRESENTATIONS

1. Staels B., Auwerx J., Chan L., van Tol A., Rosseneu M., Verhoeven G.: Regulation of mRNA levels for apolipoprotein A-I, A-II and E in the rat liver: effects of development and sex hormones. *Abstract contactgroep "Multidisciplinair Onderzoek van Atherosclerosis", Brussels, 1988, Oral Presentation*
2. Cobbaert C., Bertels I., Staels B., Verhoeven G., Lissens W.: Aspecificity of apolipoprotein antisera. *IVth International Symposium of the Belgian Society of Clinical Chemistry, Brugge, 1988, Poster Presentation*
3. Staels B., Auwerx J., Chan L., van Tol A., Rosseneu M., Verhoeven G.: Changes in rat liver and intestinal apolipoprotein A-I, A-II and E mRNA levels after ovariectomy and ethinylestradiol. *International Atherosclerosis Congress, Vienna, 1989, Oral Presentation*
4. Staels B., Auwerx J., Stahnke G., Will H., Verhoeven G.: Regulation of rat liver LDL-receptor and hepatic triglyceride lipase (HTGL) mRNA levels by ovariectomy and ethinylestradiol. *5th European Symposium on Metabolism, Padova, 1989, Poster Discussion*
5. Staels B., Auwerx J., Stahnke G., Will H., Verhoeven G.: Regulation of rat liver LDL-receptor and hepatic triglyceride lipase (HTGL) mRNA levels by ovariectomy and ethinylestradiol. *12th European Lipoprotein Club Meeting, Tutzing, 1989, Oral Presentation*
6. Auwerx J., Staels B., Sassone-Corsi P.: Coupled and uncoupled induction of fos and jun. *Conférences J.Monod, Control of Gene Expression during Development, Roscoff, 1989, Poster Presentation*
7. Staels B., Auwerx J., Szpirer J., Szpirer C., Vautmans V., Verhoeven G., Deeb S.: Developmental regulation and extinction of liver lipoprotein lipase mRNA expression. *13th European Lipoprotein Club Meeting, Tutzing, 1990, Oral Presentation*
8. Staels B., van Tol A., Chan L., Verhoeven G., Auwerx J.: Differential expression of potential ligands for the HDL-receptor. *63rd annual Scientific Sessions of the American Heart Association, Dallas, 1990, Poster Presentation*
9. Staels B., van Tol A., Chan L., Verhoeven G., Auwerx J.: Variable effects of different corticosteroids on plasma lipids, apolipoproteins, and hepatic apolipoprotein mRNA levels in rats. *Journées du GERLI, 1991, Oral Presentation*
10. Hoogerbrugge N., Jansen H., Staels B., Seip M., Birkenhager J.C.: Growth hormone affects cholesterol metabolism in hypothyroid rats. *IAS Meeting, Chicago, 1991, Poster Presentation*
11. Hoogerbrugge N., Jansen H., Staels B., Seip M., Birkenhager J.C.: Growth hormone affects hepatic lipase synthesis in hypothyroid rats. *IAS Meeting, Chicago, 1991, Poster Presentation*
12. van Tol A., Jansen H., Staels B., Auwerx J.: Specific regulation of plasma LCAT activity, apolipoproteins, and lipoprotein subfractions by different corticosteroids. *14th European Lipoprotein Club Meeting, Tutzing, 1991, Oral Presentation*
13. Staels B., van Tol A., Andreu T., Auwerx J.: Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner. *59th European Atherosclerosis Society Congress, Nice, 1992, Poster Presentation*
14. Staels B., Schoonjans K., Szpirer J., Szpirer C., Auwerx J.: Developmental extinction of liver lipoprotein lipase expression. *Conférences J.Monod, Aussois, 1993, Poster Presentation*
15. Schoonjans K., Devos P., Staels B., Verhoeven G., Auwerx J.: Developmental extinction of liver lipoprotein lipase mRNA expression is regulated by an NF-1 like site. *66th annual Scientific Sessions of the American Heart Association, New Orleans, 1993, Poster Presentation*
16. Branellec D., Berthou L., Staels B., Saldicco I., Parrott D., Fruchart J.-C., Denèfle P.: Opposite in vitro and in vivo regulation of hepatic apo A-I gene expression by retinoic acid. *1994 Keystone Symposia on Molecular & Cellular Biology, 1994, Poster Presentation*
17. Auwerx J., Schoonjans K., Vu Dac N., Staels B.: Control of gene expression by hypolipidemic fibrates and nutritional factors, a coordinating role for PPAR. *13th Joint Meeting of British Endocrine Societies, 1994, Oral Presentation*
18. Berthou L., Staels B., Toutain H., Branellec D., Denèfle P.: Regulation of apolipoprotein gene expression by fibrates in primary cultures of adult rat hepatocytes. *Rencontres Scientifiques Rhône-Poulenc Rorer, 1994, Poster Presentation*
19. Branellec D., Berthou L., Staels B., Parrott D., Saldicco I., Berthelot K., Fruchart J.-C., Denèfle P.: Opposite in vitro and in vivo hepatic apolipoprotein A-I gene regulation by retinoic acid. *Rencontres Scientifiques Rhône-Poulenc Rorer, 1994, Poster Presentation*

20. Berthou L., Duverger N., Cuine S., Berthelot K., Attenot F., Staels B., Denèfle P., Branellec D.: Use of human apo A-I transgenic mice as a pharmacological tool to validate HDL-inducers. *Rencontres Scientifiques Rhône-Poulenc Rorer, 1994, Poster Presentation*
21. Schoonjans K., Staels B., Yamamoto T., Wahli W., Grimaldi P., Auwerx J.: Induction of Acyl-Coenzyme A synthetase (ACS) gene expression by fibrates is mediated by a PPAR-responsive element in the 1C promoter of the ACS gene. *Xth International Symposium on Atherosclerosis, Montréal, 1994, Poster Presentation*
22. Staels B., Vu-Dac N., Saladin R., Fruchart J.-C., Auwerx J.: Tissue-specific down-regulation of apo C-III gene expression by fibrates. *Xth International Symposium on Atherosclerosis, Montréal, 1994, Poster Presentation*
23. Schoonjans K., Yamamoto T., Wahli W., Fruchart J.-C., Grimaldi P., Auwerx J., Staels B.: Induction of Acyl-Coenzyme A synthetase (ACS) gene expression by fibrates is mediated by a PPAR-responsive element in the 1C promoter of the ACS gene. *67th annual Scientific Sessions of the American Heart Association, Dallas, 1994, Poster Presentation*
24. Bossu J.-P., Chartier F.L., Vu-Dac N., Fruchart J.-C., Staels B., Auwerx J., Laine B.: Characterization of a negative regulatory activity in the first intron of the human apolipoprotein A II gene. *67th annual Scientific Sessions of the American Heart Association, Dallas, 1994, Poster Presentation*
25. Staels B.: Induction of Acyl-Coenzyme A synthetase expression by fibrates and fatty acids is mediated through activation of the peroxisome proliferator activated receptor. *64th European Atherosclerosis Society Meeting, Utrecht, 1995, Oral Presentation*
26. Staels B., Schoonjans K., Wahli W., Yamamoto T., Grimaldi P., Auwerx J.: Induction of the Acyl-Coenzyme A synthetase gene by fibrates and fatty acids is mediated through activation of the peroxisome proliferator activated receptor. *Liver Development, Gene Regulation and Disease, Arcachon, France, 1995, Poster Presentation*
27. Berthou L., Duverger N., Emmanuel F., Auwerx J., Fruchart J.-C., Denèfle P., Staels B., Branellec D.: Opposite regulation of human versus mouse apo A-I by fibrates in human transgenic mice. *68th annual Scientific Sessions of the American Heart Association, Anaheim, 1995, Oral Presentation*
28. Staels B., Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Fruchart J.-C., Auwerx J.: Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. *68th annual Scientific Sessions of the American Heart Association, Anaheim, 1995, Poster Presentation*
29. Schoonjans K., Staels B., Deeb S., Auwerx J.: Fibrates and fatty acids induce lipoprotein lipase gene expression via the peroxisome proliferator activated receptor. *68th annual Scientific Sessions of the American Heart Association, Anaheim, 1995, Oral Presentation*
30. Guerre-Millo M., Lagrange D., Saladin R., Auwerx J., Staels B.: Effet de la mutation fa sur l'expression du gène ob au cours du développement. *13ième Conférence Annuelle de l'Association Française d'Etudes et de Recherches sur l'Obésité, Paris, 19 janvier 1996, Poster Presentation*
31. Staels B., Vilaro S., Hum D., Reina M., Peinado J., Martin G., Saladin R., Auwerx J.: Expression and regulation of lipoprotein lipase in human adrenal cortex. *65h European Atherosclerosis Society Meeting, Firenze, 1996, Oral Presentation*
32. Vu-Dac N., Schoonjans K., Kosykh V., Dallongeville J., Heyman R.A., Auwerx J., Staels B.: Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor. *65h European Atherosclerosis Society Meeting, Firenze, 1996, Poster Presentation*
33. Saladin R., Vu-Dac N., Fruchart J.-C., Auwerx J., Staels B.: Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile tissue-specific protein. *65h European Atherosclerosis Society Meeting, Firenze, 1996, Oral Presentation*
34. Auwerx J., Staels B.: Regulation of gene expression by fenofibrate: role of PPAR. *65h European Atherosclerosis Society Meeting, Firenze, 1996, Oral Presentation*
35. Schoonjans K., Staels B.: L'induction de l'expression de l'acyl-CoA synthétase par les fibrates et les acides gras est PPAR-dépendante. *Réunion de l'Association pour les Etudes sur les Peroxysomes en Biologie (AEP-BIO), Lille, 1996, Oral Presentation*
36. Fajas L., Staels B., Auwerx J.: PPAR γ : structure génomique et régulation. *Réunion de l'Association pour les Etudes sur les Peroxysomes en Biologie (AEP-BIO), Lille, 1996, Oral Presentation*
37. Casaroli-Marano R.P., Reina M., Peinado-Onsurbe J., Staels B., Auwerx J., Vilaro S.: Lipoprotein lipase in human and bovine eyes. *24th Meeting of the Federation of European Biochemical Societies (FEBS), Barcelona, 1996*
38. Staels B., Mamontova A., Grötzinger T., Séguret-Macé S., Vu-Dac N., Schoonjans K., DeVos P., Gervois P., Delhaye-Bouchaud N., Fruchart J.-C., Mariani J., Duverger N., Auwerx J., Tedgui A.: Functional role of the nuclear receptor ROR α in lipid metabolism and cardiovascular disease. *EMBO Workshop, Structure and Function of Nuclear Receptors, May 2-5 1997, Erice, Italy, Oral Presentation*
39. Staels B., Mamontova A., Grötzinger T., Séguret-Macé S., Vu-Dac N., Schoonjans K., DeVos P., Gervois P., Delhaye-Bouchaud N., Fruchart J.-C., Mariani J., Duverger N., Auwerx J., Tedgui A.: Functional role of the nuclear receptor ROR α in lipid metabolism and cardiovascular disease. *79th Annual Meeting of the Endocrine Society, Minneapolis, June 11-14 1997, Poster Presentation*
40. Gervois P., Staels B.: PPAR α . *Réunion de l'Association pour les Etudes sur les Peroxysomes en Biologie (AEP-BIO), Paris, May 23 1997, Oral Presentation*
41. Lefebvre A.-M., Auboeuf D., Vidal H., Staels B., Auwerx J.: High level expression of PPAR γ in colon. *79th Annual Meeting of the Endocrine Society, Minneapolis, June 11-14 1997, Poster Presentation*
42. Martin G., Schoonjans K., Staels B., Auwerx J.: Regulated expression of the fatty acid transporter (FATP) gene: control by PPAR α and γ . *79th Annual Meeting of the Endocrine Society, Minneapolis, June 11-14 1997, Poster Presentation*

43. Lefebvre A.-M., Peinado-Onsurbe J., Briggs M.R., Paterniti J.R., Fruchart J.-C., Fievet C., Auwerx J., Staels B.: Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct, but complementary mechanism relative to fibrates. *68th Meeting of the European Atherosclerosis Society on Molecular Cell Biology & Atherogenesis, Brugge, Belgium, may 8 1997, Poster Presentation*
44. Staels B., Habib A., Merval R., Lebret M., Pineda-Torra I., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Tedgui A., Maclouf J.: Negative regulation of human aortic smooth muscle cell activation by PPAR α , but not by PPAR γ activators. *Keystone Meeting on Nuclear Receptors, Lake Tahoe, march 28 - april 2 1998, Poster Presentation*
45. Trottein F., Angeli V., Nutten S., Delerive Ph., Capron A., Staels B., Capron M. : Role of schistosome/endothelium interactions in the synthesis of endothelial adhesion molecules and in the recruitment of immune cells to the lungs. *Annual Congress of SFI, November 24-26, 1999, Lille, France.*
46. Chinetti G., Gbaguidi FG., Griglio S., Mallat Z., Antonucci M., Poulain Ph., Chapman J., Fruchart JC., Tedgui A., Najib J., Staels B. : CLA-1/ R-BI is expressed in atherosclerosis lesion macrophages and regulated by activators of peroxisome proliferator activated receptors (PPARs). *SFA, June 10-11, 1999, Arcachon, France. Poster presentation*
47. Duez H., Besnard S., Fruchart J.C., Fievet C., Tedgui A., Staels B. : IL10 et métabolisme des lipides et lipoprotéines : approche in vivo. *SFA, June 10-11, 1999, Arcachon, France. Poster presentation*
48. Duez H., Mansen A., Fievet C., Raspé E., Fruchart J.C., Vennström B., Staels B. : Rev-erba : an orphan nuclear receptor regulating lipoprotein metabolism. *SFA, June 10-11, 1999, Arcachon, France. Poster presentation*
49. Staels B. : "La famille des récepteurs nucléaires PPARs : rôle dans le contrôle métabolique et inflammatoire". *Univertité Libre de Bruxelles, December 22, 1999, Gosselies, Belgium. Oral presentation.*
50. Neve B., Corseaux D., Chinetti G., Zawadzki C., Duriez P., Staels B., Jude B. : PPAR α -agonists inhibit tissue factor expression in THP-1 cells and human monocytes. *Keystone Meeting on Nuclear Receptors, march 25-31, 2000, Poster Presentation*
51. Furman C., Delerive P., Martin-Nizard F., Fruchart J.C., Duriez P., Staels B., Teissier E. : Les phospholipides des LDL oxydées modifient les capacités antioxydantes des cellules endothéliales. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Poster Presentation.*
52. Martin-Nizard F., Furman C., Briand O., Delerive P., Kandoussi A., Fruchart J.C., Staels B., Duriez P. : PPAR α and PPAR γ activators inhibit lipoproteins induced endothelin-1 secretion in endothelial cells. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Poster Presentation*
53. Corseaux D., Neve B., Chinetti G., Zawadzki C., Duriez P., Jude B., Staels B. : PPAR α agonists inhibit tissue factor expression in monocytic cells. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Poster Presentation*
54. Jeanpierre E., Corseaux D., Neve B., Duriez P., Jude B., Staels B. : Effect of fenofibrate on tissue factor expression after angioplasty in rabbits. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Oral Presentation*
55. Pilon A., Martin G., Junquero D., Delhon A., Fruchart J.C., Staels B., Clavey V. : Régulation du HDL récepteur, SR-BI et du LDL récepteur par l'angiotensine II et les esters de phorbol dans la lignée de cellules surrénales humaines NCI-H295R. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Oral Presentation*
56. Duez H., Poulain P., Fiévet C., Fruchart J.C., Staels B. : PPAR α is required for the In Vivo regulation of human Apo AI gene expression by fibrates. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Oral Presentation*
57. Dol F., Mares AM., Martin G., Staels B., Schaeffer P., Herbert JM. : The angiotensin AT1 receptor antagonist irbesartan decreases lesion size, MCP-1 expression and macrophage accumulation in apo E-deficient mice. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Oral Presentation*
58. Chinetti G., Lestavel S., Remaley T., Neve B., Pineda Torra I., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., Staels B. : PPAR activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABC-1 pathway. *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Poster Presentation*
59. Luc G., Jacob N., Bouly M., Fruchart J.C., Staels B., Giral P. : Les fibrates augmentent l'homocystéine par un mécanisme lié au PPAR α . *2nd annual congress of the French Atherosclerosis Society, Arcachon, May 18-22, 2000, Oral Presentation*
60. Darteil R., Mahfoudi A., Staels B., Finer M. : In vivo regulation of gene expression in murine muscle using the PPAR γ nuclear receptor and its ligands as a new gene switch system. *International Symposium of CBT and Eurosterone on Nuclear Receptor in Health and Disease, Huddinge, Sweden, Sept.24-27,2000, Poster Presentation*
61. Pineda Torra I., Fruchart J.C., Staels B. : Different nuclear receptors modulate hPPAR α promoter activity via a common binding site. *International Symposium of CBT and Eurosterone on Nuclear Receptor in Health and Disease, Huddinge, Sweden, Sept.24-27,2000, Poster Presentation*
62. Corseaux D., Neve B., Chinetti G., Zawadzki C., Duriez P., Jude B., Staels B. : Tissue factor is inhibited by PPAR alpha-agonists in monocytic cells. *42nd ASH Annual Meeting, San Francisco, USA, Dec. 01-05, 2000, Poster Presentation*
63. Gervois Ph., Kleemann R., Fruchart J.-C., Staels B., Kooistra T : PPAR α and inflammation : modulation of the hepatic acute phase response. *Keystone Symposium, USA, 04-09 Feb. 2001, Poster presentation*
64. Delerive P., De Bosscher K., Vanden Berghe W. Fruchart J.C., Haegeman G., Staels B. : Molecular mechanisms of the NF-kB / PPAR α cross talk. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Workshop*

65. Deplanque D., Gelé P., Six I., Bouly M., Staels B., Fruchart JC., Duriez P., Bordet R : PPARalpha : a new pharmacological target for stroke ?. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Workshop*
66. Bouly M., Masson D., Gross B., Peters JM., Fievet C., Castro G., Gonzalez FJ., Fruchart JC., Staels B., Lagrost L., Luc G. : Induction of mouse PLTP expression by fenofibrate through a PPARalpha dependent mechanism. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Workshop*
67. Berge RK., Madsen L., Guerre-Millo M., Berge K., Bergene E. Flint EN., Sebkova E., Rustan AC., Jensen J., Mandrup S., Kristiansen K., Klimes I., Staels B. : Expression of PPARalpha target genes improves insulin action and reduces adiposity. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Workshop*
68. Martin G., Duez H., Blanquart C., Berezowski V. Poulain P., Fruchart JC., Fruchart JN., Glineur C., Staels B. : Statins induce PPARalpha activity via inhibition of the geranylgeranyl-pp/Rho signalling pathway . Contribution to HDL raising activity of statins. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
69. Chinetti G., Lestavel S., Fruchart JC., Clavey V., Staels B. : PPARalpha controls cholesterol homeostasis in human monocyte derived macrophages. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
70. Six I., Jaboureck O., Bouly M., Deplanque D., Caliez A., Staels B., Fruchart JC., Duriez P., Bordet R. : PPARalpha activator (fenofibrate) restores endothelial function and decreases cyclooxygenase-1 media expression in spontaneously hypertensive rat. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
71. Blanquart C., Barbier O., Fruchart JC., Staels B., Glineur C. : The nuclear receptor PPARalpha is degraded by proteasome in a ligand dependent manner. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
72. Barbier O., Blanquart C., Fruchart J., Fruchart JC., Staels B., Glineur C. : The interaction of PPARalpha with the creb binding protein (CBP) seems to be regulated by phosphorylation. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
73. Bouly M., Majd Z., Fievet C., Fruchart J., Staels B., Fruchart JC., Luc G. : Fenofibrate increases the selective uptake of HDL cholesteryl esters in livers of human apolipoprotein AI transgenic mice. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
74. Helleboid S., Minnich KA., Mahfoudi A., Orsini C., Bertrand K., Fruchart J., Fruchart JC., Staels B. : Adenovirus mediated over expression of PPARdelta do not affect CPTI and apolipoprotein AII gene expression, two PPARalpha target genes, in HepG2 cells. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
75. Duez H., Poulain P., Fievet C., Bertrand K., Fruchart JC., Staels B. : PPAR α is required for the in vivo regulation of human apo A-I gene expression by fibrates. *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
76. Pineda-Torra I., Claudel T., Duval C., Fruchart JC., Staels B. : Bile acid regulation of human PPAR α gene expression is mediated by the farnesoid-X receptor (FXR). *1st International Symposium on PPARs : from basic science to clinical applications, 4-7 April 2001, Florence, Italy. Poster Presentation*
77. JeanPierre E., Corseaux D., Neve BP., Fruchart JC., Duriez P., Jude B., Staels B. : Tissue factor expression is reduced by fenofibrate in hypercholesterolemic rabbits after angioplasty.
78. Bouly M., Lagrost L., Staels B., Fruchart JC., Luc G. : In vivo induction of HDL size enlargement by fenofibrate is dependant on phospholipid transfer protein (PLTP). 18^{ème} congrès du GRRC et 3^{ème} congrès de la SFA, April 26-27, 2001 Montpellier, France. *Poster presentation*
79. Blanquart C., Barbier O., Fruchart JC., Staels B., Glineur C. : Le récepteur nucléaire PPARalpha est dégradé par les protéasomes de manière ligand dépendant. 18^{ème} congrès du GRRC et 3^{ème} congrès de la SFA, April 26-27, 2001 Montpellier, France. *Poster presentation*
80. Pineda Torra I., Fruchart JC., Staels B. : Fibrates negatively modulate PPARalpha expression in human hepatocytes.. 18^{ème} congrès du GRRC et 3^{ème} congrès de la SFA, April 26-27, 2001 Montpellier, France. *Poster presentation*
81. Gosset Ph., Charbonnier AS., Staels B., Tonnel AB., Trottein F. : Modulation of phenotype and cytokine production in monocyte 6 derived dendritic cells by PPAR γ activation. *American Thoracic Society Congress, May 2001, San Francisco, Poster presentation ?*
82. Bouly M., Masson D., Gross B., Jiang XC., Fievet C., Castro G., Tall AR., Fruchart JC., Staels B., Lagrost L., Luc G. : Induction of the plasma phospholipid transfer protein (PLTP) gene accounts for the HDL enlargement in mice treated with fenofibrate. *72nd European Atherosclerosis Society Congress, 20-23 May 2001, Glasgow, UK. Poster presentation*
83. Lestavel S., Chinetti G., Barbeau R., Fruchart J-C., Clavey V., Staels B. : Cholesterol homeostasis is controlled by PPAR alpha in human macrophages. *72nd European Atherosclerosis Society Congress, 20-23 May 2001, Glasgow, UK. Poster presentation*
84. Westergaard M., Henningsen J., Johansen C., Svendsen ML., Jensen UB., Schroder HD., Staels B., Berge RK., Iversen L., Bolund L., Kragballe K., Kristiansen K. : Reciprocal regulation of PPAR δ and NF-kB activity in lesional psoriatic skin. *42nd International Conference on the Bioscience of Lipids, 5-9 June 2001, Bergen, Norway. Poster presentation*

85. Madsen L., Berge RK., Guerre-Millo M., Berge K., Bergene E., Flint EN., Sebokova E., Rustan AC., Jensen J., Mandrup S., Kristiansen K., Klimes I., Staels B. : Expression of PPAR α target genes improve insulin action and reduce adiposity. *42nd International Conference on the Bioscience of Lipids, 5-9 June 2001, Bergen, Norway. Poster presentation*
86. Lestavel S., Chinetti G., Barbeau R., Fruchart J-C., Clavey V., Staels B. : PPAR activators induce cholesterol removal from human macrophage foam cells. *24th ELC meeting, 10-13 September 2001, Tutzing, Germany. Poster presentation*
87. G. CHINETTI, S. LESTAVEL, J.C. FRUCHART, V. CLAVEY, B. STAELS : PPAR α controls cholesterol homeostasis in human monocyte-derived macrophages. *74th Scientific Sessions of American Heart Association, Anaheim, USA, 11-14 november 2001*
88. T. CLAUDEL, H. DUEZ, I. PINEDA-TORRA, J.C. FRUCHART, B. STAELS : Bile acids suppress human apolipoprotein A-I gene expression via a negative response element for the nuclear receptor FXR. *74th Scientific Sessions of American Heart Association, Anaheim, USA, 11-14 november 2001.*
89. H. DUEZ, Y.S. CHAO, P. POULAIN, C. FIEVET, J.C. FRUCHART, S.D. WRIGHT, B. STAELS : Fenofibrate treatment reduces lesion size and aortic cholesterol content in human apo A-I transgenic X apo E-deficient and apo E-deficient mice. *74th Scientific Sessions of American Heart Association, Anaheim, USA, 11-14 november 2001.*
90. E. RASPE, G. MAUTINO, H. DUEZ, J.C. FRUCHART, B. STAELS : Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor Rev-erb α . *74th Scientific Sessions of American Heart Association, Anaheim, USA, 11-14 november 2001.*
91. R. SINGARAJA, V. BOCHER, E.R. JAMES, S. CLEE, L.H. ZHANG, A. BROOKS-WILSON, A. KWOK, N. BISSADA, Y.Z. YANG, G. LIU, C. WELLINGTON, C. FIEVET, B. STAELS, M.R. HAYDEN : Increased HDL-C and apo A1 dependant efflux modulated by LXREs in human ABCA1 BAC transgenic mice. *74th Scientific Sessions of American Heart Association, Anaheim, USA, 11-14 november 2001.*
92. A. PILON, G. CHINETTI, I. PINEDA TORRA, J.C. FRUCHART, B. STAELS : Adenovirus mediated overexpression of PPAR α induces ABCA1 expression and promotes cholesterol efflux from human THP-1 cells. *Metabolic Syndrome and Atherosclerosis, Lille, France, 27-29 march 2002.*
93. P. GELE, D. DEPLANQUE, I. SIX, C. FURMAN, M. BOULY, S. NION, B. DUPUIS, D. LEYS, J.C. FRUCHART, R. CECHELLI, B. STAELS, P. DURIEZ, R. BORDET : Prophylactic PPAR α activation decreases brain injury after transient ischemia in mice. *Metabolic Syndrome and Atherosclerosis, Lille, France, 27-29 march 2002.*
94. G. CHINETTI, S. LESTAVEL, J.C. FRUCHART, V. CLAVEY, B. STAELS : PPAR α controls macrophage cholesterol homeostasis by reducing cholesterol esterification. *Metabolic Syndrome and Atherosclerosis, Lille, France, 27-29 march 2002.*
95. T. CLAUDEL, E. STURM, H. DUEZ, I. PINEDA TORRA, V. KOSYKH, J.C. FRUCHART, J. DALLONGEVILLE, F. KUIPERS, B. STAELS : Bile acid FXR agonists suppress human apolipoprotein A-I gene expression. *Metabolic Syndrome and Atherosclerosis, Lille, France, 27-29 march 2002.*
96. H. DUEZ, P. POULAIN, I. PINEDA-TORRA, J. M. PETERS, F.J. GONZALEZ, J.C. FRUCHART, C. FIEVET, B. STAELS. Fibrates regulate human apolipoprotein A-I gene expression in a PPAR α gene-dosage dependent manner. *Metabolic Syndrome and Atherosclerosis, Lille, France, 27-29 march 2002.*
97. F. MARTIN-NIZARD, C. FURMAN, P. DELERIVE, A. KANDOUSSI, J.C. FRUCHART, B. STAELS, P. DURIEZ : PPAR activators inhibit oxidized-LDL induced endothelin-1 secretion in endothelial cells. *Metabolic Syndrome and Atherosclerosis, Lille, France, 27-29 march 2002.*
98. I. SIX, O. JABOURECK, P. GELE, D. DEPLANQUE, M. BOULY, J.C. FRUCHART, B. VALLET, B. STAELS, P. DURIEZ, R. BORDET : PPAR α activation restores endothelium responses and prevents remodelling in spontaneously hypertensive rat by modulation of cyclo-oxygenase 1 pathway. *Metabolic Syndrome and Atherosclerosis, Lille, France, 27-29 march 2002.*
99. C. FURMAN, A. KANDOUSSI, F. MARTIN-NIZARD, M. HAZZAN, C. NOEL, J.C. FRUCHART, B. STAELS, P. DURIEZ : HMG CoA inhibition and PPAR α activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells. *4^{ème} Congrès Annuel de la Société Française d'Athérosclérose, Arcachon, France, 6-8 june 2002*
100. D. KITSBERG, I. ALKALAY, F. SZAFER, K. MEIR, H. ROSEN, S. SHPIZEN, L. BEN AVI, B. STAELS, C. FIEVET, V. MEINER, I. BJORKHEM, E. LEITERSDORF : Human sterol 27-hydroxylase (CYP27) overexpression transgenic mouse model. Evidence against 27-hydroxycholesterol as a critical regulator of cholesterol homeostasis. *73rd Congress of the European Atherosclerosis Society, Salzburg, 7-10 july 2002.*
101. P. SCHAEFFER, G. MARTIN, F. DOL, A.M. MARES, V. BEREZOWSKI, B. STAELS, D.W. HUM, J.M. HERBERT : Effect of the ATI angiotension II receptor antagonist irbesartan on lesion progression and chemokine expression in apo E deficient mice. *73rd Congress of the European Atherosclerosis Society, Salzburg, 7-10 july 2002.*
102. P. GERVOIS, N. VU-DAC, H. JAKEL, M. NOWAK, B. STAELS, L.A. PENNACCHIO, E.M. RUBIN, J. FRUCHART, J.C. FRUCHART : Apolipoprotein A-V is a crucial determinant of plasma triglyceride levels highly responsive to PPAR α activators. *75th Scientific Sessions of American Heart Association, Chicago, USA, 17-20 november 2002.*
103. R.R. SINGARAJA, C. FIEVET, G. CASTRO, E. JAMES, S. CLEE, N. HENNUYER, J. CHOY, N. BISSADA, B. McMANUS, B. STAELS, M.R. HAYDEN : Increased HDL and changes in lipoprotein composition are associated with increased efflux and atheroprotection in an ABCA1 BAC transgenic mouse model. *75th Scientific Sessions of American Heart Association, Chicago, USA, 17-20 november 2002.*
104. E. TEISSIER, G. CHINETTI, B. STAELS : PPAR α but not PPAR γ agonists induce generation of hydrogen peroxide in human macrophages. *75th Scientific Sessions of American Heart Association, Chicago, USA, 17-20 november 2002*

105. T. KOK, H. WOLTERS, V.W. BLOKS, R. HAVINGA, P.L.M. JANSEN, B. STAELS, F. KUIPERS : Induction of hepatic ABC transporter expression is part of the PPAR α -mediated fasting response in the mouse. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, Italy, 19-22 march 2003.*
106. M. WESTERGAARD, J. HENNINGSEN, C. JOHANSEN, S. RASMUSSEN, M.L. SVENDSEN, U.B. JENSEN, H.D. SCHRODER, B. STAELS, L. IVERSEN, L. BOLUND, K. KRAGBALLE, K. KRISTIANSEN : Expression and localization of PPAR and nuclear factor κ B in normal and lesional psoriatic skin. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, Italy, 19-22 march 2003.*
107. E. HONDARES, I. PINEDA-TORRA, R. IGLESIAS, B. STAELS, F. VILLARROYA, M. GIRALT : PPAR α activates fatty acid oxidation in skeletal muscle cells without impairing glucose metabolism. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, Italy, 19-22 march 2003.*
108. P. GELE, D. DEPLANQUE, I. SIX, S. NION, J.C. FRUCHART, R. CECHELLI, B. STAELS, P. DURIEZ, R. BORDET : Prophylactic PPAR α activation decreases brain injury after transient ischemia in mice. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, Italy, 19-22 march 2003.*
109. A. TAILLEUX, G. TORPIER, H. MEZDOUR, J.C. FRUCHART, B. STAELS, C. FIEVET : Human apolipoprotein E2/E2 knock-in mouse : a suitable murine model for pharmacological interventions on the dyslipidemia and atherosclerosis development. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, Italy, 19-22 march 2003.*
110. K. BERTRAND, R. DARTEIL, P. VERWAERDE, D.W. HUM, N. PROVOST, P. POULAIN, Z. MADJ, S. HELLEBOID, J.F. DELHOMEL, R. BORDET, J. FRUCHART, B. STAELS, J.C. FRUCHART : A novel class of hypolipidemic/antioxidant compounds with beneficial effects in mice models of dyslipidemia and cerebral ischemia. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, Italy, 19-22 march 2003.*
111. R. DARTEIL, K. BERTRAND, P. VERWAERDE, D.W. HUM, E. RASPE, P. POULAIN, Z. MAJD, S. HELLEBOID, E. BOUEY, R. BORDET, J. FRUCHART, B. STAELS, J.C. FRUCHART : GFT14, a novel compound with hypolipidemic and neuroprotective activities. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, Italy, 19-22 march 2003.*
112. C. CARMONA, K. LOUCHE, B. LEFEBVRE, A. PILON, P. LEFEBVRE, B. STAELS, P. FORMSTECHE, P. RENARD, C. DACQUET, L. CASTEILLA, L. PENICAUD : S26948, a new non TZD drug with potent antidiabetic activity without adipogenic effect. *Second International Symposium on PPARs : From Basic Science to Clinical Applications, Florence, 19-22 mars 2003*
113. N.M. MORTON, J.M. PATERSON, H. MASUZAKI, M.C. HOLMES, B. STAELS, C. FIEVET, B.R. WALKER, J.S. FLIER, J.J. MULLINS, J.R. SECKL : Reduced intra-adipose glucocorticoid regeneration : a novel adaptive response to, and therapy for the metabolic syndrome. 22nd Joint Meeting of the British Endocrine Societies, Glasgow, UK, 24-26 March 2003.
114. P. GELE, D. DEPLANQUE, I. SIX, S. NION, J.C. FRUCHART, R. CECHELLI, B. STAELS, P. DURIEZ, R. BORDET : Prophylactic PPAR α activation decreases brain injury after transient ischemia in mice. 7th annual meeting of the Societe Française de Pharmacologie, Lille, France, 14-16 April 2003.
115. CLAUDEL T., INOUE Y, BARBIER O, DURAN SANDOVAL D, FRUCHART J, KOSYKH V, FRUCHART JC, GONZALEZ J, STAELS B : Farnenoid X receptor agonists suppress apolipoprotein CIII expression : a potential mechanism contributing to the hypotriglyceridemic action of bile acids. *6th European Congress of Endocrinology, Lyon, France, 26-30, April 2003. Oral Presentation*
116. D. DURAN SANDOVAL, G. MAUTINO, F. PERCEVAULT, O. BARBIER, J.C. FRUCHART, F. KUIPERS, B. STAELS : Glucose regulates the expression of the farnenoid X receptor in liver. *6th European Congress of Endocrinology, Lyon, France, 26-30, April 2003. Poster Presentation*
117. F. GIZARD, E. TEISSIER, A. PILON, V. LUU THE, B. STAELS, D.W. HUM : The transcriptional regulating protein of 132 KDA (Trep-132) influences steroidogenesis in human adrenal cells. *6th European Congress of Endocrinology, Lyon, France, 26-30, April 2003. Poster Presentation*
118. F. GIZARD, A. PILON, A. CORSINI, C. DUHEM, J.C. FRUCHART, C. GLINEUR, B. STAELS : PPAR α inhibits vascular smooth muscle cell proliferation and trans-activates the gene encoding p16^{INK4a}, a crucial inhibitor of G1 \rightarrow S progression. *5ème Congrès Annuel de la Société Française d'Athérosclérose - ARCOL, Biarritz, France, 19-21 June 2003*
119. N.M. MORTON, J.M. PATERSON, H. MASUZAKI, M.C. HOLMES, B. STAELS, C. FIEVET, B.R. WALKER, J.S. FLIER, J.J. MULLINS, J.R. SECKL : Reduced 11 β -hydroxysteroid dehydrogenase type 1-mediated intra-adipose glucocorticoid regeneration : a novel protective adaptation to and treatment for the metabolic syndrome. *Endo 2003 ; 85th Annual Meeting, Philadelphia, USA, 19-22 June 2003.*
120. J.M. PATERSON, N.M. MORTON, M.C. HOLMES, C. FIEVET, B. STAELS, J. NEWTON, C.J. KENYON, J.R. SECKL, J.J. MULLINS : Metabolic syndrome without obesity : liver-specific over-expression of 11 β -HSD1 in transgenic mice. *Endo 2003 ; 85th Annual Meeting, Philadelphia, USA, 19-22 June 2003.*
121. S. LESTAVEL, G. CHINETTI, L. HELIN, B. STAELS, V. CLAVEY : Les récepteurs nucléaires PPAR et LXR α contrôlent l'homéostasie du cholestérol dans les macrophages humains en vue de son efflux par la voie ABCA1. 1^{er} Congrès de Lipidomique « Diversité Moléculaire et Physiopathologies », Paris, 2-5 Sept. 2003.
122. B. STAELS : Nuclear receptors controlling the metabolic syndrome and atherosclerosis. *13th International Symposium on Atherosclerosis, Kyoto, Japan, Sept. 28 – Oct. 2, 2003*
123. L. MILLATT, K. BERTRAND, R. DARTEIL, P. VERWAERDE, D.W. HUM, N. PROVOST, P. POULAIN, Z. MAJD, S. HELLEBOID, J.F. DELHOMEL, R. BORDET, J. FRUCHART, B. STAELS, J.C. FRUCHART : A novel family of

- compounds with beneficial effects in mouse models of dyslipidemia and ischemic stroke. *13th International Symposium on Atherosclerosis, Kyoto, Japan, Sept. 28 – Oct. 2, 2003*
124. L. MILLATT, R. DARTEIL, K. BERTRAND, P. VERWAERDE, DW. HUM, E. RASPE, P. POULAIN, Z. MAJD, S. HELLEBOID, E. BOUEY, R. BORDET, J. FRUCHART, B. STAELS, J.C. FRUCHART : GFT14, a novel compound with hypolipidemic and neuroprotective properties. *13th International Symposium on Atherosclerosis, Kyoto, Japan, Sept. 28 – Oct. 2, 2003*
 125. M. NOWAK, A. HELLEBOID-CHAPMAN, H. JAKEL, C. ROMMENS, E. BAUGE, P. GERVOIS, N. VU-DAC, G. MARTIN, D. DURAN-SANDOVAL, B. STAELS, MR TASKINEN, L. PENNACCHIO, E. RUBIN, J. FRUCHART-NAJIB, J.C. FRUCHART : Transcriptional regulation of the apolipoprotein A5 gene by insulin. *13th International Symposium on Atherosclerosis, Kyoto, Japan, Sept. 28 – Oct. 2, 2003*
 126. O. BARBIER, B. STAELS : Lipid-activated nuclear receptors control bile acid glucuronidation. *Keystone meeting, USA, Feb. 28-March 4, 2004 – poster presentation*
 127. TEISSIER E., NOHARA A., CHINETTI G., PAUMELLE R., FRUCHART JC., SHAH A., STAELS B. : Generation of LDL-derived PPAR α agonists with anti-inflammatory properties via PPAR α stimulation of NADPH oxidase activity in macrophages. *Meeting on PPARs and Inflammation, Pasteur Institute Paris, France, March 26, 2004 – oral presentation*
 128. M. NOWAK, A. HELLEBOID-CHAPMAN, H. JAKEL, C. ROMMENS, G. MARTIN, D. DURAN-SANDOVAL, B. STAELS, E.M. RUBIN, L.A. PENNACCHIO, M.R. TASKINEN, J. FRUCHART-NAJIB, J.C. FRUCHART : Apo A5 down-regulation by insulin is mediated through USF1 phosphorylation. *Metabolic Syndrome, Type II Diabetes and Atherosclerosis Congress, Marrakesh, 19-23 may 2004.*
 129. M. GROENENDIJK, S. M. POST, C. FIEVET, H. PRINCEN, B. STAELS, P. RENSEN : Cholesterol 7 α -hydroxylase deficiency in hyperlipidemic APOE*3 –leiden transgenic mice increases HDL cholesterol by induced hepatic ABCA1 expression. *13th European Congress on Obesity May 26-29 2004, Prague, Czech Republic.*
 130. C. ROUAULT, B. HANCZAR, J. D. ZUCKER, B. STAELS, K. CLÉMENT, M. GUERRE-MILLO : Microarray analysis of gene expression changes induced by high fat diet in skeletal muscle of PPAR α -null mice. *13th European Congress on Obesity May 26-29 2004, Prague, Czech Republic.*
 131. F. GIZARD, C. AMANT, F. PERCEVAULT, A. CORSINI, C. GLINEUR, J.C. FRUCHART, G. TORPIER, B. STAELS PPAR α inhibits vascular smooth muscle cell proliferation through trans-activation of the gene tumor suppressor P^{16^{INK4A}} 1^{er} Congrès Annuel de la Nouvelle Société Française d'Athérosclérose, Biarritz, France, 10-12 June 2004.
 132. E. TEISSIER, A. NOHARA, G. CHINETTI, R. PAUMELLE, A. SHAH, B. STAELS : Generation of LDL-derived PPAR α agonists with anti-inflammatory properties via PPAR α stimulation of NADPH oxidase activity in macrophages. 1^{er} Congrès Annuel de la Nouvelle Société Française d'Athérosclérose, Biarritz, France, 10-12 June 2004.
 133. D. BASTELICA, A. MAVRI, B. STAELS, S. EL AYACHI, I. JUHAN-VAGUE, M.C. ALESSI : PPAR α deficiency does not modify age dependent but prevents high fat diet increase in plasma PAI-1 as well as insulin resistance. 1^{er} Congrès Annuel de la Nouvelle Société Française d'Athérosclérose, Biarritz, France, 10-12 June 2004.
 134. B. STAELS : Beyond lipid targets : regulation of non lipid parameters by PPAR α from molecular mechanisms to clinical practice management. 2004 Symposium on The role of PPARs in metabolic syndrome and atherosclerosis – Taiwan, Taipei, June 25-27, 2004. Oral presentation
 135. B. STAELS : The protein kinase C signalling pathway regulates a molecular switch between transactivation and transrepression activity of PPAR α . 27th ELC meeting, Tutzing, Germany – Sept 6-9, 2004
 136. J.M.G. PRINCEN : Deficient bile acid synthesis in hyperlipidemic mice enhances. International symposium on « Drugs affecting lipid metabolism », Venice, Italy, October 24-27, 2004
 137. F. GIZARD, C. AMANT, O. BARBIER, F. PERCEVAULT, A. CORSINI, C. GLINEUR, FRUCHART JC, G. TORPIER, B. STAELS : PPAR α inhibits vascular smooth muscle cell proliferation through trans-activation of the gene tumor suppressor p16^{INK4a}. AHA Scientific Sessions 2004 in New Orleans, Louisiana, USA November 7-10.
 138. H.M. PRINCEN, GROENENDIJK M., POST S., FIEVET C., STAELS B. : Deficient bile acid synthesis in hyperlipidemic mice enhances HDL cholesterol via increased hepatic ABCA1 activity. AHA Scientific Sessions 2004 in New Orleans, Louisiana, USA November 7-10
 139. Duriez P., Brigadeau F., Gelé P., Wibaux M., Marquié C., Martin-Nizard F., Torpier G., Fruchart J.C., Staels B., Lacroix D. : Protective effect of PPAR α activation in porcine pacing induced heart failure. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.
 140. Staels B. : PPARs and the metabolic syndrome. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.
 141. Staels B. : Preclinical analysis of PPAR α agonist action on diabetes and the metabolic syndrome. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.
 142. Kok T., Claudel T., Staels B., Kuipers F. : The role of PPAR α in control of hepatobiliary lipid transport. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.
 143. Schupp M., Gineste R., Clemenz M., Witt H., Janke J., Helleboid S., Hennuyer N., Ruiz P., Unger T., Staels B., Kintscher U. : PPAR γ activating angiotensin receptor blockers exhibit differential cofactor recruitment and induce a divergent gene expression profile in 3T3-L1 adipocytes. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.
 144. Staumont D., Honda K., Brenuchon C., Woerly G., Fleury S., Staels B., Capron M., Dombrowicz D. : Role of PPAR α , γ and δ in skin and airway allergic inflammation. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.

145. Fracchiolla G., Loiodice F., Laghezza A., Carbonara G., Tortorella P., Tortorella V., Crestani M., Pinelli A., Godio C., Mitro N., Lavecchia A., Novellino E., Staels B., Fruchart JC. : New chiral clofibric acid analogs as ligands of PPARalpha and gamma. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005.
146. Godio C., Mitro N., Loiodice F., Lavecchia A., Tortorella A., Tortorella V., Staels B., Fruchart JC., Crestani M. : LT160 is a lead compound for the development of novel dual PPARalpha/gamma agonists. 3rd Int. Sympo on PPARs : Efficacy and Safety – Monte Carlo, Monaco, March 19-23, 2005
147. R.S.Sverdlov-Shiri, K.Wouters, PJJ Van Gorp, MJJ Gijbels, B.Staels, M. Van Bilsen, MH. Hofker : The apoE2 knock-in mouse as a model for type III hyperlipidemia and steatohepatitis. 75th Congress of the European Atherosclerosis Society – Prague, Czech Republic, April 23-26, 2005
148. B.Staels : PPARs as targets for anti-atherosclerotic therapies. 75th Congress of the European Atherosclerosis Society – Prague, Czech Republic, April 23-26, 2005
149. T.Claudiel, BM.Elzinga, V.Bloks, B.Staels, PJ. Voshol, F.Kuipers : Role of farnesoid X receptor (FXR) in control of plasma lipid levels. 75th Congress of the European Atherosclerosis Society – Prague, Czech Republic, April 23-26, 2005
150. A.Tailleux, F.Lalloyer, S.Lestavel, G.Torpiere, S.Yous, JC.Fruchart, B.Staels, C.Fievet : Atheroprotective effect of the rexinoid targeting in a murine model of atherosclerosis. 75th Congress of the European Atherosclerosis Society – Prague, Czech Republic, April 23-26, 2005
151. F.Lalloyer, F.Percevault, G.Torpiere, JC.Fruchart, F.Kuipers, C.Fievet, B.Staels : PPARalpha deficiency aggravates diabetes in OB/OB mice. 75th Congress of the European Atherosclerosis Society – Prague, Czech Republic, April 23-26, 2005
152. S.Lestavel, C.Duval, V.Touche, A.Tailleux, V.Carriere, JC.Fruchart, B.Staels, V.Clavey : Regulation of genes encoding intestinal cholesterol transporters by nuclear receptors in human CaCo-2/TC7 enterocytes. 75th Congress of the European Atherosclerosis Society – Prague, Czech Republic, April 23-26, 2005
153. Costet P., Cariou B., Lalanne F., Lambert G., Jarnoux AL., Staels B., Krempf M. : PCSK 9 expression is altered in diabetic rats and its expression is regulated by glucose and insulin. 2nd Annual Congress of the NSFA, Biarritz, France – June 9-11, 2005.
154. Brienne S., Lestavel S., Clavey V., Rigamonti E., Chinetti-Gbaguidi G., Staels B. : LXR régule la captation des esters de cholestérol par le macrophage primaire humain. 2nd Annual Congress of the NSFA, Biarritz, France – June 9-11, 2005.
155. Rigamonti E., Helin L., Lestavel S., Lepore M., Fontaine C., Bouhrel A., Fruchart JC., Clavey V., Staels B., Chinetti-Gbaguidi G. : LXR controls intracellular cholesterol trafficking and esterification in human macrophages. 2nd Annual Congress of the NSFA, Biarritz, France – June 9-11, 2005.
156. Gizard F., Amant C., Barbier O., Bellosta S., Corsini A., Glineur C., Krimpenfort P., Percevault F., Sevestre H., Rochette J., Fruchart JC., Torpiere G., Staels B. : PPARalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia by inducing the tumor suppressor gene p16^{INK4a}. ENDO 2005, Endocrine Society's 87th annual meeting, San Diego, California USA, June 4-7.
157. Straka RJ., Burkhardt RT., Tsai M., Peacock JM, Stephenson SH., Hopkins PM., Staels B., Arnett DK. : Fenofibrate (fenofibric acid) exposure and magnitude of triglyceride (TG) response from NHLBI sponsored genetics of lipid lowering drugs and diet network (GOLDN) study. 2nd Int. Sympo on Triglycerides and HDL : Role in cardiovascular disease and the metabolic syndrome – New York, USA – July 14-17, 2005
158. Cariou B., Duran-Sandoval D., Van Harmelen K., Van Dijk TD., Bouchaert E., Fruchart JC., Kuipers F., Staels B. : Farnesoid X Receptor (FXR) regulates peripheral insulin sensitivity. EASD 41th annual meeting, Athens, Greece – Sept 10-15, 2005
159. Van Harmelen K., Cariou B., Duran-Sandoval D., Van Dijk TD., Bouchaert E., Fruchart JC., Kuipers F., Staels B. : Impaired adaptive response to fasting in FXR-deficient mice. EASD 41th annual meeting, Athens, Greece – Sept 10-15, 2005
160. Nohara A., Chinetti-Gbaguidi G., Fontaine C., Rigamonti E., Fruchart JC., Teissier E., Marceau M., Simonet M., Staels B. : LXR activation induces phagocyte NADPH oxidase activity in human macrophages and inhibits salmonella replication within these cells. 3rd European Meeting on Vascular Biology and Medicine 2005, Hamburg, Germany – Sept 28-30, 2005 (poster presentation)
161. Fontaine C., Rigamonti E., Duhem C., Bertout J., Fruchart JC., Marx N., Chinetti-Gbaguidi G., Staels B. : PPARgamma upregulates CXCR2 expression in human macrophages and atherosclerotic plaques. 3rd European Meeting on Vascular Biology and Medicine 2005, Hamburg, Germany – Sept 28-30, 2005 (poster presentation)
162. Gizard F., Tailleux A., Fievet C., Millat L., Marx N., Staels B. : Induction of the tumor suppressor p16^{INK4A} (p16) gene by thiazolidinedione PPARgamma agonists in atherosclerotic plaques. 3rd European Meeting on Vascular Biology and Medicine 2005, Hamburg, Germany – Sept 28-30, 2005 (poster presentation)
163. Chairman of the poster session : Insulin, insulin resistance and metabolic syndrome. 3rd European Meeting on Vascular Biology and Medicine 2005, Hamburg, Germany – Sept 28-30, 2005
164. Nielsen R., Grontved L., Brozek J., Staels B., Hum D., Mandrup S. : PPARsubtype specific activation of genomic target genes in hepatocytes upon adenoviral transgene delivery. Keystone meeting, Banff, Canada, March 18-23, 2006. Oral Presentation